University of Montana

ScholarWorks at University of Montana
Graduate Student Theses, Dissertations, &
Professional Papers

Graduate School

2006

Serotonin transporter inhibitor ligands: Synthesis of 2-(2-alkylpiperazin-1-yl)-6-nitroquinoline analogs as potential positron
emission tomography imaging agents
Brian R. Kusche
The University of Montana

Follow this and additional works at: https://scholarworks.umt.edu/etd

Let us know how access to this document benefits you.
Recommended Citation
Kusche, Brian R., "Serotonin transporter inhibitor ligands: Synthesis of 2-(2-alkylpiperazin-1-yl)-6-nitroquinoline analogs as potential positron emission tomography imaging agents"
(2006). Graduate Student Theses, Dissertations, & Professional Papers. 9613.
https://scholarworks.umt.edu/etd/9613

This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an
authorized administrator of ScholarWorks at University of Montana. For more information, please contact
scholarworks@mso.umt.edu.

Maureen and Mike
MANSFIELD LIBRARY

The University of

Montana
Permission is granted by the author to reproduce this material in its entirety,
provided that this material is used for scholarly purposes and is properly
cited in published works and reports.

**Please check "Yes" or "No" and provide signature**
\ /

Yes, I grant permission
No, I do not grant permission

__________

Author's Signature:
Date:

< T /? /

___________

Any copying for commercial purposes or finapcial gain may be undertaken
only with the author's explicit consent.

8/98

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

SEROTONIN TRANSPORTER INHIBITOR LIGANDS: SYNTHESIS OF
2-(2-ALKYL-PIPERAZIN-1-YL)-6-NITROQUINOLINE ANALOGS AS
POTENTIAL POSITRON EMISSION TOMOGRAPHY IMAGING AGENTS

by
Brian R. Kusche
B.S. Chemistry, Central Washington University, 2001
B.A. Biology, Central Washington University, 2001
presented in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy
The University of Montana
July 2006

Approved by:

Chairperson

Dean, Graduate School

8 - 4 - Q4>
Date

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

UMI Number: 3238375

Copyright 2007 by
Kusche, Brian R.

All rights reserved.

IN F O R M A TIO N TO U SER S

The quality of this reproduction is dependent upon the quality of the copy
submitted. Broken or indistinct print, colored or poor quality illustrations and
photographs, print bleed-through, substandard margins, and improper
alignment can adversely affect reproduction.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted. Also, if unauthorized
copyright material had to be removed, a note will indicate the deletion.

®

UMI
UMI Microform 3238375
Copyright 2007 by ProQuest Information and Learning Company.
All rights reserved. This microform edition is protected against
unauthorized copying under Title 17, United States Code.

ProQuest Information and Learning Company
300 North Zeeb Road
P.O. Box 1346
Ann Arbor, Ml 4 8 106 -1 346

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Kusche, Brian R. Ph.D., July 2006

Chemistry

Serotonin Transporter Inhibitor Ligands: Synthesis of 2-(2-alkyl-piperazin-1-yl)-6nitroquinoline Analogs as Potential Positron Emission Tomography Imaging
Agents
Chairperson: John M. Gerdes
The pre-synaptic serotonin transporter (SERT) membrane protein is responsible
for the clearance of the endogenous neurotransmitter serotonin (5-HT) from the
synaptic cleft. The SERT protein is an established target for serotonin selective
reuptake inhibitor (SSRI) therapeutic drugs. Alterations in SERT population
densities and/or function have been implicated in a number of mental health
disorders, including depression, anxiety, schizophrenia, and Parkinson’s disease.
Efforts to assess SERT changes in living brain utilizing positron emission
tomography (PET) have been limited based on the availability of efficacious (as a
function of in vivo kinetics and nonspecific binding), potent and selective SERT
PET imaging radioligands. To satisfy the demand for new PET SERT imaging
agents, investigations have encompassed the interpretation of a SERT
pharmacophore model of the SSRI binding domain to identify new lead ligands.
The novel SERT inhibitor 2-(2-methyl-piperazin-1-yl)-6-nitroquinoline has been
used to design new SERT inhibitors 2-(2-(methoxymethyl)-piperazin-1-yl)-6nitroquinoline and 2-(2-(3-fluoropropyl)-piperazin-1-yl)-6-nitroquinoline, among
others. The syntheses of these new SERT inhibitors were designed to allow for
late stage introduction of carbon-11 and fluorine-18 radionuclides. The analogs
of 2-(2-methyl-piperazin-1-yl)-6-nitroquinoline have been found to be highly
potent (rSERT Kj = 2-100 pM, [3H]Paroxetine), and selective (relative to
dopamine and norepinephrine transporters) for SERT. Additionally, specific
enantiomers of 2-(2-methyl-piperazin-1-yl)-6-nitroquinoline and inhibitors 2-(2(methoxymethyl)-piperazin-1-yl)-6-nitroquinoline are more potent than their
respective opposing enantiomeric forms. These results provide two new non
radioactive ligands that are considered as plausible carbon-11 and fluorine-18
PET SERT imaging agents.
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Chapter 1
Introduction and Background
1.1

Introduction.
Alterations in serotonergic function within the central nervous system

(CNS) are believed to be associated with a number of neurological and mental
health disorders, including depression, schizophrenia, anxiety and Parkinson’s
syndrome.1,2

The serotonin reuptake transporter (SERT) is located on the

presynaptic neuron cell surface and is responsible for the clearance of serotonin
(5-HT, 3) from the synaptic cleft after neuronal firing.

Presynaptic cell surface

densities of SERT may be an excellent marker for measuring the integrity of the
5-HT terminals and 5-HT neurotransmission in relation to neurological and mood
disorders.3 Visualization and quantification of SERT densities in living tissue can
be accomplished by positron emission tomography (PET) functional brain
imaging (FBI) techniques, allowing for the determination of serotonergic system
integrity.

Considering SERT cell densities vary depending on the cerebral

region, it is important for the understanding of the role of 5-HT 3 and SERT in a
disease state to be able to image SERT density in high to low regions. There is
currently a need for new PET imaging probes for the measurement of the brain
regions with low (e.g. cerebellum) to medium (e.g. limbic system, particularly the
hippocampus and amygdala) SERT densities.
We are interested in developing new SERT PET imaging agents with
appropriate properties for the imaging of brain regions implicated in SERT related
disorders.

A desirable imaging agent should have high SERT affinity and

1
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selectivity, good in vivo kinetics (K d, kon and koff), low nonspecific binding and
high target to cerebellum ratios (>2, important for imaging low SERT density
regions). The objective of the Gerdes research group has been to develop new
PET imaging agents for the in vivo imaging of SERT receptor densities of select
brain regions.

1.2

The Neurotransmitter Serotonin.
5-hydroxytryptamine

(serotonin,

5-HT,

3)

is

an

endogenous

neurotransmitter of the central nervous system (CNS) in addition to peripheral
tissues. Serotonin 3 was initially described as a substance present in clotting
blood that acted as a vasoconstrictor (constriction of blood vessels).4 Serotonin
3 was isolated from beef serum and purified by Rapport et al. in 1948.5 They
proposed that 3 contained an indole moiety and was likely related in structure to
tryptophan 1 or tryptamine (not shown).5 In 1951 5-hydroxytryptamine 3 was
independently synthesized and compared to the vasoconstrictive substance (3)
isolated by Rapport and was found to possess vasoconstrictive properties and to
be structurally identical to 3.6 It was later determined that serotonin was involved
in neurotransmission among other peripheral tissue functions.7 Furthermore, the
presence of 5-HT receptors was presented by Gaddum and Picarelli in 1957.8
The existence of two separate 5-HT receptors was shown by Peroutka and
Snyder in 1979.9 They were able to demonstrate the presence of separate
receptors utilizing the radioligands [3H]5-HT 3 and [3H]spiperone (not shown) to
label the different receptor sites termed 5-HT-i and

5 -HT2

2
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respectively.9

Continuing research on the serotonergic system has identified fourteen known 5HT receptors and the 5-HT transporter (5-HTT, known as SERT). Outlined in
Table 1-1 are the known 5-HT receptors and transporter located peripherally and
centrally, along with their associated therapeutic potential.10
Table 1-1 : 10 The different 5-HT receptor families their subtypes and associated therapeutic
potential.
Receptor Family
5-HT!

Subtype

Receptor Type

Therapeutic Potential

"\
5-HT i A

Anxiety

5-HT1b

Migraine, Excessive Aggression

5-HT1c
5-HT1d

Migraine

5-HT1e

Unknown

5-HT1f

Migraine

5-HT2

V

G-protein Coupled

5-HT2A

Schizophrenia

5-HT2B

Migraine

5-HT2C

Anxiety, Depression, Obesity

5-HT4

Irritable bowel syndrome

5-HT5

Unknown

5-HT6

Bipolar, Parkinson's

5-HT7

J

Sleep disorders, Depression

5 -HT 3

Ligand-gated ion channel

Irritable bowel syndrome

SERT

Transporter (Reuptake)

Depression

In the CNS the biosynthesis (Figure 1-1) of 5-HT 3 is accomplished in the
serotonergic neurons from the amino acid tryptophan 1.

Tryptophan 1 is

hydroxylated by the enzyme tryptophan hydroxylase to give 5-hydroxytryptophan
2. Decarboxylation of 2 by aromatic-L-amino-acid decarboxylase gives 5-HT 3.
The biosynthesis of 3 is dependent upon the transport of tryptophan 1 across the
blood brain barrier (BBB).

Serotonin 3 is degraded by deamination to 5-

hydroxyindoleaccetic (5-HIAA, 4) by the enzyme monoamine oxidase (MAO),
and 4 is then excreted by the urinary tract (Figure 1-1).

3
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HO
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tryptophan

NH2

hydroxylase

decarboxylase

N
H

tryptophan, 1

5-hydroxytryptophan, 2

HO

serotonin, 3

HO
MU

,C02H

2 monoamine
oxidase

serotonin, 3

5-HIAA, 4

Figure 1-1: Biosynthesis and degradation pathway for serotonin in the CNS.

1.3

Serotonin Neurotransmission at the Synapse.
The signaling processes of the body and the brain are propagated through

neuronal circuitry by electrical action potentials and chemical synaptic potentials.
The nerve impulse is carried through the axon to the nerve terminus, for the
nerve impulse to be carried from one neuron to the next the signal must be
transferred across the synaptic cleft (the junction between the presynaptic and
postsynaptic cell). The electrical impulse is not simply transferred form cell to
cell. The process occurring at the nerve terminal is summarized in Figure 1-2.
As the nerve impulse reaches the nerve terminal there is an influx of calcium ions
through voltage gated ion channels.

The influx of calcium ions causes the

vesicles to fuse with the presynaptic neuron membrane and release stored
serotonin 3 neurotransmitters. The neurotransmitters rapidly diffuse across the
synapse by a concentration gradient where they are bound to receptors on the
post synaptic terminal.

Binding of the neurotransmitters propagates the nerve

impulse by inducing a change in the membrane potential of the postsynaptic

4
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neuron through a ligand gated ion channel. This can also occur via G-protein
coupled receptors that activate a second messenger system within the
postsynaptic neuron to propagate the nerve impulse.

Following release the

neurotransmitters are removed from the synaptic cleft by the serotonin reuptake
transporter (SERT) located on the presynaptic nerve terminal and then packaged
again into vesicles to await the next nerve impulse.
Presynaptic Neuron
Voltage-gated
Ca2+ Channel

Mitochondria

Vesicles

Exocytosis
|
®

ReuptakeV
Transporter

Synaptic Cleft

Serotonin

Postsynaptic
Receptor
Response

Postsynaptic Neuron
Figure 1-2: Signals from the pre-synaptic neurons to the post-synaptic neurons of the
serotonergic system are linked by the neurotransmitter serotonin (5-HT). Release of 5-HT from
the vesicles and subsequent binding with the postsynaptic receptors induces a response in the
postsynaptic neuron and propagates the nerve impulse.

1.4

Serotonin Reuptake Transporter (SERT).
The SERT protein is an integral membrane protein and consists of 12

transmembrane

regions with the amino and

carboxyl terminals

5
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located

intracellularly.11 The SERT protein is a member of the subfamily monoamine
transporters (which includes, noradrenaline (norepinephrine) and dopamine
transporters) of the Na7CI" neurotransmitter transporter family.12 After neuronal
firing,

the

reuptake

transporter

is

responsible

for

the

termination

of

neurotransmission by uptake of serotonin from the synaptic cleft for later
packaging into vesicles for use in subsequent neuronal firing events (Figure 1-2).
The SERT protein actively transports 5-HT from the synaptic cleft with the
cotransportation of 1 Na+ and 1 Cl", with the counter ion transport of K+ (the
transport of 5-HT is dependent on the presence of K+ on the cytoplasmic side of
the membrane).11 The SERT protein is important for the regulation of the levels
of 5-HT in the synaptic cleft.13 The rat and human SERT proteins are of identical
length (630 amino acids) and possess 92% amino acid identity.14 The SERT
protein is a well known target for selective serotonin reuptake inhibitors (SSRIs)
for the treatment of depression among other disorders (Figure 1-3). By blocking
SERT uptake of 5-HT, extracellular levels of 5-HT are increased activating 5-HT
neurotransmission.11

6
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h 3c

Sertraline, 5

(+)-MCN5652,6

NH

(S)-Citalopram, 7

HN

o0

F

Indatraline, 8

—0

O

0

\ —0
Paroxetine, 9

Fluoxetine, 10

Fluvoxamine, 11

Figure 1-3: Typical SSRIs and related SERT inhibitors.

High SERT density is found in the raphe nuclei, substantia nigra,
thalamus,

hypothalamus

and

straitum.15'19 Medium

SERT

densities

are

associated with the limbic and paralimbic structures, including the hippocampus,
amygdala, and the cingulate cortex.16,18,20 Low to negligible levels of SERT are
found in the neocortex (occipital, and orbital frontal) and the cerebellum.15,18 The
cerebellum is used as a reference region for cerebral comparison of non-specific
binding and for calculation of target-to-cerebellum ratios. Alterations in SERT
density and function have been attributed to a variety of neuropsychiatric
disorders, including depression21"23 anxiety,22,24 suicide,20,25,26 schizophrenia,27'30
and eating disorders,31,32 among others. Studies of the distribution of the SERT
protein in postmortem human brain samples suggest that the structures of the
limbic system (including the amygdala, hippocampus, and hypothalamus) are

7
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connected to the pathology of depression.33"36

To better understand the

pathology of the diseases related to SERT density changes, in vivo imaging
studies of SERT densities would be beneficial for diagnosis and monitoring
therapies of mental health disorders.

1.5

Functional Brain Imaging (FBI).
Non-invasive in vivo analysis of CNS receptor and transporter densities

can be accomplished by positron emission tomography (PET) and single photon
emission computed tomography (SPECT).37,38 In vivo imaging techniques refer
to the use of radioligand tracers containing relatively short lived radionuclides
(11C, 18F, 76Br and

123l, t-1/2 = 20 - 960 minutes), that are selective for the

receptor, transporter or enzyme of interest.

The PET and SPECT imaging

techniques can measure receptor protein concentrations in the nanomolar (nM)
to picomolar (pM) concentration range.

These techniques are superior over

magnetic resonance imaging measures that detect compounds in the micromolar
(pM) range.39 One benefit of the PET or SPECT imaging technique is that the
radioligand is used in small amounts reducing the possibility of adverse side
affects.39 The disadvantages to PET and SPECT imaging is the number of tracer
exposures for the subject is limited due to radiation exposure (dosimetry)
restrictions,

availability of the radioligand, and in the case of the short lived

radionuclide (11C and 18F) the proximity of the imaging scanner to the source of
the radioligand production facility.

8

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1.6

Criteria for SERT PET Tracers.
Radioligand selection criteria for PET and SPECT imaging studies are a

major hurdle to overcome before any imaging analysis can be accomplished. A
number of criteria have been delineated in the literature for the selection of the
appropriate ligand and radioisotope to be used, these include: i) the ligand
should be selective for the protein of interest, ii) the ligand should have high
affinity (KD < 1 nM), iii) appropriate ligand lipophilicity (LogP 1.5-4, able to cross
the blood brain barrier (BBB), but is not so lipophilic the agent suffers from
nonspecific binding), iv) radioactive metabolites should not be active in the CNS,
and v) the ligand should be non-toxic.3,13,39 For low density target protein
measurement a higher affinity agent is required. According to Laruelle et al., a
ligand with a binding affinity in the range of
sufficient.39

1

and

0 .0 1

nM is considered

However, the measurement of the ratio of specific-to-nonspecific

binding may truly define a ligand’s potential as an imaging agent.39
At equilibrium the ratio of specific-to-nonspecific tracer binding is equal to
V 3" (V3” is defined as the specific-to-nonspecific equilibrium partition coefficient).
A

V 3”

value of 0.5 in the region of interest is desirable.

3

The partition coefficient

V3” is equal BmaxA/2 KD, where Bmax is the density of the binding site, V 2 is a
measure of nonspecific binding and KD (equilibrium dissociation constant) is the
affinity of the ligand for the binding site .39,40 The greater the nonspecific binding
of the radioligand the lower the value of V3” (less desirable). Also as the binding
site density increases (Bmax) and the ligand’s affinity increases (smaller KD) so
does

V 3 ”

(more desirable).

Comparison of

V 3”

values allows for direct

9
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comparison of potential radioligands. Where the greater the ligands associated
V3” value corresponds to a lower nonspecific binding (V2) and a better signal-tonoise ratio. The signal-to-noise ratio is especially important when attempting to
measure the density of the tracer binding site in regions of medium density, i.e.
SERT density in the limbic and paralimbic system implicated as the regions
related to 5-HT and SERT disorders.

1.7

SSRIs as Potential PET Imaging Agents.
The use of the SSRIs citalopram 7 and paroxetine 9 was investigated as

potential SERT radiotracers based upon their respective SERT affinities and
selectivity for SERT. The more biologically active enantiomer (S)-citalopram 7
has high affinity and selectivity for SERT and a relatively low lipophilicity.41 The
N-methyl carbon-11 analog [11C]7 was prepared from norcitalopram (not shown)
and evaluated for its efficacy as a SERT PET imaging agent.42 Ex vivo studies
of [11C]7 showed low target-to-background ratios and very low specific signal in
human volunteers in PET studies.42,43 A derivative of the SSRI paroxetine 9
(Paxil) was prepared [18F]fluoropropylparoxetine 12, by treatment of 9 with
[18F]fluoropropyltosylate.44

However, the functionalized radiotracer [18F]12

suffered from reduced affinity for SERT (3 orders of magnitude) and brain
distribution studies showed no distinct localization in SERT rich regions of the
brain.

10
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\-o
(S)-[11C]Citalopram, 7

N-(3-[18F]Fluoropropyl)paroxetine, 12

Figure 1-4: Commercial SSRI analogs developed as potential SERT PET imaging agents.

1.8

Current SERT Imaging Agents.
Initially, imaging the SERT protein was difficult due to the lack of a specific

radioligand with suitable in vivo binding kinetics.38 Attempts at utilizing known
radiolabelled SSRIs (Figure 1-4) have been unsuccessful.

The first useful

radiotracer for SERT imaging in primates was (+)-[11C]MCN5652 6 (Figure
1-5).38,45,46

Subsequently (+)-[11C]6 became a standard for comparison to

determine the efficacy of new radiolabeled agents for PET SERT imaging. 3,18,19
Unfortunately, the in vivo kinetics of (+)-[11C]6 were too slow for the carbon-11
radionuclide to be useful (carbon-11, t-1/2 = 20.4 min).19 Additionally, nonspecific
binding was too high for quantification of SERT in low density regions of interest
(ROI) within the brain, particularly the limbic system.3
Attempts to prepare a radiotracer with a longer half life have been made.
Suehiro et al. prepared [18F]FET-MCN 13 (Figure 1-5), where the fluorine-18
radioisotope with a longer half-life might prove to have better in vivo
characteristics allowing for a longer analysis tim e 47 However, [18F]13 did not
improve upon the lead [11C]6. It actually showed less favorable properties due to

11
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reduced BBB penetrating abilities. Additionally, [18F]FET-MCN showed a lower
19,47

tissue to cerebellum ratios than the lead [11C]6 .ia,4/

The fluoromethyl analog

[18F]14 (Figure 1-5) was also investigated and showed faster kinetics than the
lead [11C] 6 and higher specific binding in porcine brain, which is suggestive of its
potential in humans. 19,34

18

(+)-[11C]MCN5652,

6

(+)-[1 8 F]FEt-MCN, 13

(+)-[1 8 F]FMe-MCN, 14

Figure 1-5: Radiolabelled derivatives of the potent and selective SSRI MCN5652.

The second generation SERT imaging agents have been based upon the
general structure of the diarylsulfide SSRI 403U76 15 (Figure 1-7).

The first

tracer introduced for use as a SERT SPECT imaging agent was [123I]IDAM
16.48’49 The tracer [ 123I]IDAM 16 had very good SERT selectivity compared to the
norepinephrine

reuptake transporter

transporter (DAT).
[11C]6 . 49

(NET)

and

the

dopamine

reuptake

The SPECT images had similar distribution compared to

Following IDAM 16, the iodinated congener of [125I]ADAM 17 was

prepared and found to have superior in vivo profile compared to 16.
[123I]ADAM 17 is expected to be an excellent SPECT imaging tracer.2,50

12
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The

SSRI 403U76, 15

IDAM, 16

ADAM, 17

Figure 1-6: The Diarylsulfide SERT inhibitor 403U76 15 and the potential SERT SPECT analogs
IDAM 16 and ADAM 17.

For PET imaging a series of carbon-11 diarylsulfide class of compounds
have been evaluated and compared to [11C] 6 (Figure 1-7).

The diarylsulfide

ligands (Figure 1-1) have been shown to be selective for rSERT and have the
appropriate regional distribution in rat brain for SERT .3 Of the four diarylsulfides,
[11C]DAPA 20 and [ 11C]ADAM 17 showed no benefit over [11C]6 .

However,

[11C]DASB 19 and [11C]AFM 18 were demonstrated to outperform [11C]6 . The
radioligand [11C]AFM 18 with a significantly higher V 3 ” value than the other tracer
has the potential to be an excellent imaging agent for low to medium SERT
density regions .3 The excellent profile of [ 11C]AFM 18, lead to the development
of [18F]AFM 21, where the inclusion of the fluorine-18 atom has the advantage of
increased scanning time compared to carbon- 1 1 and a fluorine-18 tracer can be
transported to off-site imaging facilities if needed .3 Biodistribution studies in rat
of [18F]21, showed high brain uptake and

high SERT binding affinity and

selectivity. Based upon the current in vivo rat studies, [18F]21 has been proposed
to be an excellent SERT imaging agent.51

It remains to be seen whether the

benzyl fluoride moiety of [18F]21 will provide suitable imaging performance
qualities in primates.

13
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[11C]AFM, 18

[11C]DASB, 19

[11C]DAPA, 20

18

[1 1 C]ADAM, 17

[11C]MCN5652,

6

FH2C
[ 1 8 F]AFM, 21

Figure 1-7: Second generation SERT PET agents.

1.9

6-Nitroquipazines as SERT Inhibitor Tracers.
The lead structure

6 -nitroquipazine

22 (6 -NQP, 6-nitro-2-piperazin-1-

ylquinoline, DU-24565) (Figure 1-8) is known to be one of the more potent and
selective agents for SERT . 1,52,53 It seems plausible that analogs of

6 -NQP

22

would lead to an efficacious SPECT or PET agent. The current functional brain
imaging (FBI) analogs of 6 -NQP are outlined in Table 1-1, including: [ 123l]5-iodo6 -nitroquipazine

(INQP) 23,54,55 [76Br]5-bromo-6-nitroquipazine 24,56 [18F]5-fluoro-

6 -nitroquipazine

25,57 and [11C]5-methyl-6-nitroquipazine 26 (Table

6

-NQP, 22

Figure 1-8: SSRI 6-nitroquipazine.

14
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1 ) . 58'59

Table 1-2: Structures of the current 5-halo-6-nitroquipazines and their respective SERT imaging
radioligands.

x

X

k / NH

X*
123

23
24

Br

25

F

26

CH3

However, the metabolic dehalogenation fate of INQP 23 in primate brain,
led to the presence of free [123l] that ultimately obscures the SPECT images.
Additionally, the BrNQP 24 suffers from high non-specific binding.59 The [18F]5fluoro-6 -nitroquipazine tracer 25, showed lack of selectivity (readily displaced by
maprotiline (not shown) a norepinephrine re-uptake inhibitor) and lack of binding
affinity (readily displaced by citalopram 7 ) . 57 The [11C]5-methyl-6-nitroquipazine
radioligand 26, was also shown to be a plausible agent for PET imaging.
However, the carbon-11 analog suffered from slow binding kinetics,58 where the
short half life of carbon- 1 1 did not allow the tracer to reach apparent equilibrium
of binding.

1.10

Pharmacophore Development.
Many of the radiolabeled versions of the SSRIs (Figure 1-1), have

lipophilic qualities that may interfere with the PET or SPECT imaging through
non-specific binding.

It is our hypothesis that a portion of the non-specific

binding may be related to SSRIs (and their labeled forms) acting as steroid
mimics, perhaps interacting at neuroendocrine receptors in the brain .60 Analysis
of the structural similarities of the various SSRIs currently in the literature (Figure
15
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1-3),

61

shows that each SSRI possess dual aromatic ring moieties connected by

a central connecting carbon.
It is well known that SSRI treatment can lead to sexual dysfunction, a side
effect that has profound implication on a patients willingness to stay on the
treatment course .62

A comparison of the SSRIs in Figure 1-3, shows that

fluvoxamine 11 is the only SSRI shown to be devoid of a second aromatic
moiety. Additionally, 11 has a marked attenuated difference in its respective side
affects.63,64 We believe the presence of the dual aromatic ring structure may lead
to the side effects observed during SSRI treatment. Recently, SSRIs have been
shown to be actively involved in the modulation of the neuroendocrine system .60
It is our hypothesis that in the absence of a second aromatic ring the ability of an
SSRI to interact with the neuroendocrine system is diminished, resulting in
decreased side effects and prospectively reduced non-specific binding.

Sertraline, 5

(+)-MCN5652,6

(S)-Citalopram, 7

Indatraline,

8

Figure 1-9: SERT pharmacophore training set SSRIs.

Therefore, we have developed a pharmacophore model constructed from
a superposition of four semi-rigid SSRI ligands (Figure 1-9), in an effort to
elucidate key structural features for an efficacious SERT PET tracer.65,66
Examination of our model suggests there are a number of distinct features

16
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necessary for SERT binding: i) an electronegative region (X group), ii) two
aromatic regions (Ar1, and Ar2) iii) a heteroatom moiety and iv) a terminal amine
group.

It is our belief, based upon the structural diversity of known SERT

inhibitor ligands all of the pharmacophore points need not be activated in order to
maintain high SERT affinity. Our effort has been to develop ligands devoid of the
Ar2 aromatic moiety which may play a key role in eliminating activity as a steroid
mimic while maintaining the other structural characteristics of the pharmacophore
(Figure 1-10).
Of particular interest to us was the SSRI 6 -nitroquipazine 22 that has been
shown to be potent and highly selective for SERT. The most interesting feature
of 22 is the structural qualities compared to other SSRIs (Figure 1-1).

The

structure of 22 is composed of one aromatic ring moiety (Ar1), an X-group (ArNO2 ), a heteroatom moiety (3° piperazine nitrogen or quinoline nitrogen),
terminal amine (2 ° piperazine nitrogen), but is devoid of a second aromatic ring
moiety (Ar2).

We then proposed that alkyl-substitution of 22 at the 2- or 3-

position of the piperazine ring would likely probe the Ar2 binding pocket of our
model.

17
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X Group

Connecting
Carbon

Terminal
Amine

t

(1 S,4S)-(+)-c/s-Sertraline

Front

(1 R,3S)-(+)-frans-lndatraline
(1 S)-(+)-Citalopram
Top View

Het

(6S,10bR)-(+)-McN-5652

Figure 1-10: Superposition of the SERT pharmacophore training set SSRIs (Figure 1-9), and key
SERT binding features.
X Group

Terminal amine
N

N

Het
Figure 1-11: Structural qualities of 22 related to the SERT pharmacophore features.

1.11

Me-NQP 28 and (±)-30, Implications to the Pharmacophore.
We became interested in developing new PET imaging radioligands for

SERT based upon the lead selective and potent SSRI 6 -NQP 22. The current 6 NQP FBI agents described above (Figure 1-8) have been shown in vitro to be
highly selective for SERT. However, due to variety of factors i.e. dehalogenation,

18
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low ROI-cerebellum ratios and low synthetic yields of the desired agent.
aromatic halogenated analogs of
We believe that functionalizing

22

The

have failed to be useful for imaging studies.

6 -NQP

22 at the piperazine ring with alkyl groups

that are amenable to late stage introduction of a radioisotope will likely show
enhanced SERT binding by mimicking the interaction of the Ar2 moiety described
in the pharmacophore model.

2-CI-quinoline
HN

HN03, h 2 s o 4
/= \

NH
toluene, A

02N—^

0°C

CH3

X

//— H

^ —N

^NH

55%, 2 steps

X—^
ch3

7

27

28

Trityl-CI, Et3 N,
CH2 CI2, 0 °C
HN03, h 2 s o 4
2-CI-quinoline
/~ A
Ph3 C—N
NH --------------------------- ►
\— /
toluene, K2 C 03, A;
0°C
CH3
HCI’ Et0H

.— i

°9N- \
x

n— N

/>-N
7

29

NH

10%, 4 steps

) —/
h 3c
(±)-30

Scheme 1-1: Synthesis of 28 and (±)-30, the 2- and 3-alkyl derivatives of 6-NQP 22.

To initially determine if alkyl substitution on the piperazine ring of the lead
structure 6 -NQP 22 would increase SERT binding affinity, the racemic forms of 2and 3-substituted 2-piperazinyl-6-nitroquinoline (±)-30 and 28 were prepared
(Scheme

1-1)

and

evaluated

for

SERT

binding

against the

[3 H]paroxetine (Table 1-3) . 67

19
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standard

Table 1-3: SERT binding affinities of the first generation of 6-nitro-alkylpiperazin-1-ylquinolines.

A

NH
Y

X

Y

Ki (nM)a'°

22

H

H

0.163 ± 0 .0 5 3
0.081 ± 0.061

(±)-30
28
(±)-31

CO
X
o

Cmpd #

H

H
CH2OCH3

ch3

4.56 ± 2.4

H

2.48 ± 0.28 (pM)

aGerdes, 2002. bData determined from competition
assay utilizing rat cortical membrane suspensions
labeled with [3H]paroxetine, method is discussed in
Chapter 4.

From this study we were able to determine that substitution at the 2position of the piperazine ring is 56 times more potent for SERT than the 3substituted analog.

Additionally, (±)-30 is 2 times more potent than 22,

suggesting that the alkyl substituent at the

2 -position

has added beneficial

interaction for SERT binding compared to the lead 22. Also, we can deduce from
the binding data that the 3-position involves negative interaction at the binding
site leading to its decreased affinity for SERT.

As shown in Figure 1-12, an

overlay of the enantiomer ((S)-2-(2-methylpiperazin-1-yl)-6-nitroquinoline ((S)MeNQP 30) with the SERT pharmacophore shows the methyl group positioned
for interaction within the Ar2 pocket. This led us to investigate the synthesis of
an extended alkyl chain version of MOM-NQP (±)-31 that could interact deeper
within the Ar2 binding region. We also investigated the production of a potential
radiolabeling precursor by substitution of the piperazine ring at the

2 -position,

with a substituent that can be later converted to its radiolabeled equivalent.
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nitro
group

hetero
atom

. terminal
amine

methyl
group

■ S-Citalopram, Indatraline, MCN-5652, Sertraline

Figure 1-12: Alignment of (S)-Me-NQP 30 with the pharmacophore ligand superposition.

1.12

MOM-NQP (±)-31.
In an effort to extend the 2-alkyl-piperazine substituent into the Ar2 binding

pocket, as well as to generate a precursor for the development of a FBI agent for
SERT, we investigated the synthesis of 2-(2-methoxymethylpiperazin-1-yl)-6nitroquinoline (MOM-NQP) (±)-31. Computational analysis and superposition of
(±)-31 suggests an excellent fit of the methoxymethyl side chain into the region
we have defined as Ar2, likely serving as a highly potent SERT inhibitor.
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nitro

hetero-

terminal
amine

methoxymethyl
group

Arf

■ S-Citalopram, Indatraline, MCN-5652, Sertraline

Figure 1-13: Alignment of MOM-NQP 31 with the pharmacophore ligand superposition.

The synthesis of MOM-NQP (±)-31 was accomplished from the starting
material ethyl 1,4-dibenzylpiperazine-2-carboxylate 32 in six synthetic steps
(Scheme 1-2) . 68"70 The key step of the synthesis was the utilization of the Gilman
coupling method.71

We have found that the Gilman method is particularly

sensitive to the ratio of the reagents used. For successful Gilman coupling the
ratio of reagents must be strictly adhered to (150 mol% of the amine, 150 mol%
of n-BuLi, and 100 mol% of 2-chloroquinoline).

Use of the lithium amide of

piperazine 36 according to Gilman procedure proved to be a more facile method
for the preparation of 2-alkylpiperazin-1-yl-quinolines. The method is far superior
to previous methods of amine

2 -chloroquinoline

couplings that required heating

the two components for extended amounts of time resulting in low yields ( - 2 2 %)
of the desired product (Scheme 1-2) . 67 The Gilman method allowed us to couple
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the 2-substituted N-trityl-protected piperazine 36 with 2-chloroquinoline in the
consistent range of 80-95% yield, as per Scheme 1 _2 . 69’72’73
BrKM/ \
V

E,0 Y

l

LiAIH4, Et20

^ N' -

-------------- '

H°

32

^

|

^

N'Bn

NaH, CH3 I,

N

HCI(g)

34

33

H2 , 5% Pd/C

* 2HCI

abs. EtOH

H3C '

HIJ ^

HN

C(Ph)3 CI, Et3N
CH2 CI2, 0 °C

Hz° '

35

. 2 H CI

,
" °

P h 3

36
0 2N

n-BuLi, 2-CI-quinoline
Et2 0, 0 °C;
6 M HCI, EtOH
(Gilman Coupling)

^

h n o 3, h 2 s o 4
N

N
NH
(±)-31

Bn =

Scheme 1-2: Synthesis of 2-(2-(methoxymethyl)piperazin-1-yl)-6-nitroquinoline, MOM-NQP (±)31.

The synthesis of MOM-NQP (±)-31 not only expanded our knowledge of
coupling piperazines to 2 -chloroquinoline but also further exemplified our study of
the SAR of the 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline series.
MOM-NQP (±)-31

Synthesis of

gave us another ligand to further establish that our

computational model is predictive. Extension of the 2-alkyl-piperazine group into
the Ar2 region improves the ligands affinity. Table 1-1 shows the binding affinity
of (±)-31

is 33 times more potent than our lead (±)-Me-NQP 30 and

more potent than the initial lead 6 -NQP 22.
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66

times

1.13

R- and S-Me-NQP ((/?)-30 and (S)-30).
Based upon the success found with the methyl (Me-NQP (±)-30) and the

methoxymethyl (MOM-NQP (±)-31) analogs of 6 -NQP 22 we began to investigate
the synthesis and subsequent in vitro pharmacological evaluation of the
enantiomers of (±)-30. The synthesis of (SJ-30 and (R)- 30 was accomplished
utilizing the enantiomeric forms of 2-methyl piperazine available from SigmaAldrich.

Each quipazine enantiomer was prepared according to the methods

described in the MOM-NQP (±)-30 (Scheme 1-2). Briefly, the desired enantiomer
of 27 was protected as the N-trityl and coupled to 2-chloroquinoline using the
Gilman method.

Deprotection of the trityl group and selective nitration at the

quinoline 6 -position gave the enantiomers (fi)-30
([a ]20D

([a ]20D

-62° (EtOH)) and (S)-30

= +65° (EtOH)) in 51% and 49% yields, respectively, over four steps

(Scheme 1-3).

HN
H3C
H
(R)-27

as per scheme 1-2

(R)-30

H

(S)-27

(S)-30

Scheme 1-3: Chiral synthesis of (R)- and (S)-Me-NQP 30.
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1.14

Proposed Work.
The goal of this work has been to utilize our SERT pharmacophore model

to develop new more selective and potent agents for the SSRI SERT binding
domain.

In particular, we were interested in developing ligands devoid of a

second aromatic ring moiety (Ar2) in the hopes that SERT ligands with only one
aromatic moiety would show less nonspecific binding. In doing this we wanted to
expand our SAR knowledge of the SSRI SERT binding domain by synthesizing
new 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines to probe the area defined as Ar2.
We have shown that functionalizing the 2-position of the piperazine ring with a
methyl (±)-30 and methoxymethyl group (±)-31 greatly enhances SERT binding
affinity. In addition to expanding the SAR study of the 2-(2-alkyl-piperazin-1-yl)6 -nitroquinolines,

we were

interested

in preparing

potential

radiolabeling

precursors for incorporation of carbon- 1 1 and fluorine-18 radioisotopes to explore
the development of new PET imaging agents for SERT. We also hoped to show
that our 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines are selective for the SERT
and have appropriate vitro binding kinetics for PET imaging studies of low to
medium SERT density regions through a kinetic binding study.
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Chapter 2
Synthesis of Racemic Targets
2.1

Introduction and Goals.
The initial SAR study, encompassing synthesis and biological evaluation

of the racemic and chiral 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines (Me-NQP (±)30 and MOM-NQP (±)-31), has shown that structural alteration of the lead 6 -NQP
22 at the piperazine 2-position increases SERT binding affinity of the ligand.
This chapter describes the synthesis of six new SERT ligands to expand our
knowledge of the SAR of the SERT binding domain.

This work has also

prompted us to develop new racemic radiolabeled (carbon- 1 1 and fluorine-18)
analogs of our lead (±)-31. Outlined in this chapter are the syntheses of the new
potential radiotracers [11C]MOM-NQP 31 and [18F]PROF-NQP 58.
2.2

Synthesis of [11C]MOM-NQP 31.
Preliminary work in our group attempted the synthesis of the radiolabeling

precursor N-trityl-HOM-NQP 39 according to Scheme 2-1. The synthesis began
by demethylation of MOM-NQP (±)-31 with boron tribromide to give the methyl
alcohol HOM-NQP 38. Once the alcohol 38 was made, our initial thought was
that protection of the terminal amine with a trityl group would be the simplest
protecting group for us to use giving the N-trityl protected HOM-NQP 39.
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0,N
C(Ph3)CI
-78 °C
2) NaHC03(aq)

f,
(±)-31

HCk ^ \ / N H Et3 N, CH2 CI2
H

H

CPh3

39

38

Scheme 2-1: Synthesis of the radiolabeling precursor N-trityl-HOM-NQP 39.

The synthesis of the 39 from HOM-NQP 38 proved to be more challenging
than expected. Unfortunately, the mono-N-protected species 39 was difficult to
prepare due to the formation of the undesired di-protected (terminal amine and
alcohol) HOM-NQP (not shown).

Multiple attempts to selectively protect the

nitrogen of 39 were preformed at varying temperatures; -78 °C, 0 °C and ambient
temperature .74
Due to the difficulties of the trityl protecting group, we decided that
protection of the free amine of HOM-NQP 38 as the f-butyl carbamate (N-Boc)
may be a viable alternative radiolabeling precursor.

We again began by

demethylation of (±)-31 with BBr3 to give 38. The boron tribromide demethylation
was followed by Boc protection of the amine using an excess of di-terf-butyl
dicarbonate in dichloromethane (DCM) to give the carbon-11 radiolabeling
precursor 40 (Scheme 2-2).

1) BBr3, CH2 CI2, -78 °C
XL

X

.NH

2)[(CH 3 )3 COCO]2 O,CH 2 CI2 , 0 ° C
H
40

Scheme 2-2: Preparation of the radiolabeling precursor, N-Boc-HOM-NQP 40.
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Boc

To determine the feasibility of the radiolabeling precursor 40, we ran
control methylation and deprotection reactions that were designed to simulate the
conditions that would be used during the radiolabeling synthesis (Scheme 2-3).
Compound 40 was deprotonated in dimethyl formamide (DMF) with sodium
hydride (NaH) at ambient temperature to give the alkoxide as a bright red
solution. The alkoxide was quenched with the addition of methyl iodide (CH3 I) to
give the nonradioactive (cold) agent N-Boc-MOM-NQP 41. The cold agent was
isolated by aqueous workup and extraction with DCM, the resulting dried (K2 CO 3 )
DCM solution was treated with trifluoroacetic acid at ambient temperature. The
crude reaction mixture was made basic (pH 12) and the deprotected product (±)31 was extracted with DCM, followed by purification by reversed phase HPLC
utilizing

a

C-18

column

eluting

with

50:30:20:0.2

(methanol/acetonitrile/

water/triethylamine).

y
\

J

]

o 2n

NaH, DMF;

HOJ ^ N
H

. Boc CH3'

TFA, 100°C
H3 C ' ° ^ K - N'Boc CH2 CI2

40

h3 C

41

' ° ^ ^ NH
H
(±)-31

Scheme 2-3: Simulated reaction sequence for the production of the desired radiotracer
[11C]M OM -NQP(±)-31.

Upon

completion

of the

nonradioactive

synthesis

of

(±)-31,

the

radiolabeling precursor N-Boc-HOM-NQP 40 was shipped to our collaborators at
Lawrence Berkeley National Laboratory (LBNL), Berkeley California to attempt
carbon-11 methylation of the alcohol with [11C]methyl iodide and subsequent N-
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Boc deprotection to give the desired radiolabelled ligand [11C]31.

Initial

experiments performed by our collaborator Dr. James P. O’Neil resulted in a 5%
decay corrected, end of bombardment (EOB) purified yield of [11C]31.

The

radiosynthesis encompassed the methylation and N-Boc deprotection of [11C]31
using trifluoroacetic acid, according to Scheme 2-4 .75

The N-Boc protected

HOM-NQP 40 was deprotonated by NaH as a solution in DMF and added to a
solution of [11C]methyl iodide. The reaction was sealed and heated at 100 °C for
2-3 minutes. The crude product was isolated by C-18 Sep-Pak eluting with DCM.
Trifluoroacetic acid (TFA) as a 1:9 mixture in DCM was added to the N-Boc
protected intermediate [11C]41 and the reaction mixture was concentrated in
vacuo at 100 °C to give the crude product [11C]31.

The crude labelled product

was purified by reverse phase semipreparative HPLC, eluting w/ 50:30:20:0.2
(methanol/acetonitrile/water/triethylamine) to provide [11C]31 in a 2-5% end of
bombardment (EOB) decay corrected yield. The [11C]CH3 l used in the synthesis
was generated from 14N gas using the LBNL onsite cyclotron. Carbon-11 was
generated by irradiation of nitrogen-14 in a

14N(p,a)11C

nuclear reaction in the

presence of oxygen giving [11C]C02. The reduction of [11C ]C0 2 over a nickel
catalyst in the presence of H2 gave [11C]CH4 and the [11C]CH4 is halogenated
with l2 to give [11C]CH3 I.
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Scheme 2-4: Radiosynthesis of [11C]MOM-NQP 31.

Later during the investigation it was proposed that due to the binding
kinetics of a related agent [3 H]/>Prop-NQP 52 (preparation and pharmacology
are discussed in Chapter 4), the time needed to reach apparent binding
equilibrium with SERT was greater than 100 min which exceeded four carbon-11
half lives (20.4 min), precluding the effective use of [11C]31 for PET imaging. A
similar finding has been described for the SERT PET agent [11C](+)McN5652

6 . 19

Marjamaki et al. proposed that incorporation of the fluorine-18 radionuclide (ti /2 =
109.8 min) would allow for increased time need to reach apparent binding
equilibrium . 19

We were interested in the preparation of MeF-NQP 42 of a

fluorinated version of (±)-31 (Figure 2-1).

The inclusion of the fluorine-18

radionuclide would allow us to reach apparent equilibrium of binding by
increasing the time the radiolabelled agent would be useful for imaging,.

H
[18F]42

43

42

Figure 2-1: Desired fluorine-18 radiolabelled ligand [18F]MeF-NQP 42, tosylate precursor 43 and
the cold fluorinated agent, MeF-NQP 42.

This led us to try to synthesize the cold agent of [18F]MeF-NQP 42 (Figure
2-1). Initial efforts looked into the preparation of MeF-NQP 42 from the precursor
30
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N-Boc-HOM-NQP 41 by preparing the O-tosylate 43. The O-tosyl moiety is a
useful leaving group for radiofluorination. Additionally, our collaborators had an
efficient process for the generation of [18F"] fluoride that could be used for nonaqueous nucleophilic fluoride ion substitution reactions.

However, all efforts in

our lab could not produce the desired tosylate product 43.
number of attempts to synthesize the cold

Furthermore, a

2 -(2 -(fluoromethyl)piperazin-1 -yl)-6 -

nitroquinoline 42 via other methods, i.e. (diethylamino)sulfur trifluoride (DAST),
resulted in only the formation of undesired side products.74 With these results,
we decided that lengthening the carbon side chain by two carbons may increase
the possibility of making a viable tosylate radiolabeling precursor with reduced
chances of any side reactions occurring.
2.3

Synthesis of PROM-NQP (±)-51.
Described

in

this

section

is

the

overall

synthesis

of

methoxypropyl)-piperazin-1-yl]-6-nitroquinoline (PROM-NQP, (±)-51).

2-[2-(3With the

information gained from the one carbon series, efforts in our lab were focused on
the production of the three carbon

2 -(2 -alkyl-piperazin-1 -yl)-6 -nitroquinoline

precursor 59 that we believed would be better suited for late stage introduction of
a fluorine-18 atom. In order to accomplish this task we decided to lengthen the
piperazine alkyl chain at an early stage in the

2 -(2 -alkyl-piperazin-1 -yl)-6 -

nitroquinoline synthesis, versus the alternate strategy of a later carbon chain
extension post quipazine framework formation.

The complete synthesis of

PROM-NQP (±)-51 is shown in Scheme 2-13. This synthesis was afforded in 11
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steps with an overall yield of 19%. The following describes the work leading up
to the optimized synthesis of (±)-51.
As shown in Scheme 2-5, initial experiments were focused on the
controlled reduction of ethyl 1,4-dibenzylpiperazine-2-carboxylate 32 to its
corresponding aldehyde 44 using diisobutylaluminum hydride (DIBAL). Following
reduction the aldehyde 44 would be used in a Horner-Emmons76 type olefination
reaction to extend the length of the chain by two carbons giving the desired
piperazine fragment with a three carbon chain length. The ester 32 was reduced
with DIBAL to the corresponding aldehyde 44 at -78 °C.

The resulting

intermediate was converted to the corresponding a,(B-unsaturated ethyl ester 45
(74%, 2 steps) using triethyl phosphonoacetate as the Horner-Emmons reagent
and n-BuLi as the base (Scheme 2-5).

“y ' 1
3 2

—i

"T
74%, 2 steps

4 4

4 5

Scheme 2-5: Initial synthetic route to the a,(3-unsaturated ethyl ester 45.

However, we found it difficult to drive the DIBAL reduction of 32 to 44,
leaving a portion (10-25 mol%) of the starting material ester 32 remaining.
Attempts to improve the reduction by titration of the DIBAL reagent before the
reduction with salicylaldehyde phenylhydrazone did not improve the yield
(Scheme 2-6).
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v ^ P h

^

.

^ v ^ N '^ h

^

o©

OH
Salicylaldehyde
phenylhydrazone

(ye|low)

(red)

Scheme 2-6: Titration reagent for determining the concentration of organometallic reagents.

After the Horner-Emmons homologation we also found that the resulting
a,(3-unsaturated ethyl ester 45 was difficult to isolate from the starting material
32 by column chromatography.

The successfully purified fraction of the

unsaturated ester 45 was reduced to the unsaturated alcohol 46 (94%) utilizing
lithium aluminum hydride (LiAIH4), followed by methylation of 46, forming 47 in a
53% yield (Scheme 2-7). Subsequent catalytic reduction of the alkene and
hydrogenolysis of the benzyl groups of 47 gave 2-(3-Methoxy-propyl)-piperazine
48

(8 6 %).

The

least

hindered

nitrogen

of

48

was

protected

with

triphenylmethane chloride (trityl, CPh3) in DCM giving 49 in a 70 % yield. For this
reaction an excess of Et3N was used to in situ to give the free base form of the
starting material, as well as to act as an acid scavenger for the HCI generated in
the reaction.

Bru

LiAIH4, Et20

NaH, CH3 I,

45

Nv

Bn

94%

DMF, 0 °C;
HCI (g)

46

•2 HCI
H3C

Bn

.0

47

53%
H2, 5% Pd/C

--------------abs. EtOH
86%

C(Ph)3 CI, Et3N

* 2 HCI

-O ^ /^ K /N H
H3C

H

CH2 CI2, 0 °C

48

70%

CPh3

3C

49

Scheme 2-7: Initial synthesis of the coupling precursor 3-(3-methoxypropyl)-1-tritylpiperazine 49.
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The protected trityl piperazine 49 was coupled to 2-chloroquinoline using
the

Gilman

method

(discussed

in Chapter 1) and

purified

by column

chromatography to give the N-trityl-PROM-QP (not shown, 75%). The purified
coupled product N-trityl-PROM-QP was deprotected by dissolving the material in
a minimal amount of acetone and treating with
methoxypropyl-piperazin-1 -yl)quinoline was

6

M HCI. The deprotected 2-(3-

easily

isolated

from

any

non-

nitrogenous side products (quinoline and trityl alcohol) by diluting the reaction
mixture with 1 M HCI and extracting with DCM. The resulting aqueous layer is
then brought to basic pH and the 2-(3-methoxypropyl-piperazin-1-yl)quinoline
was extracted from the aqueous layer with DCM. The extracted product was
found to be of sufficient purity to continue with the nitration step without further
purification.

Compound 50 was selectively nitrated at the

6 -position

of the

quinoline ring using HN0 3 in H2 SO4 at 0 °C to give the 2-[2-(3-methoxypropyl)piperazin-1 -yl]-6 -nitroquinoline (±)-51.

1)n-BuLi, 2-chloroquinoline
Et2 0, 0 °C
2) 6 M HCI, acetone

0 2N

.

NH

0.

48%

0°C
99%

NH
(±)-51

Scheme 2-8: Coupling and nitration to give the desired compound PROM-NQP (±)-51.

The NMR spectra of the final product PROM-NQP (±)-51 (Figure 2-2) when
compared to a MOM-NQP (±)-31 NMR (Figure 2-3) (our standard for 2-(2-alkylpiperazin-1-yl)-6-nitroquinolines) looked promising.

We were intrigued by the
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doubling of the peak at 7.00 (Figure 2-2).

We initially attributed the splitting

pattern to the presence of the longer piperazine side chain. The extend alkyl
chain was thought to be interacting with and changing the inherent environment
of the hydrogen at the quinoline 3-position thus affecting its splitting pattern,
possibly through a rotational barrier. Similar splitting patterns have occurred with
N-formyl-6 -nitroquinoline compounds.

Protection as the N-formyl results in

splitting of the quinoline signals in the proton spectrum due to amide rotamers
where the peak (quinoline 3-position) at 7.00 ppm is typically the most influenced
by the amide rotamer.

o2n

.

H3C '

NH

NH

0.

52

i— !— I— I— |— I— r

8.6

8.2

i—
r
8.0

i — i— |— i— i— r

7.8

t'T

7.6

i

i

i

i

|

7.4

i

1

i

i

|

i

7.2

i

i

i

]

i

i

i

i

7.0

Figure 2-2: NMR of the Aromatic region of PROM-NQP (±)-51, showing the splitting of the C3 quinoline hydrogen.
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8.20
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7.80

7.60

7.40

7.20

7.00

Figure 2-3: NMR of the Aromatic region of MOM-NQP (±)-31 as a comparison to the PROMNQP (±)-51 NMR.

However,
deprotection

analysis

(Scheme

of

2-8)

the
by

crude
thin

reaction

layer

mixture

before

chromatography

N-trityl

(TLC)

(1:9

EtOAc/hexanes) showed the presence of three distinct coupled products.

Suggesting that at some point during the initial reaction sequence (Scheme 2-5,
Scheme 2-7 and Scheme 2-8) two side products had formed in addition to the
desired compound (±)-51.
We were able to isolate each coupled product as their respective N-trityl
protected

species from the

crude

reaction

Subsequent deprotection of each purified product

by column
(6

chromatography.

M HCI, EtOH), followed by

NMR and mass spec analysis determined that the three products were n-PROPNQP 52, MOM-NQP (±)-31 and the desired product PROM-NQP (±)-51 (Table
2- 1).
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Table 2-1: 2-alkylpiperzin-1 -yl-6-nitroquinoline products from the initial PROM-NQP synthesis.

rA

/N H

R

Cmpd

c h 2o c h ;

(±)-31

c h 2c h 2c h 3

52

c h 2c h 2c h 3o c h 3

(±)-51

The methoxymethyl product was determined to be carry over of the
starting material ethyl ester piperazine 32 due to the incomplete reduction with
DIBAL.

To eliminate the carry over of 32, other methods of preparing the

aldehyde 44 were investigated; i.e., PCC, PDC, and Swern. We decided that a
more efficient method of preparing the aldehyde 44 was to fully reduce the ethyl
ester 32 to the alcohol 33 in a similar manner to a literature procedure,68,70
followed by oxidation of the methyl alcohol 33 to the desired aldehyde 44.
Outlined in Scheme 2-9 is the modified synthesis of the key intermediate
45 for the preparation of PROM-NQP (±)-51. The ethyl ester 32 was reduced to
its corresponding alcohol 33 via LiAIH4 reduction at room temperature in Et2 0 to
give the alcohol 33 in a 96% yield. This reaction proceeds smoothly in less than
one hour to give the alcohol, which after quenching the reaction and isolation
from the inorganic salts was of sufficient purity to continue with the next
transformation.

When necessary, the alcohol can be purified by column

chromatography over silica gel eluting with 3:2 EtOAc/hexanes. The aldehyde
44 was generated by Swern oxidation77' 79 (DMSO, COCL and Et3 N), according to
the previous synthesis (Scheme 2-5) the aldehyde 44 was used immediately in
the Horner-Emmons olefination to give the unsaturated ester 45 in a 64% yield
over two steps (Scheme 2-9).
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Bn

DMSO, (COCI)2,

UAIH4 , Et20

EtO
H

O
32

Et3 N, CH2 CI2, -78 °C

33

N ^ " '|
N
' j ^ NvBn

H

Bn

n-BuLi,
(Et0) 2 P(Q)CH2 C 02Et
THF, 0 °C

O

EtO.

Bn

O
44

64%, 2 steps

45

Scheme 2-9: Modified synthesis of the key intermediate 45 for the synthesis of PROM-NQP (±)51.

The reaction sequence outlined in Scheme 2-9 proved more facile for the
preparation of 45 than the previous controlled reduction of the ester with DIBAL
and subsequent Horner-Emmons homologation. Additionally, the purification of
the resulting a,(3-unsaturated ethyl ester 45 proved to be much easier,
considering both the LiAIH4 reduction and Swern oxidation go to completion.
This eliminated the carryover of any of the starting material ester 32 and the
presence of MOM-NQP (±)-31 after coupling was no longer detected.
This left us to determine where the n-propyl side product 52 was being
generated. We proposed that the n-propyl side product 52 may be the result of a
1,4 addition of the hydride to the a,|3-unsaturated system of 45 during the LiAIH4
reduction of ester to the propenyl alcohol 46. A proposed mechanism for the 1,4
hydride addition is detailed in Scheme 2-10. To possibly further support this
mechanism similar conditions of the reaction (Scheme 2-5, Scheme 2-7 and
Scheme

2 -8

) could be run using lithium aluminum deuteride (LiAID4).

The

resulting reaction mixture could be analyzed for the presence of the deutero npropyl product at the 1- and 3-position of the propylene side chain.

38

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

R
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H

H

R

R

H3/
H

H

Scheme 2-10: Proposed mechanism for the production of the n-allyl side product that would lead
to the n-PROP-NQP 52 product after completing the synthetic steps outlined in Schemes 2-7 and

2- 8 .

To eliminate the possibility of the 1,4 hydride addition, saturation of the
alkyl chain of 45 was necessary before LiAIH4 reduction.

If this was to be

accomplished using catalytic hydrogenation, it would be necessary to reduce the
alkene selectively and avoid hydrogenolysis of the N-benzyl groups of 45. To
avoid the possibility of cleaving the N-benzyl protecting groups we looked into the
reduction of the alkene by a non-catalytic hydrogenation technique. A literature
search for the reduction of a,0 -unsaturated esters found that the use of
magnesium metal in methanol reduced unsaturated esters in good yields (6599 % ) . 80,81

For example, Fadel, et al. were able to selectively reduce an a,(3-

unsaturated ester in the presence of a non-conjugated alkene by treatment with
Grignard grade magnesium metal in dry methanol (Scheme 2-11 ) . 80

Mg°, MeOH

CO2M6

CO2MS

Scheme 2-11: Example of a selective reduction of a conjugated system utilizing Mg°.
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According to the literature this was a simple process of reacting the
unsaturated ester with magnesium turnings in methanol, quenching with acid to
consume any remaining magnesium metal, and isolation of the product by
aqueous extraction.

This is a useful reaction when there are non-conjugated

alkenes present (as above) as well as other catalytic hydrogenation sensitive
groups, i.e. cyano and nitrile. The reaction did seem to progress well giving the
saturated methyl ester 53, although the yields were not as expected, ranging in
the 26-32% yield (Scheme 2-12). During the reaction progress a large amount of
baseline material by TLC material was formed, which has been proposed to be
due to chelation of Mg2+ by the piperazine nitrogen atoms.

This is likely,

considering piperazine is a cyclic version of ethylenediamine, a well known metal
chelating agent (Figure 2-4 ) . 82

B n -N

\

N -B n

/ ’

FfeN

Nhfc

/

M g/

Ma>+

Figure 2-4: Chelating potential of piperazine and related chelator ethylenediame.

In light of the failed Mg° reduction we attempted a “gentle” hydrogenation
of 45 using 5% Pd/C and H2 at atmospheric pressure and hydrochloric acid (12
M). When using 12 M HCI the alkene was easily reduced.

Unfortunately the

cleavage of the benzyl groups also occurred, giving compound 54 in a 95% yield
(Scheme 2-12). This was both a positive and negative result, we now knew that
a pressure of 50 psi and 50 °C was not necessary to cleave the benzyl groups, a
standard method in our group. However, selective reduction of the alkene in the
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presence of the benzyl groups was still elusive.

We decided to attempt the

hydrogenation using acetic acid instead of the typical 12 M HCI. A solution of the
dibenzyl a,(3-unsaturated ethyl ester 45 was treated with excess of acetic acid
and a catalytic amount of 5% Pd/C. The reaction was sealed with a septum and
hydrogen was bubbled through the solution. The reduction in the presence of
acetic acid allowed us to selectively reduce the alkene leaving the benzyl groups
intact, thereby giving the saturated ethyl ester 55 in a 78% yield (Scheme 2-12).

Bru
Mg°, MeOH

MeO

Bn

o°c
53
26-32%
Bn.

N

EtO
H
45

H2, 5% Pd/C
'Bn

MeOH, 12M HCI

•2 HCI

H N ^

Et ° Y ^ 4 ^ NH
°

95%

54

H2, 5% Pd/C
MeOH, AcOH

EtO.

Bn

67-78%

Scheme 2-12: Attempted selective reduction of the conjugated alkene of 45.

The saturated propyl ester 55 was reduced to the propyl alcohol 56 with
UAIH4 in Et2 0 (95%, Scheme 2-13) in a similar manner to the one carbon side
chain case (Scheme 1-2).

The propyl alkoxide was generated in DMF using

NaH, and then methylated by the addition of CH3 I to give 57. The benzyl groups
of the free-base form of methoxypropyl 57 were cleaved at

atmospheric

pressure and ambient room temperature hydrogenolysis conditions, as a solution
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in MeOH and an excess of 12 M HCI, to give the dihydrochloride salt of the
piperazine 48 (53%, 2 steps).
The more accessible nitrogen atom was selectively protected with tritylchloride to give the N-trityl-piperazine 49 in a 99% yield. Then 49 was coupled to
2-chloroquinoline utilizing the Gilman coupling conditions and the resulting crude
material was purified by column chromatography (1:9 EtOAc/hexanes). The Ntrityl protected product (not shown) was deprotected in acetone with

6

M HCI,

aqueous workup afforded the desired compound 50 in an 82% yield over two
steps. Selective nitration at the quinoline six position gave the desired 2 -(2 -alkylpiperazin-1-yl)-6-nitroquinoline (±)-51 (99%). The overall synthesis is shown in
Scheme 2-13 and was accomplished in 11 steps with an overall yield of 19%.
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n-BuLi,
(Et0) 2 P(0)CH 2 C 02Et

44
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NaH, CH3 I
Bn

95%
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56

12 M HCI, MeOH
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•2 HCI

H2, 5% Pd/C

C(Ph)3 CI, Et3N

H3 C'

99%

48
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0 2N

1) n-BuLi, 2-chloroquinoline
Et2 0, 0 °C
2) 6 M HCI, acetone

'CPh3

CH2 CI2, 0 °C

53%, 2 steps

Bn

H

78%

45

64%, 2 steps

UAIH4 , Et20

N

N

HN03, h 2 s o 4

N

NH

^q -

82%
(±)-51

Scheme 2-13: Overall synthesis of PROM-NQP (±)-51.

2.4

Synthesis of the Radiolabeling Precursor N-formyl-ProTos-NQP 63.
Upon completion of the synthesis of (±)-51, the focus was turned towards

generating a fluorinated analog with the intent of preparing a radiolabeling
precursor for the introduction of a fluorine-18 atom (Scheme 2-14). The goal
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(±)-51

58

Scheme 2-14: Proposed fluorinated analog 58, to be prepared from PROM-NQP (±)-51.

was to prepare a stable fluorination precursor that was amenable to late stage
incorporation of the fluorine atom by Sn2 displacement technology. We set out to
generate an N-protected-propyl-O-tosylate 59 (Figure 2-5) of compound HOPNQP 146 (not shown).

59
Figure 2-5: N-protected proposed fluorinating precursor.

Our specific approach encompassed the nucleophilic displacement of the
proposed tosylate 59 by F" and subsequent nitrogen deprotection would give the
desired radiolabelled compound 58. To prepare the O-tosyl precursor, PROMNQP (±)-51 needed to be demethylated and the 2° nitrogen atom had to be
protected. Earlier work within the MOM-NQP (±)-31 series found that the MOM
group could be easily deprotected using boron tribromide in good to moderate
yields (Scheme 2-1). Furthermore the nitrogen could be protected with a BOC
group as part of the purification procedure after demethylation. What remained
unknown was whether the propyl version could undergo tosylation reaction, this
would be in contrast to the one carbon side chain version that failed to tosylate.
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Our prediction was that by extension of the carbon chain by two additional
carbons would make the oxygen more available for reaction with tosyl chloride.
When PROM-NQP (±)-51 was treated with boron tribromide under similar
conditions to the MOM-NQP demethylation procedure (Scheme 2-2), we found
that the desired alcohol 146 was generated; additionally a second more non
polar product was also formed.

Mass spectra analysis showed that the side

product was the corresponding alkyl-bromide 62.

The mechanism shown in

Figure 2-6 below provides a rationale for the formation of the two products under
the BBr3 conditions. Unfortunately, due to the high polarity of the 6 -NQP analogs
the bromide could not be easily separated from the desired product by silica gel
chromatography. It was necessary to use a high percentage of methanol in DCM
to elute the products and the resulting separation was poor.

62

Figure 2-6: Explanation for the production of the bromide side product formed during BBr3
cleavage of the methyl ether.
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In order to simplify the purification of the BBr3 reaction we decided that
protection of the terminal amine with a group that is stable to BBr3 conditions
would be beneficial.

Therefore, the free amine of PROM-NQP (±)-51 was

protected as the N-formyl according to Scheme 2-15. Treatment of (±)-51 with
acetic anhydride (AC2 O) as a solution in

88

% formic acid gave the desired N-

formyl-PROM-NQP 60 in a 91% yield .83 Protection of the amine as the N-formyl
group made the purification simple and the use of column solvents that contained
a high percent of MeOH were avoided.

The

resultant N-formyl-2-(3-

methoxypropyl-piperazin-1 -yl)-6 -nitorquinoline was purified using silica gel eluting
with 0.01:5 MeOH/CHCI3.

8 8

N

N

% Formic acid
N

N

Ac20
91%

Scheme 2-15: N-formyl protection of PROM-NQP (±)-51.

The N-formyl-PROM-NQP 60 was treated with BBr3 according to the
procedure developed in the MOM-NQP synthesis (Scheme 2-2).

In brief a

solution of N-formyl-quipazine in DCM at -78 °C was treated with a solution of
BBr3 (500 mol%) then allowed to warm to room temperature, the reaction was
quenched by the addition of a saturated solution of NaHCOs, and the organic
portions were extracted with DCM. We found the N-formyl protecting group to be
stable to the BBr3 reaction conditions. Importantly, by having the terminal amine
tied up as the N-formyl allowed for easy separation of the desired alcohol product
46
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from any unreacted starting material 60 or bromide side product 62. We found
that the BBr3 demethylation of PROM-NQP (±)-51 as the N-formyl amide gave
consistent results where the product alcohol 61 was easily isolated from any side
products by column chromatography with silica gel (6 6 %).

0 2N

o 2n

1) BBr3, CH2CI2. -78 °C

N

N

2) NaHC03(aq)

^

^

66%

X = OH 61 and Br 62

H
60

Scheme 2-16: Cleavage of the methyl ether of N-formyl-PROM-NQP (±)-51.

The N-formyl-HOP-NQP 61 was then treated with tosyl chloride in the
presence of pyridine in DCM at 0 °C for 24 hours to give the O-tosylate 63 in a
53% yield. However, we found that the resulting O-tosylate 63 was very reactive
to nucleophiles present in the reaction mixture. For example, chloride ion that
was generated during the reaction quickly converted 63 to the alkyl chloride 64.

° 2N
k

JL

H 0^

A

- ^

Tosyl-CI, pyridine

^

k
H

^

0

CH2CI2, o - r t ° c

H
H

51%

61

X = OTs 63 and Cl 64

Scheme 2-17: Synthesis of N-formyl-ProTos-NQP 63.

This result was not surprising considering the mixture of products formed
during demethylation with BBr3 . With NMR analysis it was determined that the
reaction gave a 1:1 mixture of tosylate 63 to chloride 64. The two products could
be carefully separated by column chromatography (1:1 EtOAc/CHCh). However,
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the mixture was typically carried forward to the fluorination step (Scheme 2-17),
and extensive purification was undertaken only when the precursor was to be
shipped to LBNL for radiofluorination.

2.5

Nonradioactive Fluorinations of N-formyl-ProTos-NQP 63.
To investigate the usefulness of 63 as a radiolabeling precursor, trial

fluoride ion substitutions (tetrabutylammonium fluoride, TBAF) and subsequent
deprotections (4 M H2 S 0 4) were performed.

We found that N-formyl-ProTos-

NQP 63 was readily fluorinated with TBAF in THF at 60 °C. The crude reaction
was subsequently concentrated in vacuo and then quickly purified by flushing
through a silica plug. The N-formyl group was removed using 4 M H2SO4 , at 50
°C, to give the desired fluorinated product PROF-NQP 58 in a 58% yield over 2
steps (Scheme 2-18).

TBAF, THF
55 °C
H
64%

THF, 55 °C

65

NH

90%

Scheme 2-18: Fluorination sequence to prepare PROF-NQP 58.
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r
H

With the fluorination and deprotection steps accomplished the tosylate
precursor 63 was purified and shipped to our collaborator Dr. O’Neil at LBNL for
trial radiofluorination and deprotection.

2.6

Radiofluorination of N-formyl-ProTos-NQP 63.
Based upon successful non-radioactive fluorination of the O-tosylate 63,

the precursor was shipped to LBNL for radiofluorination trials.

Outlined in

Scheme 2-19, is an overview of the radiofluorination attempts to give [18F]58.
The synthesis of [18F]58 was accomplished in 2 synthetic steps from the N-Boctosylate precursor 63.

ACN, 100 °C
N

N

N " 'N '
I
H

1 0

min

H
[ F]65

80% Activity

Silica plug
EtOAc

100 °C, Vacuum
H18F
40% Activity
4 N H 2 S 04, 80-100 °C; 10min
Sep-Pak;
C-18 HPLC

N

N

[18F]58
8-10% Actvity
Scheme 2-19: Initial radiofluorination trial using N-formyl-ProTos-NQP 63 to give [ F]PROF-NQP
58.
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Displacement of the O-tosylate with [18F“] is afforded utilizing tetrabutyl
ammonium [18F]fluoride (TBA 18F) in acetonitrile (ACN) at 100 °C (80-90%
incorporation). After heating the reaction mixture was purified from any inorganic
material by elution through a silica plug with ACN, radioactive survey showed
80% activity.

Concentration of the eluent under vacuum at 100 °C and

subsequent survey showed 40% activity and a 40% loss in activity. The loss of
activity was attributed to defluorination of the fluoroalkyl to give H 18F. The crude
material containing [18F]65 was deprotected with 4 N

H 2S O 4

at 100 °C, quenched

with NaOH(aq) and initially purified using a C-18 Sep-Pak, eluting the desired
fraction

containing

semipreparative

[18F]58 with

HPLC

(65:35:0.2

MeOH.

Purification

Me0 H/H2 0 /Et3 N)

of the

isolated

eluent
the

by

desired

radioactive fraction containing [1SF]58 in a 8-10% EOB decay corrected yield.
We were concerned with the large loss in radioactivity when the silica plug
eluent was concentrated and during the deprotection of the N-formyl protecting
group. It seemed that at high temperatures (80-100 °C) a large amount of H18F
was produced. Attempts to circumvent high temperature deprotection conditions
(4 N H2SO 4 and 16 M H2 SO4 at ambient temperature, as well as basic
deprotection with NaOH) resulted only in incomplete deprotection of [18F]65 to
give the desired product [1SF]58.
2.7

Synthesis of the Precursor N-Boc-ProTos-NQP 69.
The losses of activity during heating cycles and during deprotection of the

N-formyl group lead us to investigate the preparation of a similar precursor with a
protecting group that would be removed under more facile conditions.
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The

nitrogen protecting group ferf-butyl carbamate (N-Boc) was used with relative
ease in our laboratory as a tool for purifying polar compounds, i.e. HOM-NQP 38
and MOM-NQP (±)-31. For example, we had found that deprotection of N-Boc
compounds with H2 S 0 4 routinely gave the desired amine product in excellent
purity in 5 minutes or less. Using the same BBr3 procedures as already outlined
for MOM-NQP (±)-31 and N-formyl-PROM-NQP 60 (Scheme 2-16), PROM-NQP
(±)-51 was treated with BBr3 accordingly and the reaction was quenched and the
product was extracted with DCM. The DCM portion was dried, filtered and
concentrated to a 5-10 ml volume and an excess of di-ferf-butyl-dicarbonate was
added (Scheme 2-20).

° 2

N s

/

^

v

°2N

^

1) BBr3, CH2 CI2, -78 °C
N

N

2) [(CH3 )3 C 0C 0] 2 0, CH2 CI2, 0 °C

H

.

H

44%, 2 steps
X = OH

6 6

B“

, Br 67, and di-Boc

6 8

Scheme 2-20: BBr3 methyl ether cleavage of PROM-NQP and subsequent protection as the NBoc to give N-Boc-HOP-NQP 66.

Examination of the crude reaction by TLC after treatment with Boc20
showed the expected N-Boc protected alcohol 66 and bromide 67. However,
upon concentrating in vacuo any excess unreacted Boc20 reacted with the
alcohol group forming the respective carbonate product 68.

Thus, with this

reaction workup three products were formed, including the mono-Boc-HOP-NQP
66, the di-Boc-HOP-NQP 68 and Boc-bromo-NQP 67.

In other experimental

attempts when there was a large excess of Boc20 used all of the alcohol was
protected as the carbonate giving di-Boc-HOP-NQP 68 and the Boc-bromo 67
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

in the workup mixture. The presence of the N-Boc made purification of these
quipazines very easy (silica gel), where the three products could be separated by
column chromatography eluting with a mixture of EtOAc/hexanes.
carbonate group of

68

The

could then be selectively deprotected over the carbamate

moiety by heating to 50 °C in MeOH with an excess of powdered
the desired N-Boc-HOP-NQP

66

K 2 C O 3 ,

to give

in a 72% yield (Scheme 2-21).

K2 C 03, MeOH

68

72%

66

Scheme 2-21: Selective cleavage of the undesired Boc carbonate 6 8 .

The N-Boc protected HOP-NQP

66

could then be tosylated in a similar

fashion to the N-formyl case, giving N-Boc-ProTos-NQP 69 in a 76% yield
(Scheme 2-22).

However, the reaction conditions were improved to limit the

amount of propyl chloride side product formed, by simply increasing the amount
of pyridine to 600 mol% and tosyl chloride to 420 mol%.

Tosyl-CI, pyridine

76%
66

69

Scheme 2-22: Tosylation of N-Boc-HOP-NQP to give the fluorination precursor N-Boc-ProTosNQP 69.
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The excess pyridine acts as a scavenger of the chloride generated during
the reaction.

The resulting Boc protected tosyl quipazine 69 was fluorinated

using the technology developed for the N-formyl case (Scheme 2-23). A solution
of 69 in dry THF was treated with 150 mol% of TBAF and heated to 55 °C. The
crude reaction mixture was concentrated, purified (silica gel) to give N-BocPROF-NQP 70. The benefit gained from the new protecting group was that the
Boc group could be removed in under 5 minutes at room temperature using
concentrated sulphuric acid to give the desired fluorinated product PROF-NQP
58 in a 78% yield. The ease by which the Boc group could be removed was
thought to be very useful for the radiolabeling protocol.

TBAF, THF, 55 °C;

69

78%

58

Scheme 2-23: Trial fluorination of 69 with TBAF Boc group deprotection to give PROF-NQP 58.

An important caution and downfall of this method is that when quenching
the deprotection, one must be diligent in maintaining a cool temperature or risk
defluorination. The need to maintain a cool temperature for deprotection further

substantiates the results from the LBNL fluorination trials with 63.

We have

found the fluorinated product 58 is very easy (under aqueous acidic conditions)
to form a very polar oxidized species. The side product has been hypothesized
to be the result of elimination of the fluoride and possibly further oxidation of the
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alkene. However, the polar side product to date has not been formally isolated to
determine its identity.

2.8

Radiofluorination Attempts of N-Boc-ProTos-NQP 69.
After the successful preparation of nonradioactive PROF-NQP 58 by

utilizing the nitrogen protecting group Boc, we shipped the tosylated precursor 69
to LBNL for further [18F'] fluorination attempts.
methods were attempted.

Two separate fluorination

The first trial, as outlined in Scheme 2-24, used

Kryptofix 222 (K222), KHC03, Ag18F in ACN at 100 °C, followed by Boc
deprotection (H2SO 4 ) and purification. The second trial outlined in Scheme 2-25
was attempted according to the N-formyl case (Scheme 2-19) utilizing TBA18F in
ACN at 100 °C, and similarly deprotected.
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2.9

Radiofluorination Attempts with K222, KHCO3 and Ag18F.

KHCO3 , K222, Ag18F
TsO.

'Boc

ACN, 100 °C, 11 min
'Boc

Silica plug
ACN
16 M H2 S04, 4 min
Sep-Pak, MeOH elution

Water Fraction
43% Activity
H18F

36% Activity
C-18 HPLC
K222 =

n\

oV

o\

n

OoN
N

N

[18F]58
1.6 % Actvity
Scheme 2-24: Radiofluorination sequence utilizing K222, K H C 03, and Ag18F with the precursor
N-Boc-ProTos-NQP 69.

As outlined in Scheme 2-24, a dry solution of K222, KHCO 3 , and Ag18F in
ACN was prepared in a 4 mL vial and transferred to a vial containing a solution of
tosylate 69 in ACN. The reaction mixture was heated at 100 °C for 11 min and
then cooled on ice. The cooled reaction mixture was treated directly with H2 SO4
(16 M) to deprotect [18F]70, after 4 min the deprotection was quenched by adding
to a dilute solution of NaOH (1%), and loaded onto a C-18 SepPak. The SepPak
was washed with water and radioactive survey showed 43% activity in the wash.
The desired fraction eluted from the SepPak with methanol afforded the fraction
containing [18F]58 with 36% activity. Further purification of the SepPak eluent by
semi-preparative reverse phase HPLC (65:35:0.2 MeOH/Water/TEA) gave the
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desired fraction (eluting at 7.6-9.5 min) containing [18F]58, radioactive survey
showed 1.6% activity. Analytical HPLC (70:30 MeOH/O.17 M NH4 CO2 H, 0.5%
AcOH) confirmed the product eluting at 4.6 min. The synthesis was successful in
generating the desired radiolabelled product [1SF]58 in a 1.6% EOB decay
corrected yield.

However, the yield was considerably lower than earlier trials

using the N-formyl protecting group (8-10% EOB decay corrected yield, Scheme
2-19).
A second fluorination attempt was made using the same procedure
outlined above (Scheme 2-24). However, TLC analysis of the initial fluorination
was performed to determine if incorporation of the radionuclide was giving the
expected product [18F]70. As before, a dry solution of K222, KHC03, and Ag18F
in ACN was prepared in a 4 mL vial, treated with a solution of tosylate 69 in ACN,
heated at 100 °C for 11 min and then cooled. The crude mixture was purified by
elution through a silica plug with ACN.

Radioactive TLC analysis showed the

presence of two radioactive products eluting close to the expected product
[18F]70 Rf, product one, Rf = 0.422 and product two, Rf = 0.584 (2:3
EtOAc/hexanes) (Figure 2-7).

We were concerned with the presence of two

radioactive products and decided that returning to the original conditions
(TBA 18F) attempted with the N-formyl case (Scheme 2-19) would be beneficial.
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Figure 2-7: Radioactive TLC analysis after initial fluorination and silica purification of the K222
radiofluorination trial, showing two possible Boc protected fluorinated products.

2.10

TBA18F Radiofluorination Attempts.
As outlined in Scheme 2-25, a solution of the tosylate 69 in ACN was

treated with a solution of TBA18F in dry ACN and the reaction was heated at 100
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°C for 12 min. The reaction was cooled and flushed through a silica plug with
acetonitrile, with the desired fraction having 49% activity by radioactive survey.
Analysis of the silica plug eluent by radioactive TLC (3:2 EtOAc/hexanes)
showed one major spot (Rf = 0.59) and one minor spot (Rf = 0.48)(Figure 2-9).
The eluent was treated with H2 SO4 (16 M) at 0 °C for 9 min, quenched by dilution
into 1% NaOH (30 ml_), and loaded onto a C-18 SepPak.

The water flush

contained 41% of the radioactivity, and elution of the SepPak, to isolate the
product fraction, contained 3.6% of the original radioactivity.

At this point we

were already at a lower possible yield of [18F]58 than the N-formyl trials utilizing
TBA18F or the K222 trial with the N-Boc-ProTos-NQP 69 precursor (Scheme 224). Purification of the SepPak methanol eluent by HPLC gave the desired peak
[18F]58 eluting at 8.5-9 min with 0.6% EOB decay corrected yield.
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C-18 HPLC
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[ °F]58
0.6% Actvity
Scheme 2-25: Radiofluorination sequence utilizing TBAF.

A second trial was performed and the reaction process was stopped after
silica gel purification of the fluorination mixture (Scheme 2-25).

Again we

analyzed the purified reaction mixture by radioactive TLC. Included on the TLC
plate was a lane for the nonradioactive standard 70 and a lane for the silica gel
eluent expected to contain [18F]70.

This allowed us a direct comparison of

[19F]58 and [18F]58 and any other radiofluorinated Boc protected compounds. To
enable direct comparison, the solvent front, baseline and UV active spot
corresponding to [19F]58 were spotted with a sample of radiation to enable the
use of the radioactive TLC analyzer.

The TLC analysis of the nonradioactive

standard [19F]70 is shown in Figure 2-8.

From the nonradioactive lane we

determined that the desired product [18F]70 should have an Rf = 0.516. Figure
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2-9 shows the second lane containing the silica gel plug ACN eluent.
Comparison of the two TLC lanes shows the desired product is only 20% of the
mixture. The other TLC spot was 54% of the mixture

{R f

= 0.631), could be a

second fluorination product with a similar elution profile as the desired product.
Producing only 20% of the desired product [18F]70 during the fluorination
attempt, helps to explain why we were only able to produce 0.6% of the desired
labelled compound in the first TBA18F trial. Additionally if the compound is labile
to acidic conditions as we saw in the N-formyl case, then treatment of the ACN
eluent from the silica gel plug would likely cause a further decrease in the yield of
[18F]58.
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Method: EXAMPLE

File: JPOR5048B.RG01

10000

8000

6000

4000

2000

100

50

150

Position (mm)

(mm) (mm)
(mm)
Reg_____ Start Stop Centroid
Rgn 1
Rgn 2
Rgn 3

12L9
27J
67.1 79.3
116.7 129.8

RF

20 0 0.000
72.7 0.512
122.7 0.997

3 Peaks

Region
Region
Counts_____ CPM

% of
Total

% of
ROI

34897.0
42461.0
44307.0

34897.0
42461.0
44307.0
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34.63 36.42

121665.0

121665.0
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Figure 2-8: Radioactive TLC analysis of the N-Boc-PROF-NQP 70, co-spotted with radiation at
the baseline, front and on the product spot to allow for direct comparison to the radiofluorination
attempt.
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File: JJPOR5048A.R001
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Figure 2-9: Radioactive TLC analysis of the fluorination of 69 after silica gel purification. Two
products are visible with the smaller eluting at the same Rf as 70.

2.11

Fluorination Control Reactions.
To explain the second fluorinated product observed in the K222 and

TBA18F radiofluorination attempts we set out to attempt to reproduce the results
in our lab. It was hypothesized that at the high temperature of the fluorination
reaction that nucleophilic aromatic substitution (SnA ^ could occur. To determine
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if the aromatic system of the

2 -(2 -alkyl-piperazin-1 -yl)-6 -nitroquinolines

was

susceptible to fluoride attack, N-Boc-n-PROP-NQP 71 was used as a test ligand.
Outlined in Scheme 2-26 is the nonradioactive control reaction with 71.
Treatment of 71 with NaHC0 3 (600 mol%), K2 2 2 (1000 mol%) and KF (800
mol%) and heating at 100 °C for 10 min produced a new spot by TLC
3:2

EtOAc/hexanes),

purification

by

silica

gel

pipette

(R f

= 0.44,

column

(2:3

EtOAc/hexanes) the fluoride substitution product 72 was isolated in a 25% yield.
Proton NMR of the new product shows a distinct change in the aromatic system
that is consistent with substitution at the quinoline 6 -position.

K222 , NaHC03, KF
ACN, 100 °C, 10 min
Boc

Boc
72

Scheme 2-26: Trail nucleophilic fluorine substitution of N-Boc-n-PROP-NQP 71.

With successful incorporation of a fluoride atom onto the 2-(2-alkylpiperazinyl)-6 -nitroquipazine system we looked to repeat the results using the
radiolabeling precursor 69 in two separate control reactions.

Scheme 2-27

describes the fluorination control reaction according to the procedure used with
the N-Boc-n-PROP-NQP 71 control reaction. Accordingly, 69 was heated as a
solution in ACN at 100 °C for 10 min with K222 (1000 mol%), NaHC0 3 (600
mol%), and KF (1000 mol%).

This gave two products by TLC analysis and

separation of the products was afforded using silica gel chromatography (2:3
EtOAc/hexanes).

NMR analysis of the more nonpolar product

(R f

= 0.5, 3:2

EtOAc/hexanes) suggests the product is the result of nucleophilic fluoride
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substitution of the tosylate in addition to the aromatic substitution to give 73. The
more polar product

(R f

=

0 . 4 , 3:2 EtOAc/hexanes) by NMR comparison to

standards is the expected fluorination product N-Boc-PROF-NQP 70.

NaHC03, K222, KF

70
Scheme 2-27: Trial nucleophilic fluorine substitution with an excess of KF.

We were then interested as to what a control reaction would give using the
ratios resembling the radiolabeling protocol (K222 (1000 mol%), NaHC0 3 ( 6 0 0
mol%), but KF (50 mol%)) was used as a limiting reagent (Scheme 2-28). Using
the same procedures outlined above tosylate 69 was heated at 100 °C for 10
min, giving two products by TLC analysis of the crude reaction. The products
were purified by silica gel pipette column (1:3 EtOAc/hexanes to elute 70, and
3:2 EtOAc/hexanes to elute 66) and analyzed by NMR. The product with an Rf of
0.55 was N-Boc-PROF-NQP 70, the more polar product

(R f

= 0.2) is the result of

nucleophilic fluoride attack at the sulfur of the tosyl group to give the alcohol 66 .
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Scheme 2-28: Trail nucleophilic fluorine substitution using KF as a limiting reagent.

Based upon the fluorination control reactions it seems likely that the
difluoro species 73 is the anomalous radiofluorinated product observed during
the TBA18F and Ag18F radiofluorinations. As shown in Scheme 2-29, TBAF has
been used with successfully to displace aromatic nitro groups in the preparation
of fluoro-substituted pyridines 75 from 2, 3, and 4 nitropyridines 74, and as an
alternative for the Balz-Schiemann reaction (Scheme 2-29).84 Additionally, the
use of KF has been also been shown to give aromatic substitution by
fluorodenitration of nitropyridines.85 In order to determine if the difluoro 73 is the
unknown product of radiofluorination a standard sample would need to be sent to
LBNL, the radiofluorination attempted again and isolation of the side product for
HPLC comparison completed.
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R

TBAF, DMF

74

75

D

1)NaN02, HBF4

-fN H 2
2) A

N

Balz-Schiemann reaction
Scheme 2-29: Example fluoride aromatic nucleophilic substitution of nitropyridines using TBAF.

Based upon the three trial radiofluorinations, it is likely that the N-formyl
precursor 63 would be more suited for the preparation of the radioligand PROFNQP 58. The N-formyl case resulted in a much higher yield (8-10% EOB decay
corrected yield) of [18F]58 compared to either fluorinations using the Boc
precursor 69. In addition to a better radiofluorination yield the preparation of the
N-formyl tosylate precursor 63 is far more facile to produce, especially
considering

the

nitrogen

protecting

group

(N-CHO)

is

in

place

before

borontribromide cleavage of the ether. Also, BBr3 demethylation of the N-formylPROM-NQP 60 is more consistent than the Boc series (Scheme 2-22). With the
improvements of the tosylation conditions the likelihood of generating the
chloride side product 64 (Scheme 2-17) is diminished, thus improving the
tosylate yield and eliminating the need for cautious purification of 63.

2.12

Synthesis Pent-NQP (±)-83 and PentF-NQP 88.
As shown in Scheme 2-30 the universal starting material ester 32 for our

quipazine syntheses was reduced by LiAIH4 to give the alcohol 33 in 96% yield.
Swern oxidation of the alcohol followed Horner-Emmons olefination furnished the
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unsaturated ester 76 in a

66

% over 2 steps.

Catalytic hydrogenation at

atmospheric pressure with 5% Pd/C in MeOH and acetic acid gave the saturated
ester 77 in 78% yield.

The ester was reduced with UAIH 4 to give the pentyl

alcohol 78 (95%). Subsequently, the alkoxide was generated with NaH in DMF
and alkylated with iodomethane to give 79 in a 60% yield. Hydrogenolysis of the
benzyl groups utilizing 5% Pd/C in MeOH and HCI gave the pentyl piperazine
dihydrochloride 80 (quantitative yield), which was protected at the least hindered
amine with trityl chloride to give the N-trityl piperazine 81 (99%). The protected
piperazine was coupled to 2-chloroquinoline using the typical Gilman coupling
and subsequent deprotection with
82 (58%, 2 steps).

6

M HCI in acetone gave the pentyl quipazine

Selective nitration with HNO3 in sulphuric acid gave the

desired 2-pentyl-nitroquipazine (±)-83 (quantitative yield). Together, (±)-83 was
afforded in

11

steps in an overall yield of 16%.
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Bn =

0 °C

NH
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(±)-83

Scheme 2-30: Overall synthesis of Pent-NQP (±)-83.

The free amine of Pent-NQP (±)-83 was protected as the N-formyl
according to the procedures described in the propyl synthesis (Scheme 2-31) to
give 84 in a 97% yield. Treatment with BBr3 to generate the desired alcohol for
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subsequent tosylation, only gave the bromide product 85 in a 93% yield.

To

generate the tosylate from the bromide a new technique was used. We found
that the pentyl bromide could be transformed to the tosylate 86 by treatment with
silver tosylate (AgOTs),86 in a Finkelstein-like reaction.

For this reaction, the

nucleophilic O-tosylate group displaces the bromide affording the AgBr solid.
Treatment of N-formyl-PentBr-NQP 85 with an excess of AgOTs at 50-60 °C
gave the desired tosylate 86 in a 88% yield.

Fluoride ion displacement of

tosylate 86 was accomplished using TBAF conditions developed for the propyl
series to give 87 in a 84% yield.

Subsequent N-formyl deprotection with 4 M

H2 SO4 at 50 °C gave 88 (91%). To date, no further work has been attempted to
examine radiofluorination of 86.

8 8

B B f3 , C H 2 C I2

% Formic acid

NH
H
(—)-83

97%
84

AgOTs, CH3CN

H
85

TBAF, THF

H

88%

H
87

86

91%

H
88

Scheme 2-31: Synthesis of PentF-NQP 88.
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84%

2.13

Synthesis o f BuM-NQP 96.
The BuM-NQP analog 96 was synthesized from the common dibenzyl

starting material 32 according to Scheme 2-32.

The dibenzyl alcohol 33 was

oxidized by Swern oxidation, followed by Horner-Emmons olefination (64%, 2
steps) to give the a,p-unsaturated ester 45. The alkene of 45 was reduced with
H2 and 5% Pd/C (78%), then the ester 55 was reduced with LiAIH4 to provide the
propyl alcohol 56 (95%).

Swern oxidation of 56 gave the aldehyde 89 and

subsequent Wittig olefination with ethyltriphenylphosphonium bromide gave the
butylene 90 in 74% yield over 2 steps. The butyl alcohol 91 was prepared by
hydroboration of 90 with 9-BBN followed by oxidation gave 91 in a 73% yield. At
this stage we found that careful purification of the dibenzyl alcohol away from any
1,5-cyclooctanediol (see inset) that is generated after quenching of the borane
reagent was necessary.

If 91 is not carefully purified by chromatography, the

following methylation reaction results in a much lower yield (6-10%). We found
that monitoring the column chromatography of the alcohol product by TLC and
staining

with

vanillin

aided

in

determining

the

presence

of

the

1,5-

cyclooctanediol.
After purification, the alcohol 90 was methylated with iodomethane (DMF,
NaH, 61%). The benzyl groups were cleaved catalytically with H2 and 5% Pd/C
to give the desired piperazine hydrochloride 93 in 98% yield. The least hindered
amine of the piperazine was protected as the N-trityl and the protected
piperazine 94 (94%).
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Scheme 2-32: Overall synthesis of BuM-NQP 96.
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The trityl piperazine was coupled to 2-chloroquinoline according to the
method of Gilman.

Deprotection gave 95 in a 63% yield (2 steps).

nitration at the

6 -position

quipazine 96 in

88

Selective

of the quinoline ring gave the desired methoxybutyl

% yield. The BUM-NQP target ligand was prepared from the

dibenzyl ester 32 in 14 steps in an overall 7.7% yield.
The Boc protected alcohol N-Boc-BuOH-NQP 97 was prepared from BuMNQP 96 by treatment with BBr3 , treatment of the crude workup mixture with diferf-butyl-dicarbonate gave 97 in a 44% overall 2 step yield (Scheme 2-33). The
N-Boc-BuOH-NQP

intermediate

is

ready for tosylation

and

subsequent

fluorination when needed.

NH

2) [(CH3)3C 0C 0]20, CH2CI2, 0 °C

96

44%, 2 steps

Boc
97

Scheme 2-33: Synthesis of N-Boc-BuOH-NQP 97.

2.14

Summary and Conclusion.
The syntheses of new 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines have

been described, including PROM-NQP (±)-51, PROF-NQP 58, Pent-NQP (±)-83,
PentF-NQP 88, and BuM-NQP 96.

The syntheses of these analogs has

furthered our SERT SAR study by expanding upon the lead compound
22.

6 -NQP

We are interested how the 2-alkyl-piperazine substitutions affect SERT

binding affinity, particularly to probe the Ar2 binding domain described by the
pharmacophore model. The in vitro competitive binding studies of a select group
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of the ligands prepared here is described in Chapter 4. Furthermore, the PROMNQP (±)-51 ligand was useful in the preparation of two radiofluorination precursor
N-formyl-ProTos-NQP 63 and N-Boc-ProTos-NQP 69.

The synthesis of the

precursors 63 and 69, along with the initial nonradioactive and radioactive
fluorinations

were

used

as

foundational

synthetic

sequences

and

radiofluorination experiments for the analogous radioligand MePROF-NQP 148.74
The initial radiofluorination results with the N-formyl-ProTos-NQP 63 suggests
that [18F]PROF-NQP 58 is a plausible PET radioligand. The radiosynthesis using
63 should be revisited now that we have more knowledge from the N-BocProTos-NQP 69 radiolabeling trials. There is more work to be accomplished in
understanding the major side product formation from the N-Boc-ProTos-NQP 69
radiolabelling trials. It would be very intriguing to determine if fluoride substitution
of the aromatic nitro group is really occurring. If indeed there is aromatic fluoride
substitution occurring, perhaps a second generation of our compounds could be
prepared that possesses a dual fluorine-18 label.
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Chapter 3
Synthesis of Asymmetric Targets
3.1

Chiral Nitroquipazine Ligand Studies.
Described in this chapter are the chiral syntheses of

6 -NQP

SERT

analogs previously prepared in racemic form, including, MOM-NQP (±)-31,
PROM-NQP (±)-51 and Pent-NQP (±)-83. The chiral syntheses utilize the amino
acids glycine, serine and glutamate to form the piperazine ring structures. The
use of the optically pure forms of serine and glutamate eliminates the need for
later separation of a racemic mixture by HPLC or diastereomeric salt formation.
Chiral pharmaceuticals are commonplace in the drug industry.

A number of

commonly used drugs are sold as the racemic mixture, including ibuprofen
(Advil), citalopram HBr (±)-7 (Celexa), cetirizine HCI 99 (Zyrtec), methylphenidate
100 (Ritalin), and fluoxetine HCI 10 (Prozac) (Figure 3-1).

The application of

chiral drug development as well as “chiral switches” 87 (the development of chiral
drugs from their racemic mixture) has become a major focus to industry as more
studies

show

the

importance

of

stereoisomer

distinction

within

many

pharmacological therapies .88,89 Of the racemates mentioned above (98, (±)-7,
99, 100) all except fluoxetine 10 are currently licensed to be sold as their more
potent or preferred enantiomeric form under new brand names. The benefits of
producing enantiomerically pure forms of a racemic drug include diminished side
affects, reduction in dose, among other features. For example, the active form of
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ibuprofen, (S)-ibuprofen has a markedly faster onset of action than the racemic
form and is currently licensed in Austria and Switzerland.

CH
CHg
h 3c

^
ch3

f= 0

ho

Cl
Ibuprofen, 98

(±)-Citalopram, 7
O

Cetirizine, 99

HN

F,C

Methylphenidate, 100

Fluoxetine, 10

Figure 3-1: Example commercial drugs sold as a racemic mixture.

One of the most historically noteworthy examples on the differences
between enantiomeric drug forms is that of thalidomide. In the early 1960’s the
racemic form of thalidomide was given to pregnant mothers during their first
trimester of pregnancy as a sedative.

Sadly, it was later determined that

thalidomide resulted in the birth of ‘thalidomide babies’ that were characterized
by incomplete or missing arms and legs.

The discovery of thalidomide birth

defects lead to the removal of the drug from use. It was later proposed that the
teratogenic properties of thalidomide were attributed only to the (R)-(+)~
thalidomide enantiomer 101 (Figure 3-2).
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(R)-(+)-Thalidomide, 101
Figure 3-2: Sedative (R)-(+)-Thalidomide 101 found to cause birth defects.

The work with the chiral forms of fluoxetine 10 and citalopram 7 are
especially interesting for our research. The difference in binding potency to the
SERT target for their enantiomers suggests that the synthesis of chiral analogs of
our

2 -(2 -alkyl-piperazin-1 -yl)-6 -nitroquinolines

selective agents.

may result in more potent and

Each enantiomer of fluoxetine 10 have progressed through

phase II clinical development for their separate pharmacological actions; (R)fluoxetine

10

for its antidepressant qualities and associated fast tissue washout

and (S)-fluoxetine 10 for the prevention of migraines. Particularly interesting is
the enantiomer (S)-citalopram 7 (escitalopram) that is -150 times more potent
than the enantiomer (R)-citalopram 7 for rat SERT (rSERT)

90

and -3 0 times

more potent for human SERT (hSERT) . 90,91
3.2

Chiral Piperazine Syntheses.
As in many pharmacologically active agents, including the 2-(2-alkyl-

piperazin-1 -yl)-6 -nitroquinolines we have prepared, the racemic qualities of the
ligand is due to alkyl-substitutions of the piperazine ring.

The piperazine ring

system is an integral part of a number of biologically active ligands, that include:
c-receptor

agents,92

K-opiod

receptor

antagonists,93

inhibitor,94 and an H1-receptor antagonist.95

farnesyltransferase

Considering the selectivity of
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receptors for specific piperazine ring ligand enantiomers, the synthesis of
enantiomerically pure piperazine ring structures is important.
A brief review of the literature found multiple articles focusing on the
preparation of chiral piperazine rings for a number of pharmacological ligands.
The literature includes diastereomeric salt formation ,96,97 the use of chiral building
blocks i.e. amino acids,

92_94’98

diastereoselective hydrogenation,99 and kinetic

resolutions with bacterial cells and enzymes.100,101 Of particular interest to our
group was the preparation of chiral piperazines utilizing amino acids as the chiral
building blocks (Figure 3-3 ) . 93,94,98

Bn

h 3c o

Naylor, 1993
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Dmb = 2,4-dimethyoxybenzyl

Figure 3-3: Potential chiral piperazine syntheses utilizing amino acid building blocks.
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3.3

Synthesis of Chiral MOM-NQP 31.
The rSERT binding potency

(K j)

of the racemic forms of Me-NQP (±)-30,

MOM-NQP (±)-31, and PROM-NQP (±)-51, and also the evidence of preferred
transporter binding site selectivity for enantiomerically pure ligands (escitalopram
(S)-10) led us to investigate the synthesis and biological potencies of the related
enantiomers for our ligand series.
accomplished

utilizing

the

The synthesis of (R)- 30 and (S)-30 were

commercially

available

(R )-

and

(S)-2-

methylpiperazine hydrochloride salts (Sigma Aldrich), according to procedures
used in the Gerdes laboratory (Scheme 1-3) . 72

Attempts at preparing the ( R )-

and (S)-2-methoxymethyl-piperazine diastereomeric salts using D- and L-tartaric
acid according to the procedure of Kawachi et al. failed .96

Following their

procedure our efforts to generate the diastereomeric salts resulted in the
formation of oils. The diastereomeric salt formation method of producing analogs
of ( R )- and (S)-2-methoxymethyl-piperazine was abandoned.

However, we

opted to utilize the method of Naylor et al. (Scheme 3-3) to synthesize the
piperazine ring structure using amino acids as chiral building blocks.

The

synthesis of chiral MOM-NQP 31 outlined in Scheme 3-3 is adapted from a
synthesis

of

2-hydroxymethyl-4-benzylpiperazine

(S)-113

according

the

procedure developed by Naylor et al. as described below .93

3.3.1 Synthesis of N-Boc-N-Bn-glycine.
To begin the synthesis of chiral MOM-NQP, we needed to prepare the
starting material N-Boc-N-Bn-glycine 111 from glycine 109 (Scheme 3-1 ) . 102,103
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NaOH, Boc20

Rn
"N
A

110

X 0 2H
111

Scheme 3-1: Synthesis of N-Boc-N-Benzyl-glycine 111.

A warm solution of glycine 109 in 1:1 EtOH/hkO is treated with potassium
hydroxide (KOH) and benzyl-bromide (BnBr), then heated to reflux for 2 hours.
The crude solution is concentrated by 20%, then the reduced solution is boiled
while acetic acid (AcOH) is added, to give the free acid of dibenzyl-glycine (not
shown) as a white precipitate (79 %

) . 102

Dibenzyl-glycine is converted to mono-

benzyl-glycine 110 by catalytic hydrogenolysis with a Parr hydrogenator (5%
Pd/C in methanol (MeOH) and 12 M HCI) at an initial pressure of 50 psi.102 The
catalyst is removed by filtration and the reaction mixture is concentrated giving
the mono-benzyl-glycine HCI 110 in a 98% yield. Product 110 was converted to
N-Boc-N-Bn-glycine 111 by treatment with B0 C2 O as a basic solution in 1:1
H2 O/1 ,4-dioxane gave 111 in a

66

% yield according to the method of Bail et al. 103

3.3.2 Synthesis of 1-Benzyl-3-(hydroxym ethyl)piperazine 113.
The

preparation

of the

chiral

piperazine

(S)-113

from

D-serine

hydrochloride is shown in Scheme 3-2; the (#?)-113 enantiomer is prepared in a
similar procedure from L-serine hydrochloride .93 The methyl ester of D-serine D102 is coupled to the pentafluorophenol activated ester of N-Boc-N-Bn-glycine
111 (EDC hydrochloride and pentafluorophenol (PFP ) ) . 93 The dipeptide is easily
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purified by column chromatography eluting with 3:2 EtOAc/hexanes, to give ( R )N-Boc-N-Benzyl-glycyl-D-serine methyl ester (/?)-112 in a 96% yield. The Boc
group of the dipeptide is removed by treatment with SOCb in MeOH and
concentration in vacuo, and then triturated with Et2 0 to give the corresponding
HCI salt (not shown). The N-Boc deprotected dipeptide is dissolved in MeOH
and treated with NH4 OH, aqueous workup and extraction with 4:1 IPOH/CHCI3
gives the cyclized piperazinedione (/?)-103. Reduction of (#?)-103 with LiAIH4 in
refluxing THF affords the desired 2-hydroxymethyl-4-benzylpiperazine (S)-103
(note the stereochemistry switch from R to S after reduction). We considered
(S)-2-hydroxymethyl-4-benzylpiperazine to be a chiral structural equivalent to the
racemic 1,4-dibenzyl-2-hydroxymethyl-piperazine 33, requiring only protection of
the 2° nitrogen and the alcohol group for Gilman coupling to 2-chloroquinoline
according to the racemic syntheses (Scheme 1-2 and Scheme 2-13).

CO2M6

EDC —
N-Boc

SOCI2, MeOH;

Et3 N, CH2 CI2

Bn

O

H

N H 4O H ,

(R)-112

D-102

O
reflux

(R)-103

Scheme 3-2:

(S)-113

33

Synthesis of the key synthetic intermediate (S)-113.
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MeOH

3.3.3 Synthesis of Chiral MOM-NQP 31.
After

completion

of

the

synthesis

of

chiral

2-hydroxymethyl-4-

benzylpiperazine (R)-113 and (S)-113, we extended the methodology of the
racemic synthesis of (±)-31 to the chiral synthesis of (/?)-31 and (S)-31 (Scheme
3-3).74 The N-formylation of the free amine (S)-113, using acetic anhydride in
formic acid, gave the N-formyl-monobenzyl-HOM (S)-114. Treatment of (S)-114
with NaH (300 mol%) in DMF gave the
methylated with methyl iodide

( C H 3I)

alcoxide, which was subsequently

gave (S)-115.

deprotected with 4 M H2SO 4 at 60 °C.

The N-formyl group was

The resulting piperazine (S)-116 was

coupled to 2-chloroquinoline according to the standard Gilman procedure, to give
the N-benzyl-MOM-QP (S)-117. Deprotection of the benzyl group was preformed
by

heating

(S)-117

with

1-chloroethyl

chloroformate (ACE-CI)

in

1,2-

dichloroethane at 80 °C, with cleavage of the intermediate carbamate (structure
not shown) by heating in methanol, thereby affording the debenzylated product
MOM-QP (S)-31. Nitration of (S)-31 at the 6-position of the quinoline ring gave
the desired product (S)-31 typically with a 40% yield overall in seven steps.
Repeating the synthesis using L-serine gives the alternate enantiomer (R)-MOMNQP (/?)-31 also in 40% overall yield.74
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O
U

O
Ac2 0,

HN

A

NaH, CH3I

n
Q
H

H

N'B n DMF, 0 - RT °C

H3 C ^°

(S)-114
4 M H2 S 0 4
THF, 60 °C

H3 C''0 v ^

H

'Bn

(S)-115

n-BuLi, 2-CI-quinoline

HN

N

X / N 'Bn
6

N

Et2 0, 0 °C;
M HCI, acetone

N

H3C"0v^

(S)-116

^

rl

NvBn

(S)-117
o 2n

ACE-CI,
1,2-DCE, 80 °C;
N

N
NH

MeOH, A

H2 S 0 4

NH

(S)-31

O Cl
A JL

ACE-CI = d A

0

CH3

Bn ;

V

Scheme 3-3: Overall synthesis of chiral MOM-NQP (S)-31.

3.4

Application of the Chiral Synthesis, Chiral PROM-NQP 51.
With the success of the chiral MOM-NQP synthesis we turned our focus to

using the technology developed for the production of (R )- and (S)-PROM-NQP
((/?)-51 and (S)-51, respectively. Naylor et al. were successful in using a Swern
oxidation of 118 to generate the corresponding aldehyde (not shown).93 To
minimize racemization during the oxidation, N-methylmorpholine was used by
Naylor, instead of employing EtsN amine as a base. After oxidation, Naylor was
successful in using the aldehyde in a reductive amination with pyrrolidine to give
119. According to Naylor et al. they were able to accomplish the oxidation and
reductive amination with minimal racemization giving the desired compound 119
in a >99% ee (HPLC).93
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C/C^M©
NL

CO2 M6
(COCI)2, DMSO
N-methylmorpholine;
NaBH3 CN, pyrrolidine
>99% ee

Cl

Cl

119

118

Scheme 3-4: Potential oxidation of the methyl alcohol according Naylor et al.93

We examined the possibility of using the Naylor method to oxidize a Nprotected version of (S)-113 followed by a Horner-Emmons olefination according
to the racemic PROM-NQP (±)-51 synthesis (Scheme 2-13). However, we
thought that it would be more beneficial to investigate the use of other amino
acids with the appropriate piperazine side chain all ready in place as the amino
acids side chain (R) group. We were particularly interested in the methyl esters
of D- and L-glutamate 120, as well as the D- and L- forms of 5-hydroxynorvaline
121 (an equivalent to serine for the three carbon case) for the synthesis of (#?)-51
and (S)-51.

o
glutamate,

o

o
5-hydroxynorvaline, 121

1 2 0

Figure 3-4: Potential amino acid starting materials for the chiral PROM-NQP 51 synthesis.

If 5-hydroxynorvaline 121 could be readily prepared in our lab, we could
utilize all the procedures developed with the earlier chiral MOM-NQP (±)-31
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synthesis. Scheme 3-5 shows the retrosynthetic strategy for the synthesis of the
propyl (f?)-126 equivalent to the methyl hydroxy (R)-103.
o
NH'2
*

HO^

'Bn

N ' ^ Y lNl^
Bn O H

X

^

0H =

>

h

o

^ ^ o

O

O
(R)-126

h

(R)-123

(R )-121

Scheme 3-5: Retrosynthetic analysis for the formation of (R)-126.

A search of the literature found that 121 could be synthesized from D- or
L-glutamic acid 120 by selective protection of the a-carboxylate as the
boroxazolidone and reduction of the terminal carboxylate, according to Scheme
3-6.

The a-carboxylic acid of glutamic acid 120 is protected as the

boroxazolidone according to the procedures of Nefkens and Gong . 104,105 The 5carboxylate was selectively reduced with borohydride-THF complex (BH3-THF) to
give the alcohol and the boroxazolidone was cleaved by refluxing in 1.5M HCI,
purified by ion exchange to give 5-hydroxynorvaline (/?)-121 according to the
procedure of Garcia . 106
l_l

H Et,
-

o-Et
OH

0

0
D-120

THF' A

O

O

1.5MHOI.A

(R)-122

a
(R)-121

Scheme 3-6: Synthesis of 5-hydroxynorvaline from glutamic acid.

Attempts to generate the methyl ester of 5-hydroxynorvaline (/?)-121
resulted in the formation of the cyclized lactone (/?)-124 according to Scheme
3-7.

The lactone (/?)-124 was posed as a possible substrate for the peptide

coupling to give compound (R)- 126, where the lactone of dipeptide (f?)-125
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would act as the methyl ester of (/?)-112 for the cyclization to the piperazine ring
in the chiral MOM-NQP synthesis (Scheme 3-2).
©
ft
H3 N v J ^ q

EDC HCI, PFP
N-Boc-N-Bn-glycine

9 C lO

Et3 N,CH 2 CI2

O
BrK

.

N

_________

HN
HO.
nv^ ^ V

(R)-124

(R)-125

lV

" 'B

n

(R)-126

Sr°
J
(R)-127

Bn

^

(R)-128

Scheme 3-7: Potential synthesis of the piperazinedione ring utilizing the iactone (R)-126.

As shown in Scheme 3-8 the lactone form of 5-hydroxynorvaline (S)-130
has been prepared and similarly used in a dipeptide coupling with N-Boc
protected amino acids, including alanine, glycine among others to give the
peptide (S)-131 after deprotection of the N-Boc group .94,107 While only the (S)enantiomer of the lactone (prepared from L-glutamic acid) was used in the
preparation of the dipeptide, the (R)-lactone can be afforded using the same
procedure. 105 The missing experiment in our research would be to attempt a
cyclization to the piperazine (/?)-126 as solution in MeOH and NH4 OH according
to Scheme 3-8.

However, due to the expense and labor intensive process of

preparing large quantities (>10 g) of 5-hydroxynorvaline 121 and its associated
lactone 124, we decided on using a more economical route.
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EDC, HOBt

129

HCI

(S)-130

(S)-131

Scheme 3-8: Example peptide coupling using a cyclic lactone derived from 5-hydroxynorvaline

121.

As shown in Scheme 3-9, the dimethyl ester of D-glutamic acid D-132
easily couples with N-Boc-N-Bn-glycine 111, according to the chiral MOM-NQP
31 synthesis (Scheme 3-2), to give the dipeptide (/?)-133 in an 87% yield.
Dipeptide (/?)-133 was deprotected (SOCI2 , MeOH) and cyclized to give
compound (/?)-134 in an 84% yield. The cyclization required stirring overnight at
room temperature to achieve complete conversion.

This is in contrast to the

MOM-NQP synthesis where 2-3 hours were required to complete the cyclization,
suggesting the kinetic differences for the reactions is a function of side chain
length or substitution, i.e. alcohol vs. ester. The cyclized piperazinedione (/?)134 was reduced with LiAIH4 and the crude material was treated with acetic
anhydride in formic acid to give the N-formyl-piperazine (/?)-136 in a 63% yield
over 2 steps. The N-formyl-piperazine (/?)-136 was treated with NaH (300 mol%)
as a solution in DMF to generate the alkoxide that was quenched by the addition
of CH3 I to give compound (ff)-137 in a 59% yield. Deprotection of the N-formyl
protecting group of (/?)-137 was afforded by treatment with 4 M H2 S 0 4 as a
solution in THF to give (/?)-138.
Importantly, the mono-benzyl propyl ester (ft)-138 was not coupled to 2chloroquinoline as in the chiral MOM-NQP 31 synthesis (Scheme 3-3), due to
difficulties at that time to get consistent benzyl group deprotection results.74
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Instead, we opted to remove the benzyl group of (/?)-138 by catalytic
hydrogenolysis conditions at atmospheric pressure, to give PROM-piperazine
dihydrochloride (/?)-48 in a 93% yield. The least hindered nitrogen was protected
with trityl-chloride (97%) and the resulting protected piperazine (/?)-49 was
coupled to 2-chloroquinoline by the standard Gilman conditions and according to
the earlier racemic PROM-NQP (±)-51 synthesis (Scheme 2-13). The coupled
product was purified accordingly and deprotected to give PROM-NQP (/?)-50 in a
75% yield. Nitration at the 6-postion gave the desired chiral agent (R)-PROMNQP (R)-51 in a quantitative yield. The R- and S-enantiomers of PROM-NQP
were prepared from D- and L-glutamic acid dimethyl esters, respectively in 11
steps in a 17% and 23% overall yield, respectively.
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Cl,© ffi

EDC HCI, PFP
OCHa N-Boc-N-Bn-glycine
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0
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N

'Bn formic acid H O v . - N H
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(R)-135

(R)-136

O
NaH, CH3 I,
3r
DMF

A .
H
N
H3C

H2, 5% Pd/C
HaC'

'Bn

93%

93%

(R)-137

(R)-138
1) n-BuLi, 2-chloroquinoline
Et2 0, 0 °C

C(Ph)3 CI, Et3N
CH2 CI2, 0 °C
(R)-48

MeOH, 12M HCI

Bn

rl

59%

4M H2 S 0 4
______
THF

^
A

CPh13

h 3 C'
(/?)-49

97%

2) 6 M HCI, acetone
75%, 2 steps

0 2N
HN0 3 ,H2 S0 4
N
h 3c

N
NH

quantitative
(R)-50

(R)-51

Scheme 3-9: Overall synthesis of (R)-PROM-NQP 51, the (S)-enantiomer is afforded according
to the same synthetic sequence starting from L-132.

3.5

Alternate Synthesis of Chiral PROM-NQP.
The alternate synthesis of (R)-51 and (S)-51 utilized the nitrogen

protecting group Boc for the protection the 2° amine of (/?)-135. To accomplish
this, the ester and the amides of (/?)-134 were reduced with LiAIH4 in refluxing
THF. Attempts to selectively protect the nitrogen of the piperazine with a Boc
group were moderate at best (25-40% yield). For example, treatment of (/?)-135
with 98 mol% of di-ferf-butyi dicarbonate (Boc20 ) according to Scheme 3-10
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gave the N-Boc-N-Bn-propylpiperazine (R)-140 in a 40% yield.

Unfortunately,

the Boc protection of the free amine was not selective and the crude reaction
workup gave a mixture with of the unprotected starting material (#?)-135, the
desired product (R)- 140, and the diprotected species (/?)-139. These results
were not surprising, considering the problems associated with Boc protection of
the racemic form of HOP-NQP 146 (Scheme 2-20).

(R)-135
Boc2 0, NaOH(aq)
10%

Boc'

THF, 0 0 - RT °C
(k )-135

Rl-139

40%

(R)-140
Scheme 3-10: Protection of the 2° amine with Boc20 .

Attempts to selectively deprotect the side chain carbonate according to
the racemic synthesis of 66 failed
BoCv.
Boc

( K 2C O 3 ,

MeOH, Scheme 2-21).

K2 C 03, MeOH

Boc

50 °C
(R)-139

R)-140

Scheme 3-11: Attempted deprotection of the Boc carbonate (R)-139.

Despite the selectivity problems with Boc protection the chiral synthesis
was completed as proof of concept as shown in Scheme 3-12.
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The Boc

protected piperazine (R)-140 was methylated (DMF, NaH and CH3I) according to
the N-formyl series to give (/?)-141 in a 68% yield.

The Boc group was

deprotected (4 M H2 SO4 , THF) (87%) and the resulting monobenzyl piperazine
(/?)-138 was coupled to 2-chloroquinoline by the standard Gilman method to give
(R)-142 in a 55% yield.

The coupled product (R)-142 was nitrated (H2 S 0 4 ,

HNO3 , 0 °C) at the 6-position of the quinoline ring and the 2 and 4 positions of
the benzyl group (R)-143 giving a mixture of regioisomers of the phenyl ring in a
92% yield. Cleavage of the nitro-benzyl groups with 1-Chloroethyl chloroformate
(ACE-CI) gave the desired enantiomers of 51, (R)-51 and (S)-51 in 49% and 62%
yields, respectively. Scheme 3-12 details the overall synthesis of (R)-51and (S)51 from (R)-135 in 6 steps and an overall yield of 6% yield for (R)-51 and 11%
yield for (S)-51.
Boc

B0 C2 O, NaOH(aq)
N' Bn THF, 0 ° - R T ° C

R)-135

4M H2 S 0 4

N'Bn

H0

40%

Boc

NaH, CH3 I,
DMF

h 3 C"

0

68%

(ft)-140

/?)-141

n-BuLi, 2-chloroquinoline

HN

"Bn
Bn
87%

55%

Ace-CI, DCE
0 - 80 °C;

HNO3 , H2 S 0 4
0°C

0,N

NH

MeOH, 80 °C

92%

49%

(R)-51

Scheme 3-12: Alternate synthesis of (/?)-51 utilizing the N-Boc protected piperazine (/?)-140.
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3.6

Synthesis of Chiral Pent-NQP 83.
To further explore the application of the chiral synthetic approach, the

synthesis of (R )- and (S)-Pent-MOM 83 were explored. Initially, we looked into
using an unnatural amino acid with a carbon chain of the appropriate length that
could be used in the peptide coupling and cyclization procedures. A survey of
the literature and chemical supplier catalogs found (±)-2-aminoheptanedioic acid
(Figure 3-5).

However, 144 Is only available as the racemate, and a chiral

synthesis for the enantiomeric forms 144 was not available.

o

o

2-aminoheptanedioic acid, 144
Figure 3-5: Potential amino acid building block for the synthesis of chiral Pent-NQP 83.

Our second option was to use an intermediate of the chiral propyl
synthesis and perform the carbon extension via Swern oxidation and HornerEmmons olefination (/?)-135. In order to accomplish the carbon extension, the
free amine of (R)-135 needed to be protected with a protecting group stable to
the Swern and Horner-Emmons conditions. An examination of protecting groups
used routinely in our lab and comparison of their respective stabilities to the
reagents utilized in Swern and Horner-Emmons was performed.108 The ease of
the

protecting

group

deprotection

procedures

was

also

taken

into

consideration.108
Considering the questionable success of protecting the chiral piperazine
(f?)-135 as the N-Boc (A?)-140 we decided a benzyl group protection of the
piperazinedione (/?)-134 (Scheme 3-13) would be the preferred route. The N-
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benzyl protecting group was also preferred, considering that after reduction of the
amides and the ester of (/?)-145 we would be afforded a chiral piperazine
matching the synthesis of theracemicpropyl

and pentylseries (compound

33,

Scheme 2-13 and Scheme2-30). Thus, wewould nowbe able to apply all the
technologies developed in those series for the preparation of chiral Pent-NQP 83.
Initial trials of the benzylation reaction using NaH and benzyl bromide in DMF
resulted in only moderate yields (54-70%) of product (/?)-145. Supplementing
the reaction with a catalytic amount (40 mol%) of tetrabutylammonium Iodide
(TBAI) improved the yields (89-93%), by changing the leaving group from a
bromide to an iodide.109
o
hnA

o
]

Me0 2 C ^ / x ^ A ^ N U Bn

Bn-Br,Bu4NI
NaH, DMF, 0°C

Bn^A^
Me0 2C\ / \ <

^ | - N' Bn

O
(R)-134

O
89%

(R)-145

Scheme 3-13: Protection of (R)-134 with benzyl bromide (BnBr)

As shown in Scheme 3-14, piperazinedione (/?)-145 was reduced with
U A IH 4

in refluxing THF to give the dibenzyl propyl alcohol (/?)-56 (92%). Swern

oxidation and Horner-Emmons olefination with triethylphosphonoacetate gave
the unsaturated pentyl ester (/?)-146 (60%, 2 steps). Subsequent saturation was
accomplished by catalytic hydrogenation using 5% Pd/C in MeOH and acetic
acid (AcOH) (60%). The saturated ester (R)-77 was reduced with LiAIH4 in Et20
(99%) and the resultant alcohol (/?)-78 was methylated as the alkoxide (NaH) in
DMF with

C H 3I

to afford (/?)-79 (56%). Hydrogenolysis of the benzyl groups gave

the Pent-MOM piperazine dihydrochloride (/?)-80 in a 83% yield, which was
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protected using trityl-chloride (99%).

The N-trityl-pentyl-piperazine (/?)-81 was

coupled to 2-chloroquinoline according to the Gilman method, deprotected with 6
M HCI in acetone to give (R)- 82 (53%, 2 steps). Nitration at the 6-position of the
quinoline ring gave Pent-NQP (/?)-83 in a quantitative yield.

The synthesis of

(/?)-83 and (f?)-83 were accomplished in 8% and 5% yield, respectively, in 11
steps.
B ru

UAIH4 , THF

(/?).145------- — _

B ru

DMSO, (COCI)2,

H0

reflux

Bn

92%

(R)-89

n-BuLi
(Et0)2 P(0)CH2 C 02Et

Bn^
H2, 5% Pd/C
Bn

THF, 0 °C
60%,

2

MeOH, AcOH
60%

(R)-146

steps

NaH, CH3 I,

UAIH4 , Et20

DMF
99%

H3 C'

56%
(R)-78

H2, 5% Pd/C

, 2

(R)-79

HCI
-NH

MeOH, 12 M HCI H3 C'
83%

C(Ph)3 CI, Et3N
--------------------- ►
CH2 CI2, 0 °C
h3 C

(R)-80

99%

1) fi-BuLi, 2-chloroquinoline
Et2 0, 0 °C
6

M HCI, acetone
53%, 2 steps

(R)-81

h n o 3, h 2 s o 4
N

2)

'Bn

Et3 N, CH2 CI2, -78 °C

N

N
NH

h 3o

N

0°C
quantitative

(R)-82

Scheme 3-14: Overall synthesis of (/?)-Pent-NQP 83, the (S)-enantiomer was similarly prepared
from (S)-145.
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3.7

Synthesis of Chiral BuM-NQP 96.
Preliminary accomplishments for the synthesis of the chiral butyl variant

(/?)-91 have been realized, as shown in Scheme 3-15. However, at the time of
this writing this (R )- and (S)-BuM-NQP 96 have not been prepared.

The

intermediate chiral dibenzyl-HOP (R)-56 was prepared as described above in the
chiral pentyl synthesis from the cyclized piperazinedione (f?)-145 (Scheme 3-13).
Swern oxidation of alcohol (/?)-56 to the aldehyde (R)-89 was followed by Wittig
olefination with methyltriphenylphosponium and n-BuLi gave the terminal alkene
(/?)-90 in a 49% yield over two steps.

Hydroboration of (/?)-90 with 9-BBN

followed by oxidation gave the desired butyl alcohol (R)- 91 (94%). For this
reaction careful purification was required to remove the side product 1,5cyclooctanediol by column chromatography, before the subsequent methylation
reaction.

Attempts to methylate the alcohol (/?)-91 after aqueous acid-base

workup gave low yields (<10%) of the desired product (/?)-92.
DMSO, (COCI)2,
HO
H

Bn Et3 N, CH2 CI2, -78 °C

n-BuLi, [(Ph)3 P+CH3]|-

m-m
THF, 0 °C

(R)-56

H

Bn

(R)-90

49%

9-BBN THF, 50 °C;
H2 0 2, NaOH, 0 °C
94%
Scheme 3-15:
technology.

HO
(R)-91

(R)-92

Initial synthesis of the BuM-NQP precursor (/?)-92, by Wittig olefination

Completion of the synthesis of (R)- and (S)-BuM-NQP 96, can be afforded
during the future by repeating the reaction sequence for the preparation of the
(±)-BuM-NQP 96 as outlined in Chapter 2.

Briefly as per Scheme 3-16, the
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alcohol (/?)-91 would be methylated and the benzyl groups cleaved. The less
hindered nitrogen of the piperazine can be protected as the N-trityl group. The
N-trityl

piperazine

(/?)-94

would

be

coupled

to

2-chloroquinoline,

then

deprotected and nitrated to give the desired (R)- and (S)-BuM-NQP 96.
NaH, CH3I

• 2 HCI

H2, 5% Pd/C

(R)-91

w

C(Ph)3CI, Et3N

Bn

MeOH, 12 M HCI

H3C__
0

1) n-BuLi, 2-chlororquinoline
Et20, 0°C

HN' ^

N

H3Cv
CH2CI2, 0 °C

H N ^

' CPh3

N

2) 6 M HCI, acetone

(R)-94

h n o 3, h 2s o 4

o°c

NH
(/?)-1

Scheme 3-16: Proposed synthesis of chiral BuM-NQP 96 from the synthetic intermediate (/?)-92.

3.8

Summary and Conclusions.
Typically, the synthesis of the chiral forms of a SERT agent results in an

enantiomer with higher SERT affinity compared to the opposing enantiomer. For,
example the synthesis of (R ) and (S)-citalopram 7 resulted in discovering a more
potent SSRI in (S)-7.

This chapter summarizes our efforts to prepare the

enantiomeric forms of PROM-NQP (±)-31, Pent-NQP (±)-83 and the initial
synthesis of BuM-NQP 96.

Further work is required to accomplish the

enantiomers of 96. Chapter 4 discusses the pharmacology of the enantiomers of
Me-NQP (±)-30 and MOM-NQP (±)-31, as it has been our goal to further the SAR
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of the 6-NQP 22 analogs according to their respective SERT binding affinities.
The synthesis of the longer chain derivatives of the 2-(2-alkyl-piperazin-1-yl)-6nitroquinolines furthers our understanding of the affects of chain length and
chirality of the 6-NQP analogs and their selectivity for SERT binding.

The

synthesis of the radiolabeling precursors and the cold fluorinated analogs 58 and
88 should be accomplished to benefit the SAR studies allowing direct
comparison of binding affinities of the enantiomeric forms of the ligands to the
racemic forms.
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Chapter 4
Pharmacology
4.1

Introduction.
The pharmacological evaluation of the prepared 2-(2-alkyl-piperazin-1-yl)-

6-nitroquinoline analogs for their respective competitive binding affinities at the
serotonin reuptake transporter (SERT) is outlined in Table 4-1 and Table 4-2.
Our focus was to develop a more detailed understanding of the structure-activity
relationship (SAR) of the 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline analogs that
would afford the most favored SERT ligand binding. By doing so we would be
able to describe the pharmacological profile of the proposed PET imaging agents
58 and 148.
The

alkyl

side

chain

groups

of

the

2-(2-alkyl-piperazin-1-yl)-6-

nitroquinoline ligands are designed to probe the area of the binding domain (Ar2)
that is shared by the alkyl side chain of the antidepressant fluvoxamine (Figure
1-3). We have also proposed that this binding area is also shared by an aromatic
ring of other serotonin selective reuptake inhibitors (SSRIs) that contain two
aromatic moieties. It is thought that one of the two aromatic moieties is critical
for SERT binding (Chapter 1).67
Our research group utilizes a published in vitro competitive ligand binding
assay for the determination of the inhibition constant
analog SAR measurment.67,110

(K i)

as a comparative

Described below is the competitive inhibition

pharmacology measures, a summary of the SAR of the 2-(2-alkyl-piperazin-1-yl)-
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6-nitroquinoline ligands based upon their respective Ki values. Additionally the
synthesis of [3H]n-PROP-NQP 52

is provided, as well as the kinetic binding

profile of [3H]52. Kinetic analysis of

[3H]/i -PROP-NQP 52 will allow us to gain a

better understanding of the rate constants kon (association) and koff (dissociation)
and also kinetic and the related equilibrium dissociation constants (K d).

4.2

Competitive Inhibition, SERT Pharmacology [3H]paroxetine.
The in vitro inhibition binding constants (K) of the ligands outlined in Table

4-1 and Table 4-2 were determined using an established radioligand competition
binding assay (rat cortical SERT (rSERT), [3H]Paroxetine

9

)67110 which is a

modified method of Habert.111 The measured K data (mean ± s.e.m., n = 3 or
more runs) is summarized in Table 4-1 and Table 4-2, where a lower Kj value is
indicative of higher SERT ligand binding affinity.
The in vitro assays were performed with aliquots of partially purified male
rat cortex membrane tissue (Pel-Freeze Biologicals, Inc.). The cerebral cortex
was dissected from adult rat brains.

The cortex was homogenized using a

Polytron tissue homogenizer in Tris-HCI buffer. Centrifugation of the crude
homogenate isolated the desired membrane fraction.

The pellet material was

suspended in assay buffer (50 mM Tris-HCI, pH 7.4, 120 mM NaCI, and 5 mM
KCI). The suspensions were incubated with 0.25 nM [3H]Paroxetine (DuPontNEN, specific activity of -19.5 Ci/mmol) and decreasing concentrations (10"6 M to
10"11 M) of the inhibitors.

After 3 hours, the incubations were terminated by

dilution with ice-cold buffer and then filtered using S & S glass filter papers
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(Schleicher and Schuell #32 glass fiber filter paper) under vacuum (Brandel cell
harvester). To minimize nonspecific binding of the radioligand, the filter papers
were presoaked in a 0.05% v/v solution of polyethyleneimine. The filter papers
were washed rapidly with cold Tris-HCI buffer and transferred to scintillation vials.
To the vials was added 10 ml_ of Ecolume scintillation fluid (ICN, Irvine, CA), the
vials were shaken 24 hours and the radioactivity was counted with a Packard
scintillation counter.
Specific binding was determined as the binding difference between total
binding and non-specific binding.

Non-specific binding was defined as the

residual binding in the presence of 1pM 6-Nitroquipazine 22 to the incubation
media.

Total binding is described as the level of radioactivity of the assay

medium in the absence of unlabeled competitive inhibitor.

Binding data was

analyzed using the software program Prism (GraphPad, Inc.) where percent of
total specific binding vs. -log molar concentration of inhibitor (six or more data
points per curve) were plotted. The inhibitor concentrations

( I C 50)

required to

obtain 50% inhibition of [3H]paroxetine 9 binding were determined.112 Assay data
points were done in triplicate and the experiments were repeated a minimum of
three times on different days.
equation:

Kj

=

IC 5 o /(1 + [L ]/K d ),

The Kj value was calculated according to the
where

[L ]

is the concentration of the unbound

[3H]paroxetine 9 (0.25 nM), and Kd is the equilibrium dissociation of paroxetine
(0.15 nM).111,112 An example plot for the binding of 9 is given below (Figure 4-1).
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Figure 4-1: Example single site competition assay plot of %bound radioligand versus the Log of
inhibitor concentration (M).

4.2.1 Discussion of Pharm acology.
Based upon the lead structure 6-nitroquipazine (6-NQP) 22 a number of
racemic

(Table

4-1)

and

chiral

(Table

4-2)

2-(2-alkyl-piperazin-1-yl)-6-

nitroquinolines have been prepared, and their respective binding affinities
rSERT have been determined.

(K j)

for

Included in the table are their structural

differences from the lead 6-NQP 22 and their calculated lipophilicity values
(LogP).113
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Table 4-1: Racemic 2-(2-alkyl-piperazin-1-yl)-6-nitroquiolines, compound name and R-group are
given as well as their associated binding inhibition constant ( K j ) , and CLogP(o/w) value.

rA

^

nh

Name

R

Ki (pM)

CLogP(o/w)**

Ref

22

NQP

H

160 ± 5 0

67

(±)-30

(±)-Me-NQP

ch3

81 ±61

1.9
2.42

(±)-31

(±)-MOM-NQP

CH2OCH3

2.48 ± 0.28

1.94

72

38

HOM-NQP

CH2OH

12.65 ± 3 .0 0

1.19

74

(±)-51

PROM-NQP

(CH2)3OCH3

2.12 ± 1.13

2.21

This Work

147

HOP-NQP

(CH2)3OH

50.25 ± 35.76

1.5

This Work

58

PROF-NQP

(CH2)3F

2.48 ± 0 .1 9

2.75

This Work

52

n-PROP-NQP

c h 2c h 2c h 3

41.48 ± 19.87

3.48

This Work

(±)-83

PentOM-NQP

(CH2)5OCH3

1.02*

3.26

This Work

148

MePROF-NQP

CH20 (C H 2)3F

3.96 ± 0.88

2.28

74

PentF-NQP

(CH2)5F

79.6 ±21 . 2

3.81

This Work

88

II

‘ Preliminary Value “ Daylight Software (http://www.daylight.com/daycgi/clogp)

Early work by Gerdes et al. has shown that methyl group substitution of
the piperazine ring at the 2-position Me-NQP (±)-30 is 56 times more potent for
rSERT than methyl substitution at the 3-position 3-Me-NQP 28.67 Additionally
binding potency of Me-NQP (±)-31 was 2 times (81 pM) more potent compared to
the lead 6-NQP 22 (160 pM). The next generation ligand MOM-NQP (±)-31 was
obtained by extending the alkyl chain by two atoms as the methoxymethyl,
increased binding affinity to 2.5 pM (64 times more potent than 22).

The

increase in binding of (±)-31 suggests that the piperazine substitution is
interacting deeper in the Ar2 binding pocket (Figure 1-10). Comparison of (±)MOM-NQP (±)-31 to the all carbon case n-PROP-NQP 52 (similar chain length)
shows that in the absence of an oxygen binding potency is decreased (Ki = 42
pM). The addition of an oxygen as the propyl methyl ether PROM-NQP (±)-51,
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showed an increase in binding affinity (Ki = 2.1 pM) that is equivalent to the
affinity of (±)-31.

A similar comparison can be made between PentF-NQP 88

(void of oxygen) and MePROF-NQP 148 (oxygen present). The all carbon case
88 (79.6 pM) has the same potency as (±)-30 (81 pM). The introduction of an
oxygen atom in MePROF-NQP 148 (oxygen location is the same as (±)-31)
results in an increase in binding affinity that is consistent with the ligands
containing an ether functionality (±)-31 and (±)-51 (Ki = 4.0 pM). The increase in
binding of the alkyl chains containing an ether functional group is suggestive that
the Ar2 binding region may prefer hydrogen bonding acceptors, i.e. oxygen and
perhaps fluorine.
When comparing the binding affinities of the all carbon substitutions there
is a doubling in potency by increasing the carbon length from one carbon (±)-30
to three carbons (±)-52 Kj = 81 pM and 42 pM, respectively. The increase in chain
length may enhance potency through lipophilic interactions within the Ar2
domain.

It is interesting to note that there is relatively no change in potency

between PROM-NQP (±)-51 and (±)-MOM-NQP (±)-31

(K j

= 2.12 and 2.48 pM,

respectively), perhaps the presence of a hydrogen bond acceptor far out weighs
the chain length. Replacement of a terminal hydrogen of n-PROP-NQP 52 with a
fluorine atom to give PROF-NQP 58 (Kj = 2.5 pM) increased potency by 17 times
further substantiating the benefit of an H-bonding acceptor.

It is interesting to

note that the propyl hydroxyl version HOP-NQP 147 shows a -2 5 times drop in
potency

(K j

= 50 pM) compared to PROM-NQP (±)-51 and (±)-MOM-NQP (±)-31.

Additionally the methyl alcohol HOM-NQP 38 showed a 6 fold decrease in
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potency compared to MOM-NQP (±)-31.

It seems that the presence of a

hydrogen bonding donor is not well tolerated in the Ar2 binding domain.

The

binding potency of PROF-NQP 58 and MePROF-NQP 148 bode well for their use
as potential PET imaging agents.
Table 4-2: Chiral 2-(2-alkyl-piperazin-1-yl)-6-nitroquiolines, compound name and R-group are
given as well as their associated binding inhibition constant ( K i ) , and CLogP(o/w) value.

Q jN .

r^

N H

H

Name

R

Ki (pM)

Ref

(±)-30

(±)-Me-NQP

ch3

81 ±61

67

( R )-30
(S )-30

(R )-(-)-M e-N Q P
(S)-(+)-M e-NQP

II

91 ± 16
68 ±21

73

(±)-31

(±)-MOM-NQP

(R )-31 (R )-(+)-MOM-NQP
(S)-31 (S )-(-)-M O M -N Q P

II

11

CH2OCH3

2.48 ± 0.28

72

11

47*
1*

74
ll

ll

‘ Preliminary Values

To further expand upon our SERT SAR the enantiomeric forms of (±)-MeNQP 30 and (±)-MOM-NQP 31 were evaluated for their respective SERT binding
affinities (Table 4 - 2 ) . Comparison of the enantiomers (/?)-30 and (S)-30 binding
affinity at rSERT

(K j

=

91 ± 1 6 pM and 68

±

21 pM) shows no significant

difference in SERT preference for either enantiomer. Perhaps the methyl group
is not long enough to evoke a definite preference at the SSRI binding domain.
Initial binding affinity values of the (/?)-31 and (S)-31 enantiomers

(K j

and 1 pM, respectively) shows a 47 times higher affinity for (S)-31.

=

47 pM
This is

encouraging; suggesting that in there is a receptor preference for one
enantiomer, which is similar to the results seen for citalopram 7 and fluoxetine
10.
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4.3

Synthesis of n-PROP-NQP 52 and [3H]n-PROP-NQP.
Our interests in developing a PET imaging agent for SERT lead us to

investigate the binding kinetics of our 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline
analogs with the SERT protein. In addition we wanted to assess the selectivity of
our ligands for SERT relative to the other biogenic amine transporter targets
within the CNS. To accomplish these evaluations we investigated the possibility
of generating a tritium labeled compound based upon our 2-(2-alkyl-piperazin-1yl)-6-nitroquinoline analog series. When examining our library of compounds we
decided that n-PROP-NQP 52 would be an excellent analog for the preparation
of a tritiated [3H]2-(2-alkyl-piperazin-1-yl)-6-nitroquioline. Since 52 was complete
with a propyl side chain it could act as a good representative analog compared to
the balance of our compound library, particularly 58.
Initially n-PROP-NQP 52 was considered a side product of the PROMNQP (±)-51 synthesis. However, the synthesis of 52 and related binding affinity
for SERT was fortuitous.

We proposed that 52 could be used as a

pharmacological tool for assessing the binding kinetics of our ligand series as
well as selectivity of our ligand series for SERT over other monoamine
transporters, i.e. DAT and NET. Additionally, 52 is good replacement for PROFNQP 58 based upon the similarity of the side chain length and lipophilicity
between 52 and 58 (Figure 4-2).
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Figure 4-2: Structure and CLogP comparison of n-PROP-NQP 52 and PROF-NQP 58.

Determination of the in vitro binding kinetics using the [18F]PROF-NQP 58
agent would be more desirable,114 but due to the difficulties of preparing
[18F]PROF-NQP 58 analog at the time of this study, n- PROP-NQP 52 was a
more desirable agent.
As shown in Scheme 4-1, the synthesis of the 52 began with the Swern
oxidation of dibenzyl alcohol 33 to the aldehyde 44, followed by Wittig olefination
with

ethyl-triphenylphosphonium

bromide

to

give

149

(71%,

2

steps).

Hydrogenolysis of the benzyl groups and simultaneous hydrogenation of the
alkene with 5% Pd/C and HCI in MeOH, (atmospheric pressure) gave the npropyl piperazine dihydrochloride 150 in a 92% yield.

The piperazine was

protected with triphenylmethane chloride to give 151, then coupled to 2choroquinoline, deprotected (152, 45%, 2 steps) and then selectively nitrated at
the 6-position to give the desired n- PROP-NQP 52 in a quantitative yield. The nPROP-NQP 52 target was synthesized from the common intermediate dibenzylalcohol 33 affording 2-(2-propylpiperazin-1-yl)-6-nitroquinoline 52 in 7 steps and
a 29% overall yield.
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Bris

Bn.

DMSO, (COCI)2

HO
H

n-BuLi, [(Ph)3P+Et]Br-

33

71% (2 steps)

44

H2, 5% Pd/C

THF, 0 °C

"Bn

"Bn CH2CI2, Et3N, -78 °C

Bn .

C(Ph)3CI, Et3N

-2 HCI HN

12 M HCI, MeOH

CH2CI2, 0 °C

92%

"CPh3

quantitative

150

151

0 2N

n-BuLi, 2-CI-quinoline
Et20, 0 °C;
6 M HCI, acetone
45%

NH

0°C

NH

quantitative

Scheme 4-1: Synthesis of 2-(2-propylpiperazin-1-yl)-6-nitroquinoline 52 (n-PROP-NQP).

Upon completion of the synthesis of 52, it was shipped to SibTech, Inc.
(Newington, CT) and radiolabeled labeled with tritium. This was accomplished
by aromatic halogenation of the quinoline ring, followed by dehalogenation-tritium
exchange to give [3H]52, with a specific activity of 17.5 pCi/mmol, and a chemical
purity of 99% (Scheme 4-2).
3h

o2n^
N

SibTech, Inc.

N
NH

17.5 pCi/mmol
99% pure

52

N

N

[3H]52

Scheme 4-2: Radiosynthesis of [3H]-2-(2-propylpiperazin-1-yl)-6-nitroquinoline 52 ([3H]-n-PPOPNQP).
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4.4

In Vitro SERT Binding Studies [3H]-n-PROP-NQP 52.
In this study our aim was to examine the in vitro binding characteristics

and receptor selectivity of the radiolabeled SERT inhibitor

[z H ] n - P R O P - N Q P

52

prepared according to Schemes 4-1 and 4-2. We were interested in determining
the equilibrium dissociation constant (KD), binding site density (Bmax), association
and dissociation rate constants (kon and k0ff), and to assess the selectivity of
[3H]52 for rSERT. The equilibrium dissociation constant (Kd) is useful to describe
a ligand’s affinity for a given binding domain, considering Kd is the reciprocal of
binding affinity KA (KA = 1/KD).115 A lower the KD value represents higher affinity
of the ligand for the receptor and at equilibrium if the KD value is small the
dissociation of the ligand-protein complex will be slower. The association rate
constant (kon) is a measure of how fast the ligand-receptor complex is formed.
The dissociation rate constant (k0ff) is a measure of how tightly the ligand is
bound to the receptor.

A low Kd and a slow dissociation (k0ff) of the ligand-

receptor complex are thought to be favorable for a SERT imaging agent.
Additionally, fast association is desirable to establish binding equilibrium at the
receptor relatively quickly to benefit the imaging experiment. The Kd values can
be determined kinetically from the rate constants kon and k0ff where Kd = k0ff/k0n
and from saturation equilibrium binding studies.

Ligand +

SERT -

^on

Ligand-SERT

^off
—^on ! koff —1 / Ka
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Measurement of the dissociation constants (KD) were performed according to
the published procedures.13,110,111 The association rate constant

(k on)

and the

time to reach binding equilibrium was determined by incubation of the radioligand
[3H]52 (200 pM) with the rSERT membrane preparation at 21 °C and 37 °C for
varying amounts of time (10 minutes - 4 hours).

From the plot of association

(Figure 4-3), the apparent equilibrium time was determined to be between 2-3
hours. The time to reach apparent equilibrium is in agreement with a structurally
related compound [125l]5-iodo-6-nitroquipazine 23 as previously reported.110 The
observed association constant

(kobs)

of [3H]52 was determined from the formula

ln[Be / (Be - Bt)] = kobs’t, where Be is specific binding at equilibrium, and Bt is
specific binding at time t (Figure 4-3).

0)
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Figure 4-3: Time course association plots of [ H]-n-PROP-NQP 52 at 21 °C.
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300

The dissociation rate constant
incubation medium with 1.0

|j M

(k o ff)

was determined by treatment of the

of the non-radioactive from 52, 3 hours after the

addition of [3H]52 (Figure 4-4).

The dissociation rate constant

( k 0 ff )

was

calculated from the formula; ln[Bt / Be] = - k 0f f * t and the results are shown in Figure
4-4.

©
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Figure 4-4: Time course dissociation plots of [3H]-/7-PROP-NQP 52 at 21 °C.

The association rate constant was determined from the relationship kon =
( k 0 bs

- k0ff) / [L], where [L] is the concentration of unbound 52. From

kon

and k0ff

the kinetically derived dissociation constant (KD) can be calculated according to
Kd = (k0ff / kon). The calculated values for KD, kon and koff are outlined in Table 4-3
and compared to the SERT selective 6-nitroquinoline analog [125l]5-iodo-6nitroquinoline 23 ([125I]INQP) and the SSRIs (+)-MCN5652 6 and (S)-citalopram
7.
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Table 4-3: Comparison of the kinetically derived dissociation constants (KD), the rate constants of
association (kon) and dissociation (koff) for [3H]-n-PROP-NQP 52 and select SSRIs at 21 °C.
°c

Name

Kd (PM)

21°

[3H]52 n-PROP-NQP
[125l]23 INQP
[3H]6 (+)-MCN5652
[3H]7 (S)-Citalopram

8.5
7.9
80
310

^

(moT'min'1)
1.1 x 10B
4.8x10®
3.6x10®
4 .9 x 1 0 '

koff (m in1)

Ref

9.4 x 10-4
3.8x1 O'4
3.1 x 10'3
1.2 x 10"2

Weller, 2003
Mathis, 1993
Elfving, 2001
Elfving, 2001

Comparison of the Kd value determined for [3H]n-PROP-HQP 52 (8.42
pM) to the Kd values of other SSRIs ([125I]INQP 23, [3H]-(+)-MCN5652 6, and
[3H]-(S)-citalopram) showed [3H]52 had comparable binding potency

to the

structurally related quipazine agent INQP 23 (7.9 pM) at 21 °C (Table 4-3). Also,
[3H]52 has a much higher affinity for rSERT (lower

Kd)

compared to the SSRIs

MCN5652 6 and citalopram 7 (21 °C). The rate of association (kon) at 21 °C of
[3H]52 is essentially equivalent to that of [125I]INQP 23 and [3H]-(+)-MCN5652 6,
but was an order of magnitude faster than [3H]-(S)-citalopram 7. The dissociation
rate

(k o ff)

of [3H]52 was slightly faster than [125I]INQP 23, but slower than [3H]-(+)-

MCN5652 6, and [3H]-(S)-citalopram 7 (21 °C).

The comparison of binding

potency (KD), association rate (kon) and dissociation rate (koff) at 21 °C suggest
that the 2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline analogs will have good in vitro
binding properties for use as PET imaging agents.39

The slower dissociation

rate of [3H]52 at 21 °C compared to [3H]-(+)-MCN5652 6 and [3H]-(S)-citalopram
7, is thought to be important for the imaging of medium to low SERT density
regions.

110

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

4.5

Determination of the Apparent Equilibrium Dissociation Constant

(K d) and Receptor Density (Bmax)Determination of the receptor density (Bmax) and the apparent equilibrium
dissociation constant (KD) were determined from saturation studies of the crude
rat brain membrane preparation with the radiolabeled compound [3H]52,
according to the methods of Mathis and Habert.110,111

In brief, the crude

membrane preparations were treated with increasing concentrations of [3H]52
(0.001 - 2.5 nM) in the absence and presence of 1 mM paroxetine (to establish
non-specific binding) and incubated for three hours at 21 °C. The samples were
filtered and counted as described above.
experiments is shown (Figure 4-5).

An example plot of the saturation

From the saturation binding isotherm we

were able to calculate the apparent equilibrium Kd = 38 pM and Bmax = 395
fmol/mg of protein, using the iterative least squares curve fitting program Prism
(Graphpad).
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Figure 4-5:

Saturation binding isotherm of [3H]-a7-PROP-NQP 52 binding with rSERT at 21 °C.

The Kd (38 pM) determined for [3H]52 is similar to the equilibrium derived
Kd determined for the structurally related analog [125I]INQP 23 (23 pM) and
slightly larger than that of the kinetically derived KDfor [3H]52 (8.5 pM). The Bmax
value determined in our saturation studies is consistent with other rSERT
saturation measures (-400 fmol/mg protein).13,110

4.6

SERT Selectivity of [3H]-n-P/?OP-NQP 52.
The labeled form of [3H]52 was also useful for examining and estimating

the selectivity of the 2-(2-alkyl-piperazin-1-yl)-6-nitroquioline

ligands

for the

SERT binding site. The SERT selectivity assays are outlined in Table 4-4, the
ligand name, competitive binding affinity (K) and ligand classification are
included.

For the selectivity assays we used known selective agents for the
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biogenic amine transporters, these are classified as either a serotonin selective
reuptake inhibitor (SSRI), dopamine reuptake inhibitor (DRI), norepinephrine
reuptake inhibitor (NRI), or SSRI (quipazine).

The assays were performed by

adding a solution of the unlabelled test agent to the rat membrane preparation
containing [3H]52 and assay buffer. Total binding was determined by treatment
of the membrane preparation with [3H]52 in the absence of any competitive
ligand. Competitive drugs were screened at varying concentrations (1 pM - 10
pM), the results were plotted and the Kj values were determined using Prism,
utilizing the kinetically derived Kd of [3H]52 at 20 °C (8.42 pM).

Non-specific

binding was determined in the presence of 1 pM 6-NQP 22. The ligands tested
are summarized in Table 4-4 with their associated inhibition constants.
Table 4-4: Inhibition constants (K) for select CNS agents inhibiting the binding of [3H]-n-PROPNQP 52 with rSERT.
Cmpd #
6

7
9
153
154
58
52
(±)-31

Name
(+)-MCN5652
(S)-Citalopram
Paroxetine
GBR12935
Nisoxetine
PROF-NQP
n -PROP-NQP
MOM-NQP

K; (nM)
0.19 ±0.04
1.96 ± 0.59
0.27 ± 0.08
>500
> 10,000
0.0056 ± 0.0002
0.0018 ±0.0005
0.03 ± 0.01

SSRI
SSRI
SSRI
DRI
NRI
SSRI (Quipazine)
SSRI (Quipazine)
SSRI (Quipazine)

The ligands tested include the SSRIs (+)-MCN5652 6, citalopram 7 and
paroxetine 9 the selective DAT inhibitor GBR-12935 (not shown) and the
selective NET inhibitor nisoxetine (not shown).

Included in this study were a

select group of 2-(2-alkyl-piperazin-1-yl)-6-nitroquinolines prepared in our lab,
including; PROF-NQP 58, MOM-NQP (±)-31, and PROP-NQP 52. The results
shown in Table 4-4 are indicative that [3H]52 is binding at the same SERT
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binding domain as the known SSRIs, (+)-MCN5652 6, citalopram 7 and
paroxetine 9. Additionally, [3H]52 is selective for SERT based upon challenging
with known selective DAT and NET inhibitors.

Also, based upon the potent

inhibition constants (low nanomolar range) of the 2-(2-alkyl-piperazin-1-yl)-6nitroquinolines (±)-31, 52 and 58, it is indicative that those ligands have potent
rSERT affinity.

The selectivity and binding profiles of the quipazine ligands

indicate that these ligands will likely show very good in vivo characteristics for
PET imaging of low SERT density regions of the brain.

4.7

Summary.
Competition assay ([3H]paroxetine, 9) of the 2-(2-alkyl-piperazin-1-yl)-6-

nitroquinolines (Table 4-1 and Table 4-2) show an overall increase in binding
affinity compared to the lead agent 6-NQP 22. From these studies we can infer
that a hydrogen bonding acceptor located in the alkyl chain will benefit binding
affinity. For example (±)-31, (±)-51, 58, and (±)-83 all showed affinity for SERT in
the 2 pM range. This is a much higher affinity when compared to the all carbon
analogs 52, and (±)-30 whose affinities were >20 times less potent. We can also
comfortably say that the presence of a hydrogen bonding donor is detrimental to
binding, HOM-NQP 38 and HOP-NQP 147 both show a decrease in binding
affinity compared to their respective ether analogs. The in vitro studies of [3H]52
demonstrate the selectivity and binding affinity of [3H]52 for SERT. The in vitro
kinetic data (KD, kon and koff) for [3H]52 is representative of the kinetics we expect
for our analog series. This data suggests that a fluorine-18 radioligand derivative
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of a 2-(2-alkyl-piperazin-1-yl)-6-nitroquioline analog, such as PROF-NQP 58
could prove to be a useful ligand for PET imaging studies; especially considering
that 58 exhibits a higher binding affinity (2.5 pM) compared to 52 (42 pM), in
addition to its implied SERT selectivity.
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Chapter 5
Conclusions and Future Work
The syntheses of seven new

2-(2-alkyl-piperazin-1-yl)-6-nitroquinoline

racemic analogs of 6-NQP 22 have been completed, including PROM-NQP (±)51, HOP-NQP 147, PROF-NQP 58, n-PROP-NQP 52, Pent-NQP (±)-83, PentFNQP 88, and BuM-NQP 96.

Of these analogs all except BuM-NQP 96 have

been evaluated for their in vitro binding affinity for rSERT by radioligand
competition assay (rSERT, [3H]paroxetine 9) as outlined in Chapter 4. The 2-(2alkyl-piperazin-1-yl)-6-nitroquinolines ligands tested show higher binding affinity
(K i

= 1-80 pM) for rSERT compared to the lead SSRI 6-NQP 22

(K i

= 160 pM).

This initial SAR study of the quipazine ligands prepared during this work
suggests that probing of the Ar2 binding domain of our pharmacophore model,
with alkyl chain moieties at the piperazine 2-postion of the quipazine base
structure, is a useful method for preparing new more potent quipazine ligands.
The presence of hydrogen bonding acceptor moieties (methoxy ether and
alkylfluoride) in the alkyl chain is beneficial to ligand binding and the inverse is
seen for the presence of hydrogen bond donating moieties, i.e. hydroxyl.
Overall, the presence of any alky chain results with increased binding affinity of
the analogs for rSERT. At this time, the SAR indicates that a chain length of 3-5
atoms is acceptable as can be seen in the respective binding affinities of MOMNQP (±)-31 and the propyl series ligands (±)-51, 52, 58, and 147 (Table 4-1).
Further assessments of the racemic butyl and pentyl series will extend our
knowledge of the chain length limits for SERT binding.
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To expand our SAR studies the (R)- and (S)-enantiomers of MOM-NQP
(±)-31,

PROM-NQP

(±)-51

and

Pent-NQP

(±)-83

were

synthesized.

Unfortunately, only the enantiomers of MOM-NQP (R)-31 and (S)-31 have been
evaluated for their associated rSERT affinity at the time of this writing. The initial
studies show a difference in potency of (/?)-31 and (S)-31, suggesting that the
(S)-enantiomer (Ki = 1 pM) is more potent for SERT than the (R)-enantiomer (Ki =
47 pM). This trend could be further evaluated using the enantiomers of PROMNQP and Pent-NQP ((/?)-51, (S)-51, (/?)-83 and (S)-83). The syntheses of the
chiral forms of PROF-NQP 58, PentF-NQP 88, BuM-NQP 96 and the related
BuF-NQP (not shown) should be accomplished to afford a complete ligand
series. As per the experimental section the final compounds of the chiral propyl
and pentyl series ((/?)-51, (S)-51, (R)-8Z and (S)-83) have been analyzed for their
optical rotations. The measures are indicative that the final compounds have
retained their enantiomeric purity within reasonable experimental error. The final
chiral forms of the pentyl series ((R)-B3 and (S)-83) require more analysis when
larger quantities have been prepared. However, more rigorous determination of
enantiomeric purity should be completed by chiral HPLC, gas chromatography
(GC) or spectroscopically (Mosher amide). Furthermore, each enantiomer and
the untested racemic forms should be analyzed for their respective SERT binding
affinities. Completion of the analog series and pharmacological analysis will give
a more complete understanding of our SERT ligand SAR studies.
The tritium labelled ligand [3H]52 was prepared as a representative ligand
to asses the in vitro binding characteristics and receptor selectivity of our
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quipazine ligand family.

Ligand [3H]52 was shown to have superior in vitro

kinetic values (KD, kon and koff) for SERT binding than the SSRIs (+)-MCN5652 6
and (S)-citalopram 7.

Comparison of [3H]52 to the structurally related analog

[125I]INQP 23 shows a similar equilibrium dissociation constant (KD) value. This
suggests that our ligand family will show similar receptor selectivity and the in
vitro kinetic data looks promising for in vivo imaging.

We believe that a

radioligand, i.e. [18F]PROF-NQP 58 will show far superior in vivo characteristics
based upon the lipophilicity of 58 (LogP -2.5) and binding affinity for rSERT (Ki =
2.5 pM).
Furthermore, based on the radiofluorination trials with N-Boc-ProTos-NQP
the N-formyl-ProTos-NQP radiolabeling precursor should be reevaluated for its
potential to provide the radioligand [18F]PROF-NQP 58. Also, it would be very
interesting to determine if the fluoride substitution of the aromatic nitro group is
occurring during the radiofluorination.

This could

be accomplished

by

synthesizing more of the nonradioactive side product 73 and having it
chromatographically tested against the crude mixture from the radiofluorination of
N-Boc-ProTos-NQP 69, under the K222 conditions that gave a 1:1 mixture of the
two fluorinated products (based upon radioactive TLC) and with the TBAF
conditions that favored the formation of the side product (based upon radioactive
TLC).
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Chapter 6
Experimental Section
6.1

General Experimental.
Reactions utilizing dry solvents were performed in oven-dried glassware

under an atmosphere of argon.

Reagent grade chemicals and solvents were

purchased from commercial suppliers (Aldrich, Fisher and VWR) and used
without

further

purification

or

treatment

unless

otherwise

noted.

Methyltriphenylphosphonium Iodide was prepared according to the method of
McCortney, 1990.116 Tosyl chloride was purified according to Armarego . 117 Dry
solvents (ACN, THF, Et2 0 , DMF and CH2CI2 ) were purchased from J.T. Baker,
EMD science, and Acros, and used without further treatment. The concentration
of n-BuLi (Aldrich) was estimated according to the method of Kofron. 118
NMR spectra 1H and 13C were obtained using a Varian-Unity spectrometer
operating at 400 MHz and 100 MHz respectively. Chemical shifts were recorded
in parts per million (ppm, 5) and were reported relative to the solvent peak of
CHCI3 (7.26 ppm). High resolution mass spectra (HRMS) were obtained using
an electrospray ionization (ESI) Micromass LCT connected to a Water 2790
HPLC.

Optical rotations were determined at ambient temperature utilizing a

Perkin-Elmer 241 polarimeter at the sodium D-line (589 nm) and a 10 cm (1 dm)
cell.

Specific rotations were calculated using the relationship [a]20D = a / L*c;

where a is the observed rotation, L is the path length and c is the concentration
in grams solute / solution volume (g/mL).

Column chromatography was
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performed using EM Science, Silica gel 60 (230-400 mesh ASTM).

Reactions

were monitored by TLC using EM Science 20 x 20 cm Silica gel 60 F254
aluminum backed plates. Compound spots were detected visually by ultraviolet
light at 254nm and 365 nm or by staining with ninhydrin (0.3 g ninhydrin, 100 mL
EtOH, 3 mL AcOH) or vanillin (15 g vanillin, 250 mL EtOH, 2.5 Ml H2 SO 4 )
developed by heating. Reactions were performed at room temperature 21-25 °C
(RT °C) unless otherwise specified. All pH determinations were performed using
EM ColorpHast pH strips. All organic extractions were dried with K2 CO 3 and
filtered before concentration unless otherwise specified. Biotage purification was
carried out on a Biotage Sp1 high-performance flash chromatography system
(Biotage, Charlottesville, VA) equipped with a Biotage NH normal phase Flash
column (12-M). Elution solvents were; solvent A: hexanes and solvent B: EtOAc.
The flash column was pre-equilibrated with 10% B at 10 mL/min.

6.2

Racemic Propyl Series

LiAIH4, EtoO

O
1,4-Dibenzyl-2-hydroxymethylpiperazine (33). A suspension of LiAIH4 (1.53 g,
40.3 mmol) in dry ether (80 mL) was treated with a solution of ethyl 1,4dibenzylpiperazine-2-carboxylate 32 (11.4 g, 33.6 mmol) in dry ether (30 mL) at 0
°C under argon, maintaining a gentle effervescence. The reaction was stirred for
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30 min and the ice bath was removed. Stirring was continued at 25 °C for 1 hour.
The reaction was quenched by consecutive addition of H20 (1.5 mL), NaOH (3
mL 3 M) and H20 (1.5 mL); the inorganic salts were filtered over a pad of Celite,
and the pad was rinsed with EtOAc. The filtrate was concentrated in vacuo to
give 33 as a clear oil (9.45 g, 96%): TLC Rf = 0.33 (1:9 MeOH/CH2CI2); 1H NMR
(CDCIs, 400 MHz) 5 2.30-2.73 (3m, 7H), 2.95 (m, 1H), 3.39-3.67 (m, 4H), 3.934.14 (m, 2H), 7.20-7.40 (m, 10H); 13C NMR (CDCI3, 100 MHz) 5 49.8, 52.4, 56.0,
58.0, 58.5, 62.1, 63.1, 127.0, 127.2, 128.3, 128.8, 129.1, 137.5, 138.0.

DMSO, (COCI)2

1,4-Dibenzyl-piperazine-2-carboxaldehyde (44). DMSO (3.5 g, 44.6 mmol) in
dry CH2CI2 (15 mL) was added dropwise to a solution of oxalyl chloride (2 M in
CH2CI2, 17.7 mL, 35.4 mmol) in dry CH2CI2 (80 mL) at -78 °C (dry ice, acetone
bath). After 5 min a solution of 1,4-dibenzyl-2-hydroxymethyl-piperazine 33 (9.45
g, 32.14 mmol) in dry CH2CI2 (30 mL) was added dropwise, the solution was
allowed to stir for an additional 20 min. The reaction was treated with Et3N (16.3
g, 160.7 mmol), forming a tan precipitate and allowed to stir for 5 min.

The

mixture was allowed to warm to room temperature and stir for 1 hour.

The

reaction was quenched by the addition of water (100 mL), the organics were
separated and the aqueous phase was extracted with CH2CI2 (75 mL).

The

combined organics were washed with saturated NaHC03 (50 mL), dried with
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K2 CO 3 and concentrated in vacuo.

The aldehyde was used in the next step

without further purification: TLC R f = 0.69 ( 1 :9 MeOH/Ch^C^).

n-BuLi, Triethylphosphono-

3-(1,4-Dibenzyl-piperazin-2-yl)-acrylic acid ethyl ester (45). A stirred solution
of n-BuLi (17 mL, 2.45 M in hexanes, 40.8 mmol) in dry TH F (30 mL) was treated
with triethylphosphonoacetate (9.1 g, 40.8 mmol) at 0 °C under argon, to give a
light yellow solution.

After 15 min a solution of 1,4-dibenzyl-piperazine-2-

carbaldehyde 44 (6.0 g, 20.4 mmol) in dry TH F (10 mL) was added dropwise to
the cooled solution. The reaction mixture was allowed to warm to room
temperature and to stir for 20 h. The reaction was quenched by the addition of
water (25 mL) and concentrated in vacuo to remove THF.

The aqueous layer

was treated with 20 mL of sat. NaHCOs and extracted with CH 2 CI2 (3 x 20 mL).
The combined organics were washed with brine (20 mL), dried (K 2 CO 3 ) and
concentrated

in

vacuo.

The

crude

orange

oil was

purified

by

column

chromatography over silica gel (80 g) loaded with CHCI 3 eluted with 1:9
EtOAc/hexanes followed by 1:3 EtOAc/hexanes to elute 45 as a light tan oil (4.6
g, 64%

2

steps):

EtOAc/hexanes);

TLC R f = 0.63 (M eOH:CH 2 CI2, 1:9) or R f = 0.36 (2:3
1H NMR (CDCI3, 400 MHz)

6

1.29 (t, J = 7.1 Hz, 3H), 2.10-

2.30 (2m, 3H), 2.60-2.77 (2m, 3H), 3.12 (m, 1H), 3.50 (dd, J = 13.3 and 17.5 Hz,
2H), 3.91 and 3.12 (2d, J = 13.6 Hz, 2H), 4.19 (q, J = 7.1 Hz, 2H), 6.04 (d, J =
15.9 Hz, 1H), 6.98 (dd, J = 8.4 and 15.9 Hz, 1H), 7.20-7.35 (m, 10H); 13C NMR
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(CDCb, 100 MHz) 5 50.6, 52.8, 58.0, 59.7, 60.4, 62.8, 123.8, 126.9, 127.1,
128.1, 128.2, 128.9, 129.1, 137.7, 138.3, 148.6, 166.1.

H2, 5% Pd/C
EtO.

N 'B n

A c 0 H ’ M e0H

O

Bn' N ^
Bn

EtQ

O

3-(1,4-Dibenzyl-piperazin-2-yl)-propionic acid ethyl ester (55). 5% Pd/C (0.9
g was added to a solution of 3-(1,4-Dibenzyl-piperazin-2-yl)-acrylic acid ethyl
ester 45 (4.5 g, 12.4 mmol) in HPLC grade MeOH (60 mL) and acetic acid (3.7 g,
61.8 mmol). The reaction flask was sealed with a septum, fitted with a hydrogen
balloon and a bleed needle. One balloon of hydrogen was bubbled through the
stirred solution the needle was removed and a second balloon was attached. The
reaction was stirred overnight, then filtered over a pad of Celite, rinsing with
MeOH and concentrated in vacuo. The oil was dissolved in CH 2 CI2 , free based
with 4M NaOH to pH 12 then buffered to pH 10 with sat. N aHC 0

3

- The organics

were separated and the aqueous layer was extracted with CH 2 CI2 (3 x 20 mL).
The organic portions were combined, dried (K 2 CO 3 ) and concentrated in vacuo.
The crude oil was purified by column chromatography over silica gel (44 g)
loaded with CHCI 3 and eluted with 1:3 EtOAc/hexanes to give 55 as clear oil (3.5
g, 78%): TLC Rf = 0.26 (2:3 EtOAc/hexanes) or Rf = 0.5 (3:2 EtOAc/hexanes);
1H NMR (CDCI3 , 400 MHz) 5 1.23 (t, J = 7.3 Hz, 3H), 1.88-2.8 (5m, 12H), 3.23
and 4.02 (2d, J = 13.2 Hz, 2H), 4.11 (q, J = 7.3 Hz, 3H), 7.20-7.40 (m, 10H); 13C
NMR (CDCI 3 , 100 MHz) 5 14.2, 24.4, 30.2, 50.3, 52.7, 56.8, 57.5, 58.5, 60.3,
63.0, 126.7, 126.9, 128.1, 128.7, 129.0, 138.1, 139.0, 173.7.
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UAIH4, Et20

Bn' N ^
EtO.

HO

Bn

H

o

1,4-Dibenzyl-2-(3-hydroxypropyl)-piperazine (56).

Bn

A suspension of LiAIH4

(0.41 g, 10.9 mmol) in dry ether (20 mL) was treated with a solution of 3-(1,4dibenzyl-piperazin-2-yl)-propionic acid ethyl ester 55 (3.3 g, 9.1 mmol) in dry
ether (15 mL) at 0 °C under argon, maintaining a gentle effervescence.

The

reaction was stirred for 5 min and the ice bath was removed. Stirring was
continued at 25 °C for 35 min. The reaction was quenched by consecutive
addition of H20 (0.41 mL), NaOH (0.82 mL, 4 M) and H20 (0.41 mL).

The

inorganic salts were filtered over a pad of Celite and the pad was rinsed with
EtOAc. The filtrate was concentrated in vacuo to give 56 (2.8 g, 95%): TLC
0.1 (3:2 EtOAc/hexanes);

1H NMR (CDCI3 , 400 MHz)

6

Rf =

1.52-1.95 (3m, 4H),

2.12-2.37 (2m, 3H), 2.48-2.80 (3m, 4H), 3.20 and 4.19 (2d, J = 12.8, 2H), 3.48
(dd, J = 17.9 and 13.2 Hz), 3.66 (m, 2H), 7.20-7.40 (m, 10H); 13C NMR (CDCI3,
100 MHz)

6

27.6, 28.6, 50.5, 52.2, 56.4, 57.8, 59.4, 62.8, 63.0, 126.9, 127.1,

128.1, 128.3, 129.0, 129.3, 137.8, 138.0

1,4-Dibenzyl-2-(3-methoxypropyl)-piperazine (57).

A cooled (0 °C) stirred

solution of 1,4-dibenzyl-2-(3-hydroxypropyl)-piperazine 56 (1.7 g, 5.2 mmol) in
dry DMF (15 mL) was treated NaH powder (0.38 g, 15.7 mmol) to give a turbid
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white suspension. The flask was placed under argon and stirring was continued
for 20 min. iodomethane (0.78 g, 5.5 mmol) was added dropwise to the cooled
solution, the reaction was allowed to stir on ice for 20 min, followed by room
temperature for 3.5 h. The reaction was quenched by the addition of water (20
mL) followed by sat. NaHC0 3 (20 mL). The aqueous layer was extracted with
Et20 ( 4 x 1 0 mL), dried

(K 2 C O 3 ),

and concentrated in vacuo to give a tan oil. The

oil was purified by column chromatography over silica gel (45 g) loaded with
C H C I3

and eluted with 1 column length 1:3 EtOAc/hexanes followed by 2:3

EtOAc/hexanes to give a clear oil 57. The oil was pumped briefly and used in the
next step without further purification: Rf = 0.33 (3:2 EtOAc/hexanes); 1H NMR
(C D C I3 ,

400 MHz) 5 1.44-1.85 (m, 4H), 2.08-2.35 (m, 3H), 2.37-2.87 (3m, 4H),

3.20 and 4.03 (2d, J = 13.2 Hz, 2H), 3.31 (s, 3H), 3.35 (m, 2H), 3.48 (q, J = 13.2
Hz, 2H), 7.18-7.40 (m, 10H);

13C NMR (CDCI3, 100 MHz) 5 25.6, 26.1, 50.7,

52.8, 57.48, 57.53, 58.5, 59.3, 63.1, 72.9, 126.7, 126.9, 128.1, 128.9, 129.0,
138.2, 139.1.

H2, 5% Pd/C
12 M HCI, MeOH

2-(3-Methoxypropyl)-piperazine dihydrochloride (48).

A solution of 1,4-

dibenzyl-2-(3-methoxypropyl)-piperazine 57 in HPLC MeOH (20 mL)

and HCI

(12 M, 12.4 mmol, 1 mL) was treated with 5% Pd/C (0.21 g). The flask was
sealed with a septum and a hydrogen balloon was bubbled through the stirred
solution.

The reaction mixture was filtered over a pad of Celite rinsing with
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MeOH and concentrated in vacuo to give a white solid 48 (0.50 g, 53% 2 steps):
1H NMR (DMSO, 400 MHz) 5 1.40-1.85 (m, 4H), 2.92-3.62 (4m, 11H, overlapped
singlet 3.21, 3H), 4.14 (bs, 1H), 9.79-10.31 (2bs, 4H);

13C NMR (DMSO, 100

MHz) 6 24.3, 26.8, 39.3, 39.9, 43.4, 51.5, 57.9, 71.0.

• 2 HCI

H N ^

CIC(Ph>3, EI3N
CH2CI2, 0 ° C

Hf ^ l
H3c "

'

h

' cph3

H

3-(3-Methoxypropyl)-1-tritylpiperazine (49). A solution of 2-(3-methoxypropyl)piperazine dihydrochloride 48 (0.44 g, 1.9 mmol) in dry CH2CI2 (16 mL) and dry
EtaN (0.77 g, 1.1 mL, 7.6 mmol) at 0 °C, was treated with dropwise addition a
solution of trityl chloride (0.53 g, 1.9 mmol) in dry CH2CI2 (5 mL). The ice bath
was removed and the reaction stirred for 3 h at room temperature. The reaction
mixture was transferred to a separatory funnel, diluted to 15 mL with CH2CI2. The
organics were washed with saturated NaHCC>3 (25 mL) and brine (25 mL), dried
(K2CC>3 ) and concentrated in vacuo to give an amorphous white foam 49 (7.3 g,
99% yield): TLC Rf = 0.33 (1:9 MeOH/CH2CI2). The product was used without
further purification, or characterization.

n-BuLi, 2-chloroquinoline
_______ Et2Q, 0 °C;
CPh,
6 M HCI, acetone

H ,C

2-[2-(3-Methoxypropyl)-piperazin-1-yl]-quinoline (50).

A cooled

(0 °C)

solution of 3-(3-methoxypropyl)-1-tritylpiperazine 49 (0.50 g, 1.24 mmol) in dry
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Et2

0

(20 mL) under argon, was treated by a dropwise addition of a solution of n-

BuLi (0.51 mL, 2.45 M in hexanes, 1.24 mmol), giving a white precipitate. The
resulting

suspension was

allowed

to stir for 20

chloroquinoline (0.14 g, 0.83 mmol) in dry Et2

0

min. A

solution of 2-

(5 mL) was added dropwise to

the cooled solution under argon to give a purple solution.

The purple solution

was allowed to stir for 20 min and the ice bath was removed. The reaction was
allowed to stir overnight under argon giving a red-purple solution. The reaction
was quenched by the addition of saturated N aHC 0

3

(20 mL). The organics were

separated and the aqueous phase was extracted 1 x 20 mL with Et2 <D.

The

organic portions were combined, washed with water (50 mL), brine (50 mL), dried
(K 2 CO 3 ), and concentrated in vacuo to give an amorphous foam. The foam was
purified by column chromatography over silica gel (50 g) loaded with CHCI 3 and
eluted with 1:3 EtOAc/hexanes to give a clear yellow oil.

The trityl protected

quipazine (not shown) was dissolved in acetone (3 mL) with stirring. To the
stirred solution was added

6

M HCI (1 mL) giving an orange solution that slowly

generated a white precipitate, stirring continued for 10 min.

The reaction was

diluted out to 25 mL with 1 M HCI, the crude aqueous mixture was extracted with
CH 2 CI2 (4 x 25 mL). The aqueous layer was brought to pH 14 with 4 M NaOH,
and buffered to pH 10 with saturated NaHCOs. The aqueous layer was then
extracted with CH 2 CI2 (4 x 30 mL), dried (K2 C O 3 ), filtered, and concentrated in
vacuo, giving a yellow oil 50 (0.36 g, 82%): TLC R f =

0 .1

( 1 :9 M e O H /C ^ C h ); 1H

NMR (CDCI3 , 400 MHz) 5 1.50-1.70 (m, 2H), 1.72-2.00 (2m, 2H), 2.37 (bs, 1H),
2.88 (dt, J = 3.2 and 12.0 Hz, 1H), 2.95-3.25 (m, 4H), 3.30 (s, 3H), 3.38 (m, 2H),
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4.38 (bd, 1H), 4.52 (bs, 1H), 6.94 (d, J = 9.1 Hz, 1H), 7.20 (ddd, J = 1.3 and 7.1
Hz, 1H), 7.52 (ddd, J = 1.7 and 6.8 Hz, 1H), 7.58 (dd, J = 1.3 and 7.8 Hz, 1H),
7.84 (d, J = 8.4 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 6 24.7, 26.7, 40.0, 46.0,
47.9, 51.4, 58.6, 72.6, 109.3, 122.0, 122.8, 126.4, 127.1, 129.4, 137.4, 147.9,
157.0.

o 2n
h n o 3, h 2s o 4

H3C

NH

R T °C
H3C

H

NH
H

2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-nitroquinoline ((±)-51). A cooled (0
°C) stirred solution of 2-[2-(3-methoxypropyl)-piperazin-1-yl]-quinoline 50 (0.35 g,
1.2 mmol) in H2SO4 (16 M, 15 mL) was treated with HN03 (15.4 M, 0.32 mL) by
dropwise addition. The resultant solution was allowed to stir for 20 min, then
quenched by pouring onto ice. The acid was neutralized with 4 M NaOH to give
a bright yellow solution. The resulting solution was buffered to pH 10 with sat.
NaHC03. The aqueous solution was extracted with CH2CI2 until minimal yellow
color persisted in the aqueous layer. The organics were dried (K2C03), and
concentrated in vacuo to give a bright yellow oil (±)-51 (0.40 g, 99% yield): TLC
Rf = 0.14 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.46-1.68 (m, 2H),

1.78-2.00 (m, 2H), 1.92 (bs, 1H), 2.82 (dt, J = 3.6 and 12.0 Hz, 1H), 2.96 (dd, J =
3.9 and 12.3 Hz, 1H), 3.03-3.15 (m, 2H), 3.15-3.26 (m, 1H), 3.29 (s, 3H), 3.38
(m, 2H), 4.45 (bd, 1H), 5.59 (bs, 1H), 7.01 (d, J = 9.4 Hz, 1H), 7.57 (d, J = 9.4
Hz, 1H), 7.87 (d, J = 9.4 Hz, 1H), 8.24 (dd, J = 2.6 and 9.4 Hz, 1H), 8.47 (d, J =
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2.6 Hz, 1H);

13C NM R (CDCI3, 100 MHz) 5 25.6, 26.7, 40.1, 46.0, 48.1, 51.6,

58.8, 72.7, 111.0, 121.1, 123.8, 124.4, 127.2, 138.8, 141.9, 151.8, 158.6; HRMS
(ESI-TO F) m/z (M + H)+ calcd. for C 1 7 H 2 3 N 4 O 3 331.1770 found 331.1770.

o 2n

o 2n

88% Formic acid

h 3c -

NH

AC2O

h 3c

H

H

N-Formyl-3-(3-methoxypropyl)-4-(6-nitroquinolin-2-yl)piperazine

(60).

A

solution of 2-[2-(3-methoxypropyl)-piperazin-1-yl]-6-nitroquinoline (±)-51 (0.19 g,
0.58 mmol) in 88% formic acid (1.5 mL) was treated with acetic anhydride (Ac20 )
(0.54 g, 0.5 mL, 5.2 mmol) and the reaction stirred for 30 min. The reaction was
quenched by pouring onto ice, then brought to basic pH with 4 M NaOH, buffered
to pH 10 with sat. NaHCC>3 . The basic portion was extracted with CH2CI2 ( 3 x 1 0
mL). The organic portions were combined, dried (K2CC>3 ), and concentrated in
vacuo to give 60 as a yellow oil (0.19 g, 91%):
MeOH/CH2CI2);

TLC R f = 0.65

(1:9

1H NMR (CDCI3, 400 MHz) (1:1 mixture of amide rotamers) 5

1.45-1.90 (m, 4H), 2.9 (dt, J = 4.2 and 12.6 Hz, 0.5H), 2.98 (dd, J = 3.9 and 13.3,
0.5H), 3.14-3.43 (m, 7.5H), 3.44-3.51 (m, 0.5H), 3.58 (bd, 0.5H), 3.70 (bd, 0.5H),
4.45 (bt, 1H), 4.74 (bs, 0.5H), 4.91 (bs, 0.5H), 7.70 (dd, J = 7.4 and 9.1 Hz, 1H),
7.63 (d, J = 9.1 Hz, 1H), 7.98 (d, J = 9.4 Hz, 1H), 8.09 (s, 0.5H), 8.2 (s, 0.5H),
8.28 (dd, J = 2.6 and 9.1 Hz, 1H), 8.51 (d, J = 2.6 Hz, 1H).
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o 2n

o 2n

BBr3, CH2CI2

-78 °c

Y °

h 3c

H

H

H

N-Formyl-3-(3-hydroxypropyl)-4-(6-nitroquinolin-2-yl)piperazine
solution

of

(61).

A

N-formyl-3-(3-methoxypropyl)-4-(6-nitroquinolin-2-yl)piperazine

60

(0.19 g, 0.53 mmol) in dry CH2CI2 (25 mL) was cooled at -78 °C in a dry ice
acetone bath. A solution of BBr3 (2.6 mL, 1 M in CH2 CI2 , 2.6 mmol, Aldrich) was
added dropwise under argon giving a dark purple suspension. After 2 h the
reaction was warmed to RT °C and stirred for 2.5 h giving a yellow-orange
suspension. The reaction was quenched by the addition of sat. NaHC0 3 (20 mL),
the organic portion was separated and the aqueous was extracted with CH2 CI2 (3
x 20 mL). The organic portions were combined, dried (K2C 0 3), filtered and
concentrated

in

vacuo.

The

crude

material was

purified

by column

chromatography over silica gel (8 g) eluting with 4:1 EtOAc/CHCI3 to elute the
bromide side product 62, followed by 1:19 MeOH/EtOAc to elute the product,
concentration in vacuo gave 61 as a yellow foam (0.12 g, 66% yield): TLC
0.43

(1:9 MeOH/CH2CI2);

Rf

=

1H NMR (CDCI3, 400 MHz) (mixture of amide

rotamers) 6 1.48-1.96 (m, 5H), 2.88-3.08 (m, 1H), 3.24-3.45 (m, 1.5H), 3.50 (dd,
J = 3.9 and 13.6 Hz, 0.5H), 3.61 (bd, J = 13.3 Hz, 0.5H), 3.66-3.84 (m, 2.5H),
4.24-5.15 (bm, 3H), 7.11 (d, J = 9.4 Hz, 1H), 7.76 (bs, 1H), 8.04 (d, J = 9.1 Hz,
1H), 8.12 (s, 0.5H), 8.26 (s, 0.5H), 8.33 (dd, J = 2.6 and 9.4 Hz, 1H), 8.57 (d, J =
2.6 Hz, 1H).
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2-[2-(3-Hydroxypropyl)-piperazin-1-yl]-quinoline (147). A solution of N-formyl3-(3-hydroxypropyl)-4-(6-nitroquinolin-2-yl)piperazine 61 (0.029 g, 0.084 mmol)
in THF (1 mL) was treated with H2SO 4 (4 M, 0. 5 mL) and heated at 55 °C for 1
hour. The reaction was quenched by pouring onto ice. The mixture was brought
to a basic pH with 4 M NaOH, and buffered to pH 10 with sat. NaHC0 3 . The
aqueous layer was extracted with CH2 CI2 ( 3 x 1 0 mL), the organic portions were
combined, dried (K2C 0 3) and concentrated in vacuo to give 147 as yellow oil
(0.021 g, 90%): 1H NMR (CDCI3, 400 MHz) 5 1.61 (m, 2H), 1.80 (m, 1H), 2.07
(m, 1H), 2.49 (bs, 2H), 2.86 (td, J = 3.6 Hz, 12.3 Hz, 1H), 2.97 (dd, J = 3.9 Hz,
12.3 Hz, 1H), 3.04-3.18 (m, 2H), 3.27 (td, J = 3.6 Hz, 12.6 Hz, 1H), 3.74 (m, 2H),
4.20 (bd,1H), 4.74 (bs, 1H) 7.04 (d, J = 9.4 Hz, 1H), 7.67 (d, J = 9.4 Hz, 1H),
7.93 (d, J = 9.4 Hz, 1H), 8.26 (dd, J = 2.6 Hz, 9.1 Hz, 1H), 8.49 (d, J = 2.6 Hz,
1H); 13C NMR (CDCI3, 100 MHz) 524.7, 28.4, 41.1, 46.1, 47.7, 50.7, 62.4, 111.0,
120.9, 123.8, 124.1, 126.6, 138.7, 141.8, 151.4, 158.3; HRMS (ESI-TOF) m /z (M
+ H)+ calcd. for C 16H21 N4 O3 317.1614 found 317.1604.
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o 2n

o 2n

Tosyl-CI, pyridine
CH 2 CI2, 0 - RT °C
H

H

X = OTs, Cl

H

3-(4-Formyl-1-(6-nitroquinolin-2-yl)piperazin-2-yl)propyl-4methylbenzenesulfonate (63).

In an

8

mL vial a solution of N-formyl-3-(3-

hydroxypropyl)-4-(6-nitroquinolin-2-yl)piperazine 61 (0.081 g, 0.24 mmol) in dry
CH2CI2 (0.5 mL) and dry pyridine (0.029 g, 0.37 mmol) was cooled at 0 °C. To
the solution was added tosyl chloride (0.062 g, 0.33 mmol). The vial was flushed
with argon and sealed with a cap and Para film. The solution was allowed to stir
at RT °C for 3 h. The crude reaction mixture was purified by column
chromatography over silica gel (12 g) loaded with CHCI3 , eluting with 1:1
EtOAc/hexanes followed by 4:1 EtOAc/CHCI3 to give the product 63 as a yellow
foam (0.060 g, 51% yield): TLC Rf = 0.71 (1:9 MeOH/ChbCb); Determined by
NMR to be a 1:1 mixture of N-formyl-ProTos-NQP 63 and N-formyl-ProCI-NQP
64. 1H NMR (CDCI3 , 400 MHz) (mixture of amide rotamers) 5 1.70-2.02 (m,

8

H),

2.44 (s, ArCH3, 3H), 2.90 (dt, J = 4.2 and 12.6, 1H), 3.03 (dd, J = 3.9 and 13.3
Hz), 3.20-3.60 (m, 10H), 3.73 (bd, 1H), 4.30-4.70 (4m, 4H), 4.88 (bs, 1H), 5.10
(bs, 1H), 7.07 (dd, J = 2.9 and 9.1 Hz, 2H), 7.33 (d, J = 7.8 Hz, 2H), 7.66 (dd, J =
4.5 and 9.4 Hz, 2H), 7.78 (d, J = 8.1 Hz, 2H), 8.03 (d, J = 9.4 Hz, 2H), 8.12 (s,
1H), 8.26 (s, 1H), 8.31 (dd, J = 2.6 and 9.4 Hz, 2H), 8.55 (d, J = 2.6 Hz, 2H).

132

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

N Y °

H

55 °c

FH

H

N-Formyl-3-(3-fluoropropyl)-4-(6-nitroquinolin-2-yl)piperazine (65).

In an

8

mL vial a solution of 3-(4-formyl-1-(6-nitroquinolin-2-yl)piperazin-2-yl)propyl4methylbenzenesulfonate 63 (0.056 g, 0.11 mmol) in dry THF (0.30 mL) was
treated with a solution of TBAF (0.16 mL, 1 M in THF, 0.16 mmol, Aldrich) to give
a dark orange solution. The vial was capped and heated at 55 °C for 2 h. The
reaction was concentrated in vacuo and then dissolved in

C H C I3 .

material was purified by column chromatography over silica gel

(2

The crude

g) eluting with

1:1 EtOAc/hexanes followed by 1:19 MeOH/EtOAc and concentrated in vacuo to
give 65 as a yellow foam (0.025 g, 64%): TLC Rf = 0.22 (1:19 MeOH/EtOAc); 1H
NMR

(C D C I3 ,

400 MHz) (mixture of amide rotamers) 5 1.60-2.00 (m, 4H), 2.90

(dt, J = 3.6 and 12.3 Hz, 0.5H), 3.00 (dd, J = 4.2 and 13.3 Hz, 0.5H), 3.20-3.40
(2m, 2H), 3.44-3.62 (m, 1.5H), 3.72 (bd, 0.5H), 4.32-4.60 (m, 3H), 4.83 (bs,
0.5H), 5.07 (bs, 0.5H), 7.07 (dd, J = 3.2 and 9.4 Hz, 1H), 7.69 (m, 1H), 8.03 (d, J
= 9.1 Hz, 1H), 8.10 (s, 0.5H), 8.25 (s, 0.5H), 8.32 (dd, J = 2.6 and 9.1 Hz, 1H),
8.56 (d, J = 2.3 Hz, 1H).
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2-(2-(3-Fluoropropyl)piperazin-1-yl)-6-nitroquinoline

(58).

formyl-3-(3-fluoropropyl)-4-(6-nitroquinolin-2-yl)piperazine 65

A solution of N(0.025 g, 0.072

mmol) in THF (0.5 mL) was treated with H2SO 4 (4 M, 0.25 mL) and heated at 60
°C for 1 hour. The reaction was quenched by pouring onto ice. The mixture was
brought to a basic pH with 4 M NaOH, and buffered to pH 10 with sat. NaHC0 3 .
The aqueous layer was extracted with CH2CI2 ( 3 x 1 0 mL), the organic portions
were combined, dried (K2CO 3 ) and concentrated in vacuo to give 58 as yellow oil
(0.021 g, 90%): TLC Rf = 0.35 (1:9 MeOH/CH2 CI2); 1H NMR (CDCI3, 400 MHz)
6

1.56-2.10 (2m, 5H, CH2 CH2 CH2F and NH), 2.91 (dt, J = 3.3 and 12.3 Hz, 1H),

3.06 (dd, J = 3.9 and 12.3 Hz, 1H), 3.14-3.38 (3m, 3H), 4.40-4.60 (2m, 2H,
CH2 F), 4.81 (bs, 1H), 7.04 (d, J = 9.4 Hz, 1H), 7.64 (d, J = 9.1 Hz, 1H), 7.99 (d, J
= 9.4 Hz, 1H), 8.31 (dd, J = 2.6 and 9.4 Hz, 1H), 8.54 (d, J = 2.6 Hz, 1H).

BBr3, CH 2 CI2, -78 °C;
NH

[(CH3 )3 COCO]2 0 , CH 2 CI2> 0 °C

O.

*
ferf-Butyl-3-(3-hydroxypropyl)-4-(6-nitroquinolin-2-yl)piperazine-1carboxylate

(66).

A

solution

of 2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-

nitroquinoline 50 (0.16g, 0.48 mmol) in dry CH2 CI2 (50 mL) was cooled at -78 °C
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in a dry ice acetone bath. A solution of BBr3 (2.4 mL,

1M

in CH2CI2 , 2.4 mmol)

was added dropwise under argon giving a dark purple suspension. After 3 h the
reaction was warmed to RT °C and stirred for an additional 4 h giving a yelloworange suspension. The reaction was quenched by the addition of sat. NaHCC>3
(20 mL). The organic layer was separated and the aqueous layer was extracted
3 x

20

mL CH2 CI2 . The organic portions were combined, dried (K2CO 3 ), filtered

and concentrated in vacuo. The yellow semi-solid was transferred to a 50 mL
flask with

0

.5:9.5 MeOH/ChfeCh and concentrated. The residue was treated with

CH2CI2 (45 mL) sonicated to suspend all the material, then cooled to

0

°C and

treated with di-ferf-butyl dicarbonate (0.1g, 0.48 mmol). After 2.5 h the reaction
was warmed to RT °C and allowed to stir an additional hour. The solution was
concentrated in vacuo (25 °C) and suspended in CHCI3. The crude material was
purified by column chromatography over silica gel
EtOAc/hexanes, concentrated in vacuo to give

66

(8

g) eluting with 3:2

as a yellow foam (0.088 g,

44% yield, 2 steps): TLC Rf = 0.29 (6:4 EtOAc/hexanes); 1H NMR (CDCI3, 400
MHz) 5 1.40-1.94 (1 s and 2m, 13H), 2.90-3.22 (bm, 2H), 3.24-3.42 (m, 1H), 3.663.88 (bs, 2H), 3.94-4.34 (bm, 3H), 4.76 (bs, 1H), 7.04 (d, J = 9.2 Hz, 1H), 7.67 (d,
J = 9.2 Hz, 1H), 7.95 (d, J = 9.5 Hz, 1H), 8.25 (dd, J = 2.6 and 9.5 Hz, 1H), 8.47
(d, J = 2.6 Hz, 1H); 13C NMR (CDCI3 , 100 MHz) (mixture of amide rotamers) 5
24.9, 25.2, 28.3, 40.0, 42.7, 43.8, 44.4, 45.5, 50.7, 51.5, 62.2, 80.3, 111.1, 121.1,
123.8, 124.1, 126.7, 139.0, 141.9, 151.1, 154.9, 158.1; HRMS (ESI-TOF) m /z (M
+ H)+ calcd. for C21 H29 N4 O5 417.2138 found 417.2132.
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Tosyl-CI, pyridine
H

O.

*

*

3-(4-(ferf-Butoxycarbonyl)-1-(6-nitroquinolin-2-yl)piperazin-2-yl)propyl

4-

methylbenzenesulfonate (69). A solution of tert-butyl 3-(3-hydroxypropyl)-4-(6nitroquinolin-2 -yl)piperazine-1 -carboxylate
(1 mL) and dry pyridine

(6

66

(0.040g, 0.097 mmol) in dry CH2 CI2

drops from 18 gauge needle) in an

8

mL vial, was

cooled to 0 °C. To the solution was added tosyl chloride (0.078 g, 0.41 mmol),
the vial was flushed with argon and sealed with a cap and Parafilm. The solution
was allowed to stir warming to RT °C overnight. The crude reaction mixture was
diluted with CH2 CI2 (5 mL), washed with sat. NaHCC>3 (5 mL), dried K2 CO3 ,
filtered and concentrated in vacuo. The crude material was purified by column
chromatography over silica gel

(1 2

g) loaded with CHCI3 , eluting with 2:3

EtOAc/hexanes, concentration in vacuo gave 69 as a yellow foam (0.042 g, 76%
yield): TLC Rf = 0.37 (6:4 EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.47
(s, 9H), 1.60-1.82 (bm, 4H), 2.41 (s, 3H), 2.80-3.30 (2bm, 3H), 3.92-4.44 (bm,
2H), 4.76 (bs, 1H), 7.00 (d, J = 9.5 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.58 (d, J =
9.1 Hz, 1H), 7.73 (d, J = 8.1 Hz, 1H), 7.96 (d, J = 9.5 Hz, 1H), 8.26 (dd, J = 2.6
and 9.2 Hz, 1H), 8.50 (d, J = 2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) (mixture
of amide rotamers) 5 21.6, 24.6, 25.5, 28.3, 39.5, 42.7, 43.8, 44.9, 46.1, 50.7,
51.0, 70.0, 80.3, 110.6, 121.0, 123.6, 124.2, 125.8, 127.1, 127.8, 129.8, 132.8,
139.0, 141.9, 144.8, 151.2, 154.8, 158.0; HRMS (ESI-TOF) m /z (M + H)+ calcd.
for C28H35N4 O 7S 571.2226 found 571.2222.
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2-(2-(3-Fluoropropyl)piperazin-1-yl)-6-nitroquinoline (58). A solution of 3-(4(terf-butoxycarbonyl)-1-(6-nitroquinolin-2-yl)piperazin-2-yl)propyl-4methylbenzenesulfonate 69 (0.042 g, 0.074 mmol) in dry THF (1 mL) in an

8

mL

vial was treated with a solution of TBAF (0.11 mL, 1 M in THF, 0.11 mmol,
Aldrich) to give a dark orange solution. The vial was capped and heated at 55 °C
for 3 h. The reaction was concentrated in vacuo and dissolved in CHCI3 . The
crude material was purified by column chromatography over silica gel

(8

g)

eluting with 2:3 EtOAc/hexanes to give the product as a yellow foam (0.025 g,
79%). TLC Rf = 0.49 (3:2 EtOAc/hexanes). A portion (4 mg) of the purified NBoc-PROF-NQP 70 was treated with H2SO 4 (0.5 mL, 16 M) at RT °C and stirred
for 4 min. The reaction was quenched by pipetting the mixture onto ice, then
rinsing the vial with ice cold water. The aqueous solution was brought to a basic
pH (persistent yellow color) with 4 M NaOH at 0 °C then buffered to pH 10 with
saturated NaHC03. The aqueous solution was extracted with CH2CI2 ( 3 x 5 mL),
the organic portions were combined, dried (K2CO 3 ), filtered, and concentrated in
vacuo. The crude material was purified over silica gel

and eluted with

1 :49

MeOH/CHCh followed by

1 :9

(1

g) loading with CHCI3

MeOH/CHCh to give the final

amine product 58 as a yellow oil (0.002, 78% yield):

TLC Rf = 0.22 (1:9

MeOH/CH2 CI2); 1H NMR (CDCI3, 400 MHz) 5 1.56-2.10 (2m, 5H, CH2 CH2 CH2F
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and NH ) , 2.91 (dt, J = 3.3 and 12.3 Hz, 1H), 3.06 (dd, J = 3.9 and 12.3 Hz, 1H),
3.14-3.38 (3m, 3H), 4.40-4.60 (2m, 2H, C tf 2 F), 4.81 (bs, 1H), 7.04 (d, J = 9.4 Hz,
1H), 7.64 (d, J = 9.1 Hz, 1H), 7.99 (d, J = 9.4 Hz, 1H), 8.31 (dd, J = 2.6 and 9.4
Hz, 1H), 8.54 (d, J = 2.6 Hz, 1H).

6.3

Chiral Propyl N-formyl Series.

EDC«HCI, pentafluorophenol
N-Boc-N-Bn-glycine

G 0 2M ©
e

©

Cl H3N :

OO2M6

i
Bn

Et3 N, CH 2 CI2

II

O

j-'

CO2M6

H

(R)-N-Boc-N-Benzyl-glycyl-L-glutamate Dimethyl Ester ((R)-133). N-Ethyl-N(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (1.4 g, 7.1 mmol) was
suspended with stirring in

C H 2C I2

(30 mL), to the suspension was added a

solution of pentafluorophenol (PFP) (1.75 g, 9.5 mmol) in

C H 2C I2

stirred for 20 min. N-Boc-N-Benzyl glycine (1.6 g, 5.9 mmol) in

(10 mL) and

C H 2C I2

(20 mL)

was added to the stirred solution. The mixture was allowed to stir for 1 hour, and
EtaN (3.0 mL) was added followed by D-glutamate dimethyl ester hydrochloride
D-132 in

C H 2C I2

(20 mL). The reaction was allowed to stir for 24 h at 21 °C. The

crude reaction mixture was washed with 1 M Na2 C 0 3 (120 mL), 1 M citric acid
(120 mL), and water (60 mL). The organic layer was dried (K2 C0 3 ), filtered, and
concentrated

in

vacuo.

The

crude

material

was

chromatography over silica gel (50 g) loaded with

purified

C H C I3 ,

by

column

eluting with 1:3

EtOAc/hexanes (1 column length) followed by 2:3 EtOAc/hexanes to elute PFP
and then 3:2 EtOAc/hexanes, concentration in vacuo to elute (R)-133 as a clear
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oil (2.19 g, 87%): TLC Rf = 0.69 (1:9 MeOH/CH2 CI2); 1H NMR (CDCI3> 400 MHz)
5 1.48 (s, 9H), 1.87 (bs, 1H), 2.00-2.43 (2bs, 3H), 3.65 (s, 3H), 3.71 (s, 3H), 3.80
(m, 1H), 4.39 (d, J = 15.5 Hz, 1H), 4.48-4.72 (m, 2H), 6.56 and 6.91 (2bs, 1H),
7.12-7.40 (m, 5H); 13C NMR (CDCI3, 100 MHz) 5 50.5, 51.3, 51.7, 52.4, 81.3,
127.6, 128.1, 128.6, 137.1, 169.2, 171.7, 172.9.

The opposing enantiomer was similarly prepared:

Bn

o

H

(S)-N-Boc-N-Benzyl-glycyl-L-glutamate Dimethyl Ester ((S)-133).

Clear oil;

(2.28 g, 91%).

o
1)S O C I2, MeOH
2) NH 4 OH, MeOH

Ethyl 3-((/?)-4-benzyl-3,6-dioxopiperazin-2-yl)propanoate ((/?)-134). A cooled
(0 °C) stirred solution of (R)-N-Boc-N-Benzyl-glycyl-L-glutamate dimethyl ester
(fl)-133 (2.2 g, 5.2 mmol) in methanol (30 mL, HPLC grade) was treated with
thionyl chloride (3.2 g, 27.1 mmol) dropwise, then allowed to stir at 0 °C for 15
min and at RT °C for 2 h. The reaction was concentrated in vacuo and then
placed under high vacuum for 10 min to give a white foam. The foam was
triturated with ether (2 x 30 mL). The resultant white oily semi-solid was placed
under high vacuum overnight to give a white foam. The foam was dissolved in
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methanol (60 mL, HPLC grade) and stirred. Ammonium hydroxide (12 mL, 177
mmol, 28-30%) was added and the mixture was stirred for 24 h. The crude
mixture was concentrated in vacuo to give a white solid. The solid was dissolved
in sat. NaHC0 3 (50 mL) and 4:1 CHCI3/IPOH (50 mL), the organic layer was
separated, and the aqueous layer was extracted with 4:1 CHCI3/IPOH (3 x 30
mL). The organic portions were combined, dried (K2 CO3 ), filtered, and
concentrated in vacuo to give a clear oil (R)-134 (1.25 g, 84% yield), which
required no further purification:

TLC

Rf

= 0.39 (1:9 MeOH/Ch^Cb);

1H NMR

(CDCI3 , 400 MHz) 5 2.16 (m, 2H), 2.44 (m, 2H), 3.61 (s, 3H), 3.79 (q, J = 6.5 and
17.8 Hz, 2H), 4.1 (bt, 1H), 4.54 (m, 2H), 7.14-7.42 (m, 5H), 7.85 (s, 1H);

13C

NMR (CDCI3 , 100 MHz) 5 29.0, 29.3, 48.7, 49.5, 51.8, 54.3, 128.0, 128.2, 128.8,
135.0, 165.4, 166.1, 173.1.

The opposing enantiomer was similarly prepared:
o

Ethyl 3-((S)-4-benzyl-3,6-dioxopiperazin-2-yl)propanoate ((S)-134). Clear oil;
(1.30 g, 81%).
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o
UAIH4i THF
HO

EtO

Bn

O

0 °C reflux

H

Bn

O

3-((R)-4-Benzylpiperazin-2-yl)propan-1-ol ((/?)-135).

A stirred and cooled (0

°C) suspension of LiAIH4 (0.93 g, 24.5 mmol) in dry THF (30 mL) under argon,
was treated with a solution of ethyl 3-((f?)-4-benzyl-3,6-dioxopiperazin-2yl)propanoate (/?)-134 (1.42 g, 4.89 mmol) in THF (30 mL) by syringe,
maintaining a gentle effervescence. The reaction flask was fitted with a watercooled condenser and the reaction was heated at reflux for 2 h. The mixture was
allowed to cool to room temperature and stir overnight.

The reaction was

quenched by consecutive addition of water (0.8 mL), NaOH (1.7 mL, 4 M), then
water (0.8 mL). The inorganic solids were vacuum filtered (Celite pad) and the
rinsed with EtOAc. The filtrate was concentrated in vacuo, giving (/?)-135 as a
clear oil (1.16 g, quantitative): TLC

Rf

= 0.06 (1:9 M eOH/C^Cb)- The product

was used without further purification, or characterization.

The opposing enantiomer was similarly prepared:

3-((S)-4-Benzylpiperazin-2-yl)propan-1-ol ((S)-135). Clear oil; (1.04 g, 98%).
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o
A

AC2 0
HO.
H

Bn

88

% formic acid

HO.

Bn

H

(R)-4-Benzyl-2-(3-hydroxypropyl)piperazine-1 -carbaldehyde

((/?)-136).

A

cooled (0 °C) solution of 3-((R)-4-benzylpiperazin-2-yl)propan-1-ol (/?)-135 (1.16
g, 4.95 mmol) in formic acid (23 M, 12.5 mL) was treated dropwise with acetic
anhydride (4.2 mL, 44.6 mmol). The solution was allowed to stir for 5 min at 0
°C, then allowed to warm to room temperature and stir overnight. The reaction
was quenched by pouring onto ice, and then basified with 4 M NaOH to pH 12.
The resultant mixture was buffered to pH 10 with a saturated solution of
NaHCC>3 . The aqueous layer was extracted with CH2 CI2 , the organic portions
were combined, dried (K2CO 3 ), filtered and concentrated in vacuo, to give a light
brown oil 1.25 g (89% crude yield). The crude material was purified by column
chromatography over silica gel (50 g) loaded with CHCI3 and eluted with 0.3:9.7
MeOH/CH2 CI2 to elute (/?)-136 as a clear oil (0.81 g, 63%): TLC Rf = 0.22 (1:9
MeOH/CH2 CI2); 1H NMR (CDCI3, 400 MHz) 5 1.25-1.58 (m,

2

1H), 1.89-2.27 (m, 3H), 2.65-3.05 (m, 2H), 3.20-3.80 (m,

H), 4.05-4.55 (2m,

1H), 7.15-7.50 (m, 5H), 8.00 (s, 1H);

6

H), 1.60-1.86 (m,

13C NMR (CDCI3, 100 MHz) (mixture of

amide rotamers) 5 26.0, 26.6, 28.7, 29.1, 36.3, 42.2, 48.1, 52.6, 53.5, 54.7, 55.3,
56.6, 62.0, 62.3, 62.5, 127.2, 128.3, 128.7, 137.7, 161.0, 161.3.
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The opposing enantiomer was similarly prepared:
o

H

(S)-4-Benzyl-2-(3-hydroxypropyl)piperazine-1-carbaldehyde ((S)-136). Clear
oil; (0.73 g, 73%).

O

A

O

NaH, DMF, 0°C ;

A

(/?)-4-Benzyl-2-(3-methoxypropyl)piperazine-1-carbaldehyde ((/?)-137).

A

cooled (0 °C) stirred solution of (R)-4-benzyl-2-(3-hydroxypropyl)piperazine-1carbaldehyde (/?)-136 (0.81 g, 3.11 mmol) in dry DMF (50 mL) was treated with
NaH powder (0.22 g, 9.3 mmol) in a portion-wise fashion, giving an off-white
suspension. The resulting suspension was allowed to stir for 45 min at 0° C. To
the suspension was added (dropwise) iodomethane (0.19 mL, 3.11 mmol) with
stirring at 0 °C for 5 min and then RT °C for 2.5 h. The reaction was quenched
by the addition of water (40 mL). The aqueous solution was extracted with Et2 0
(3 x 30 mL) and EtOAc (15 mL). The organic portions were combined, dried
(K2 CO3 ), and concentrated in vacuo to give a tan oil. The crude material was
purified by column chromatography over silica gel (30 g) loaded with CHCI3
eluting with 0.3:9.7 MeOH/CH2 CI2, concentration in vacuo gave (R)-137 as a
clear oil (0.51 g, 59%): TLC Rf = 0.5 (1:9 MeOH/CH2 CI2); 1H NMR (CDCI3, 400
MHz) 5 1.30-1.54 (m, 2H), 1.60-1.75 (m, 1H), 1.86-2.20 (m, 3H), 2.66-2.99 (m,
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2.5H), 3.22-3.56 (m, 8.5H, singlet at 3.28, 3H), 4.13 (bd, 0.5H), 4.25 (bs, 0.5H),
7.18-7.40 (m, 5H), 8.00 (s,

1 H);

13C NMR (CDCI3 , 100 MHz) mixture of amide

rotamers) 5 25.9, 26.1, 26.9, 36.2, 42.1, 47.9, 52.5, 53.6, 54.6, 55.3, 56.6, 58.3,
58.4, 62.5, 72.1, 127.1, 128.2, 128.6, 137.8, 160.8, 160.9.

The opposing enantiomer was similarly prepared:
o

""A % n
(S)-4-Benzyl-2-(3-methoxypropyl)piperazine-1-carbaldehyde ((S)-137). Clear
oil; (0.30 g, 72%).

4 M H2 S 0 4
H

N
THF, 50 - 60 °C

(/?)-1-Benzyl-3-(3-methoxypropyl)piperazine ((/?)-138).

A stirred solution of

(R)-4-benzyl-2-(3-methoxypropyl)piperazine-1-carbaldehyde (R)-137 (0.51 g, 1.8
mmol) in THF (4 mL) was treated with H2 SO4 (4 M, 9 mL). The flask was fitted
with a water-cooled condenser and heated to 60° C for 3 h. The reaction was
cooled to RT °C and poured into ice cold 4 M NaOH and then buffered to pH 10
with sat. NaHCC>3 . The aqueous layer was extracted with CH2CI2 (4 x 30 mL).
The organic portions were combined, dried (K2 CO3 ), filtered and concentrated in
vacuo giving (/?)-138 as a light tan oil (0.42 g, 93%), product was used without

further purification: TLC Rf = 0.05 (1:9 M eOH/C^Ch);

1H NMR (CDCI3 , 400

144

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

MHz)

6

1.30-1.47 (m, 2H), 1.50-1.68 (m, 2H), 1.72 (t, J = 10.4 Hz), 1.96 (bs, 1H),

2.03 (dt, J = 3.2 and 11.0 Hz), 2.70-2.84 (m, 3H), 2.84-3.00 (2m, 2H), 3.30 (s,
3H), 3.31-3.39 (m, 2H), 3.49 (dd, J = 12.9 and 15.2 Hz), 7.20-7.35 (m, 5H); 13C
NMR (CDCI3, 100 MHz) 5 26.0, 31.0, 45.8, 53.8, 54.8, 58.5, 59.8, 63.4, 72.6,
127.0, 128.2, 129.2, 138.0.

The opposing enantiomer was similarly prepared:

H

13

N " Bn

(S)-1-Benzyl-3-(3-methoxypropyl)piperazine ((S)-138).

Light tan oil; (0.25 g,

92%).

H2, 5% P d/C
H

* 2H C I

12 M HCI, MeOH^

(f?)-2-(3-Methoxypropyl)-piperazine

dihydrochloride

H

((f?)-48).

Starting

material (R)-1-benzyl-3-(3-methoxypropyl)piperazine (/?)-138 (0.42 g, 1.7 mmol)
was dissolved in MeOH (50 mL, HPLC) with stirring. To the stirred solution was
added 12 M HCI (0.28 mL, 3.4 mmol), followed by 5% Pd/C (0.063 g). Flask was
sealed with a septum and H2 was bubbled through the suspension by balloon.
The reaction was filtered over a pad of Celite, rinsing with MeOH. The filtrate
was concentrated giving (R)-48 as a white salt (0.36 g, 93%). 1H NMR (DMSO,
400 MHz) 5 1.40-1.85 (m, 4H), 2.92-3.62 (4m, 11H), 3.18 (s, 3H), 4.14 (bs, 1H),
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9.79-10.31 (2bs, 4H). 13C NMR (DMSO, 100 MHz) 5 24.3, 26.8, 39.3, 39.9, 43.4,
51.5, 57.9, 71.0.

The opposing enantiomer was similarly prepared:
• 2HCI

h3C
^

H N ^

,h
^

nh

(S)-2-(3-Methoxypropyl)-piperazine dihydrochloride ((S)-48).

White solid;

(0.22 g, 95%).

•
H3 C

2

HCI
' °

H N ^ I
^

^

NH

CIC(Ph)3, Et3N
CH 2 CI2> 0 °C

H3 C

" ° ^ ^ ^ ^ N "CPh 3

(/?)-3-(3-Methoxypropyl)-1-tritylpiperazine ((/?)-49).
starting

material

(R)-2-(3-methoxypropyl)-piperazine

A stirred suspension of
dihydrochloride

(/?)-48

(0.36 g, 1.56 mmol) in dry CH2 CI2 (15 mL) was treated with EtsN (0.87 mL, 6.25
mmol) under argon, giving a clear solution. The solution was cooled at 0 °C and
trityl chloride (0.44 g, 1.56 mmol) in CH2 CI2

(1 0

mL) was added drop-wise. The

reaction was stirred overnight allowing it to slowly warm to RT °C. The crude
reaction mixture was then transferred to a separatory funnel and washed with
sat. NaHCOs (1 x 50 mL), water (1 x 30 mL), and then brine (1 x 30 mL). The
organic layer was dried (K2 CO3 ), filtered and concentrated in vacuo, to give (/?)49 as a white foam (0.60 g, 97%): TLC Rf= 0.33 (1:9 MeOH/CH2 Cl2 ); The crude
product was used directly in the next reaction without further purification or
characterization.
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The opposing enantiomer was similarly prepared:

(S)-3-(3-Bethoxypropyl)-1-tritylpiperazine ((S)-49). White foam; (0.37 g, 97%).

1)n-BuLi, 2-chloroquinoline
Et2 0 , 0 °C;
h 3c

H

CPh 3
2)

6

M HCI, acetone

NH

h 3C

H

(R)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-quinoline ((/?)-50).

A stirred and

cooled (0 °C) solution of (R)-3-(3-methoxypropyl)-1-tritylpiperazine (/?)-49 (0.60
g, 1.51 mmol) in dry EtaO (25 mL) was treated with n-BuLi (0.67 mL, 2.25 M in
hexanes, 1.51 mmol) under an atmosphere of argon, giving a cloudy suspension.
After 20 min a solution of 2-chloroquinoline (0.17 g, 1.01 mmol) in dry Et2 <D (10
mL) was added drop-wise to give initially a orange solution. The mixture was
allowed to stir for 20 min and the ice bath was removed.

The solution then

darkened to a red wine color over 2 h. The reaction was allowed to stir under
argon (4 h), where the solution returned to an orange color. The reaction was
quenched by the addition of saturated NaHCC>3 (50 mL). The aqueous phase
was separated and the organic layer was washed with brine (30 mL). The
organic phase was dried (K2 CO3 ), and concentrated in vacuo to give a yellow
amorphous foam. The foam was purified by column chromatography over silica
gel (50 g) loaded with CHCI3 and eluting with 1:3 EtOAc/hexanes to give the
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intermediate 2-((R)-2-(3-methoxypropyl)-4-tritylpiperazin-1-yl)quinoline as a clear
yellow oil (0.44 g, 83% yield).
The trityl protected quipazine (0.44 g, 0.55 mmol) was dissolved in
acetone (3 mL) with stirring. To the stirred solution was added 6 M HCI (0.7 mL,
4.2 mmol) giving an orange solution that slowly generated a white precipitate,
stirring continued for 10 min. The reaction was diluted out in 1 M HCI (50 mL),
the crude aqueous mixture was extracted with CH2CI2 (4 x 25 mL). The aqueous
layer was then basified to pH 14 with 4 M NaOH, and then buffered to pH 10 with
saturated NaHCC>3 . The aqueous layer was extracted with CH2 CI2 (4 x 30 mL).
The organic portions were combined, dried (K2 CO3 ), filtered, and concentrated in
vacuo, giving a yellow oil (/?)-50 (0.22 g, 90%; 75% 2 steps overall): TLC R f =

0.1 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.50-1.70 (m, 2H), 1.722.00 (2m, 2H), 2.37 (bs, 1H), 2.88 (dt, J = 3.2 and 12.0 Hz, 1H), 2.95-3.25 (m,
4H), 3.30 (s, 3H), 3.38 (m, 2H), 4.38 (bd, 1H), 4.52 (bs, 1H), 6.94 (d, J = 9.1 Hz,
1H), 7.20 (ddd, J = 1.3 and 7.1 Hz, 1H), 7.52 (ddd, J = 1.7 and 6.8 Hz, 1H), 7.58
(dd, J = 1.3 and 7.8 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H); 13C NMR (CDCI3, 100
MHz) 6 24.7, 26.7, 40.0, 46.0, 47.9, 51.4, 58.6, 72.6, 109.3, 122.0, 122.8, 126.4,
127.1, 129.4, 137.4, 147.9, 157.0.
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The opposing enantiomer was similarly prepared:

(S)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-quinoline ((S)-50). Yellow oil; (0.13
g, 73% 2 steps).

(/?)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-nitroquinoline

((/?)-51).

A

cooled (0 °C) stirred solution of (R)-2-[2-(3-methoxypropyl)-piperazin-1-yl]quinoline (/?)-50 (0.22 g, 0.76 mmol) in H2 SO4 (6 mL, 16 M) was treated dropwise
with HNO3 (0.20 mL, 3.0 mmol, 15.4 M). The reaction was stirred at 0° C for 20
min and quenched by pouring over ice. The solution was brought to pH 14 by the
addition of 4 M NaOH giving a bright yellow solution, and then buffered to pH 10
with saturated NaHC03 followed by extraction with CH2CI2, until no yellow color
was brought into the organic layer. The organic portions were combined, dried
(K2CC>3 ), filtered, and concentrated in vacuo to give a dark yellow oil (/?)-51 (0.25
g, quantitative):

[a]20D = -136° (c = 0.0016, CH2CI2); TLC Rf = 0.14 (1:9

MeOH/CH2CI2);

1H NMR (CDCI3, 400 MHz) 5 1.46-1.68 (m, 2H), 1.78-2.00 (m,

2H), 1.92 (bs, 1H), 2.82 (dt, J = 3.6 and 12.0 Hz, 1H), 2.96 (dd, J = 3.9 and 12.3
Hz, 1H), 3.03-3.15 (m, 2H), 3.15-3.26 (m, 1H), 3.29 (s, 3H), 3.38 (m, 2H), 4.45
(bd, 1H), 5.59 (bs, 1H), 7.01 (d, J = 9.4 Hz, 1H), 7.57 (d, J = 9.4 Hz, 1H), 7.87 (d,
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J = 9.4 Hz, 1H), 8.24 (dd, J = 2.6 and 9.4 Hz, 1H), 8.47 (d, J = 2.6 Hz, 1H); 13C
NMR (CDCIs, 100 MHz) 6 25.6, 26.7, 40.1, 46.0, 48.1, 51.6, 58.8, 72.7, 111.0,
121.1, 123.8, 124.4, 127.2, 138.8, 141.9, 151.8, 158.6.

The opposing enantiomer was similarly prepared:
02n

h

(S)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-nitroquinoline

((S)-51).

Dark

(R)-ferf-Butyl-4-benzyl-2-(3-hydroxypropyl)piperazine-1-carboxylate

((/?)-

yellow oil; [a]20D = +132° (c = 0.0011, CH2CI2); (0.15 g, 98%).

6.4

Chiral Propyl N-Boc Series.
BoC20 , NaOH(aq)

140). 3-((R)-4-benzylpiperazin-2-yl)propan-1-ol (R)-iZ5 (1.68 g, 6.41 mmol) in
NaOH (3 M, 6.4 mL) and THF (2 mL) was treated with di-te/t-butyl dicarbonate
(B oc20 ) (1.54 g, 7.05 mmol) in THF (6.4 mL) at 0 °C. The reaction was allowed

to stir for 15 min then warmed to RT °C and stirred for 2.5 hrs forming a white
solid. The reaction was concentrated in vacuo to remove the THF. The resulting
aqueous layer was extracted with

EtOAc, dried (Na2 S 0 4 ), filtered, and

concentrated. The crude material was purified by column chromatography over
silica gel (80 g) loaded with CHCI3 and then elution using 2:3 EtOAc/hexanes to
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remove nonpolar impurities, followed by 3:2 EtOAc/hexanes, then flushed with
EtOAc to elute (/?)-140 as a clear oil (0.94 g, 40%); TLC

Rf

= 0.40 (6:4

EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.43 (bs, 11H), 1.71 (bm, 1H),
1.84-2.14 (3m, 3H), 2.68 (bd, J = 11.4 Hz, 1H), 2.75 (bd, J = 11.0 Hz, 1H), 3.06
(bm, 1H), 3.46 (dd, J = 13.2 and 53.5, 2H, CH2-AxAr), 3.65 (m, 2H, CH2OH), 3.86
(bs, 1H), 4.09 (bs, 1H), 7.18-7.40 (m, 5H); 13C NMR (CDCI3, 100 MHz) 5 26.2,
28.4, 29.3, 39.1 (broad), 50.6 (broad) 53.4, 55.8, 63.0, 63.1, 79.8, 127.0, 128.2,
128.7, 138.2, 154.8.

The opposing enantiomer was similarly prepared:
Boo' n ^
H

(S)-fe/t-Butyl-4-benzyl-2-(3-hydroxypropyl)piperazine-1-carboxylate

((S)-

140). Clear oil; (0.87 g, 42%).

NaH, CH3I
%

n

DMF, 0 °C

H3 < r °

H

(f?)-ferf-Butyl-4-benzyl-2-(3-methoxypropyl)piperazine-1-carboxylate

((/?)-

141). A stirred solution of (R)-ferf-butyl 4-benzyl-2-(3-hydroxypropyl)piperazine1-carboxylate (f?)-140 (0.89 g, 2.7 mmol) in dry DMF (15 mL) was treated with
NaH powder (0.13 g, 5.3 mmol) at 0 °C and stirred for an additional 30 min. The
resulting alkoxide intermediate was treated with CH3I at 0 °C and then allowed to
warm to RT °C overnight. The reaction was quenched by the addition of water
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(15 mL) followed by the addition of sat. NaHC0 3 (15 mL). The aqueous layer was
extracted with Et2 0 , dried (K2 C 0 3), filtered, and concentrated in vacuo. The
crude material was purified by column chromatography over silica gel (35 g)
loaded with CHCI3, eluting with 1:3 EtOAc/hexanes (1 column length) followed by
2:3 EtOAc/hexanes to elute (R)-141 as a clear oil (0.63 g,

6 8 %):

TLC

Rf

= 0.55

(6:4 EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.44 (s, 11H), 1. 6 6 (bm, 1H),
1.80-2.12 (3m, 3H), 2.66 (bd, J = 11.4 Hz, 1H), 2.73 (bd, J = 10.6 Hz, 1H), 3.04
(bm, 1H), 3.13 (s, 3H), 3.33-3.41 (m, 3H), 3.50 (d, J = 13.2 Hz, 1H, CH2Ar), 3.87
(bs, 1H), 4.04 (bs, 1H), 7.20-7.36 (m, 5H); 13C NMR (CDCI3, 100 MHz) 5 26.2,
26.3, 28.4, 38.6 (broad), 51.2 (broad), 53.2, 55.7, 58.4, 62.8, 72.5, 79.3, 126.9,
128.1, 128.7, 138.2, 154.7.

The opposing enantiomer was similarly prepared:

(S)-ferf-Butyl-4-benzyl-2-(3-methoxypropyl)piperazine-1-carboxylate

((S)-

141). Clear oil; (0.61 g, 70%).

(R)-1-Benzyl-3-(3-methoxypropyl)piperazine ((/?)-138).
(R)-tert- butyl

A stirred solution of

4-benzyl-2-(3-methoxypropyl)piperazine-1 -carboxylate

(R)-141

(0.58 g, 1.67 mmol) in THF (2 mL) was treated with H2 S 0 4 (4 M, 4 mL) and was
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allowed to stir at RT °C overnight. The reaction was cooled at 0 °C and treated
with NaOH (4 M) then buffered to pH 10 with sat. NaHC0 3 - The aqueous layer
was extracted with CH2 CI2 (2 x 10 mL) and 4:1 CHCI3/IPOH (15 mL). The organic
portions were combined, dried (K2 C 0 3), filtered and concentrated in vacuo to
give (/?)-138 as a clear oil (0.36 g, 87%): TLC Rf = 0.05 (1:9 MeOH/CH2 CI2); 1H
NMR (CDCI3 , 400 MHz)

6

1.24-1.41 (m, 2H), 1.43-1.70 (m, 4H), 1.97 (dt, J = 3.7

and 11.0 Hz, 1H), 2.64-2.94 (4m, 5H), 3.26 (s, 3H), 3.31 (m, 2H, CH2 OCH3), 3.44
(dd, J = 2.2 and 13.2 Hz, 2H, C H 2.ABAr), 7.16-7.30 (m, 5H); 13C NMR (CDCI3,
100 MHz)

6

25.8, 31.0, 45.7, 53.8, 54.6, 58.4, 59.9, 63.3, 72.5, 126.8, 128.0,

129.0, 137.9.

The opposing enantiomer was similarly prepared:
HN
H3C
d

^

.... I1.
H

Bn

(S)-1-benzyl-3-(3-methoxypropyl)piperazine ((S)-138).

Clear oil; (0.32 g,

80%).

n-BuLi, 2-chloroquinoline
N
‘Bn

N

Et2 0 , 0 - RT °C

2-((/?)-4-Benzyl-2-(3-methoxypropyl)piperazin-1-yl)quinoline

((R)-142).

A

stirred solution of (R)-1-benzyl-3-(3-methoxypropyl)piperazine (/?)-138 (0.17 g,
0.69 mmol) in dry Et2 0 (20 mL) at 0 °C was treated with /i-BuLi (0.3 mL, 2.27M in
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hexanes, 0.69 mmol) giving a yellow-orange solution. The solution was allowed
to stir at 0 °C for 20 min, then treated with a solution of 2-chloroquinoline in Et20
(4 mL) to give an orange solution that was allowed to stir for 30 min. The mixture
was warmed to RT °C and stirred overnight. The reaction was quenched by the
addition water (10 mL). The organic portion was separated and washed with sat.
NaHCC>3 (10 mL) and brine (10 mL). The organic layer was dried (K 2CO 3 ),
filtered, and concentrated in vacuo. The crude material was purified by column
chromatography over silica gel (8 g) loaded with CHCI3 , eluting with 1:9
EtOAc/hexanes (1 column length) followed by 1:3 EtOAc/hexanes, concentration
in vacuo gave (/?)-142 as a light yellow oil (0.094 g, 55%): TLC R f= 0.35 (4:6

EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.42-1.62 (m, 2H), 1.74-1.88 (m,
1H), 1.92-2.08 (m, 1H), 2.14-2.32 (m, 2H), 2.82-3.04 (m, 2H), 3.20-3.50 (m, 7H,
overlapped singlet at 3.30, 3H), 3.57-3.69 (d, 1H), 4.32-4.62 (bm, 2H), 6.92 (d, J
= 9.2 Hz, 1H), 7.15-7.75 (m, 9H), 7.84 (d, J = 9.2 Hz, 1H); 13C NMR (CDCI3, 100
MHz) 5 25.6, 26.6, 39.8, 51.9, 53.4, 55.0, 58.4, 62.8, 72.7, 109.3, 121.8, 122.6,
126.3, 127.0, 128.2, 128.8, 129.3, 137.2, 138.4, 147.9, 156.7.

The opposing enantiomer was similarly prepared:

2-((S)-4-Benzyl-2-(3-methoxypropyl)piperazin-1-yl)quinoline ((S)-142).
yellow oil; (0.26, 80%).
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Light

2-((R)-4-(2-Nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline and 2((/?)-4-(4-Nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline
((/?)-143).

A

cooled

(0

°C)

stirred

solution

of

mixture

2-((f?)-4-benzyl-2-(3-

methoxypropyl)piperazin-1 -yl)quinoline (R)-142 (0.30 g, 0.80 mmol) in H2 S 0 4 (16
M, 4 mL) was treated (dropwise) with HNO3 (15.4 M, 0.16 mL). The mixture was
allowed to stir for 20 min. The reaction was quenched by pouring onto ice. The
acid was neutralized with 4 M NaOH to give a bright yellow solution, and the
resulting solution was buffered to pH

10

with sat NaHCC>3 and extracted with

CH2CI2 until minimal yellow color persisted in the aqueous layer. The organics
were dried (K2 COs), and concentrated in vacuo to give a bright yellow oil (R)-143
(0.022

g,

84%

yield).

The

crude

material

was

purified

by

column

chromatography over silica gel (3 g) loaded with CHCI3 and eluting with 1:3
EtOAc/hexanes followed by 2:3 EtOAc/hexanes, concentration in vacuo gave
(R)-143 as a yellow oil (0.34 g, 92%)(mixture of regioisomers): TLC 0.21 (4:6
EtOAc/hexanes): 1H NMR (CDCI3, 400 MHz) 5 1.40-1.52 (m, 2H), 1.80-2.08 (m,
2H), 2.20-2.32 (m, 2H), 2.80-3.00 (bm, 2H), 3.29 (s, 3H), 3.32-3.40 (m, 2H), 3.493.73 (dd, J = 13.9 and 60.8 Hz, 2H, CH2.AMAr), 4.57 (bd, 2H), 7.03 (d, J = 9.5 Hz,
1H), 7.46-7.64 (m, 2H), 7.70 (d, J = 7.7 Hz, 1H), 7.92 (d, J = 9.2 Hz, 1H), 8.108.30 (m, 3H), 8.50 (d, J = 2.9 Hz, 1H); 13C NMR (CDCI3, 100 MHz) (mixture of
BnN0 2 regioisomers) 5 26.2, 26.5, 39.8, 51.9, 53.4, 55.1, 58.6, 61.8, 72.5, 110.8,
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120.9, 122.3, 123.4, 123.6, 124.2, 127.0, 129.3, 134.7, 138.6, 140.6, 141.7,
148.4, 151.6, 158.2.

The opposing enantiomer was similarly prepared:

2-((S)-4-(2-Nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline and 2((S)-4-(4-Nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline

mixture

((S)-143). Yellow oil; (0.30 g, 94%).

0 ,N

Ace-CI, DCE
0 - 80 °C;

N

N

HqC

OoN
‘N

-frN 0 2

MeOH, 80 °C

H ,C

H

(/?)-2-[2-(3-Methoxypropyl)-piperazin-1-yl]-6-nitroquinoline ((/?)-51).
cooled

(0

°C)

stirred

solution

of

2-((/?)-4-(2

and

H

To a

4-nitrobenzyl)-2-(3-

methoxypropyl)piperazin-1-yl)quinoline (R)-143 (0.25 g, 0.54 mmol) in 1,2dichloroethane (12 mL) was added dropwise 1-Chloroethyl chloroformate (AceCI) (0.3 g, 2.2 mmol) under argon. After the addition the reaction was stirred at
80 °C for 3 h, then cooled giving a yellow precipitate and concentrated in vacuo.
The residue was dissolved in MeOH (10 mL) and heated at 70 °C for 3 h. The
crude reaction mixture was concentrated in vacuo and the residue was taken up
in 1 M HCI and then extracted with CH2 CI2 ( 3 x 1 0 mL). The resulting aqueous
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layer was brought to basic pH with 4 M NaOH and then buffered to pH 10 with
sat. NaHCOa.

The basic phase was extracted with CH2 CI2 (3 x 15 mL), the

organic portions were combined, dried (K2CO3 ), and concentrated in vacuo. The
crude material was purified by flash chromatography (Biotage). The column was
eluted by a 3 segment gradient elution; segment 1: 10% - 25% EtOAc/hexanes
over 120 mL, segment 2: 25% - 100% EtOAc/hexanes over 120 mL, segment 3:
100% EtOAc over 120 mL. The fractions containing product were combined and
concentrated in vacuo to give (/?)-51 as a yellow foam (0.087 g, 49%): TLC Rf =
0.14 (1:9 MeOH/CH2CI2);

1H NMR (CDCI3, 400 MHz) 5 1.46-1.68 (m, 2H), 1.78-

2.00 (m, 2H), 1.92 (bs, 1H), 2.82 (dt, J = 3.6 and 12.0 Hz, 1H), 2.96 (dd, J = 3.9
and 12.3 Hz, 1H), 3.03-3.15 (m, 2H), 3.15-3.26 (m, 1H), 3.29 (s, 3H), 3.38 (m,
2H), 4.45 (bd, 1H), 5.59 (bs, 1H), 7.01 (d, J = 9.4 Hz, 1H), 7.57 (d, J = 9.4 Hz,
1H), 7.87 (d, J = 9.4 Hz, 1H), 8.24 (dd, J = 2.6 and 9.4 Hz, 1H), 8.47 (d, J = 2.6
Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 25.6, 26.7, 40.1, 46.0, 48.1, 51.6, 58.8,
72.7, 111.0, 121.1, 123.8, 124.4, 127.2, 138.8, 141.9, 151.8, 158.6.

The opposing enantiomer was similarly prepared:

2-((S)-4-(2

and

4-nitrobenzyl)-2-(3-methoxypropyl)piperazin-1-yl)quinoline

((S)-51). Yellow foam; (0.11, 62%).
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6.5

Racemic n-PROP-NQP Synthesis.
n-BuLi, [(Ph)3 P+Et]Br

H

THF, 0 °C

Bn

H

1,4-Dibenzyl-2-(prop-1-enyl)piperazine (149).

Bn

A stirred suspension of ethyl

triphenylphosphonium bromide (2.73 g, 7.34 mmol) in dry THF (15 mL) was
cooled at 0° C and then treated with n-BuLi (2.9 mL, 7.28 mmol) giving an
orange-red suspension.

The mixture was stirred for one hour at 0° C.

1,4-

dibenzyl-piperazine-2-carbaldehyde 44 (1.06 g, 3.64 mmol) in dry THF (4 mL)
was added dropwise to the ylide solution. The reaction was allowed to warm to
RT° C and stirred for 18 h. The reaction was quenched with water (20 mL). The
solvent (THF) was removed in vacuo, and then treated with sat. NaHC0 3 (20
mL). The aqueous phase was extracted with CH2 CI2 ( 4 x 1 5 mL), the organic
portions were combined, dried (K2 CO 3 ) and concentrated in vacuo to give a
white/tan semi-solid (3.5 g). The crude material was purified by column
chromatography over silica gel (80 g) loaded with CHCI3 and eluting with 2:3
EtOAc/hexanes followed by 3:2 EtOAc/hexanes, concentration in vacuo gave
149 as a light tan oil (0.78 g, 71%, 2 steps overall):

TLC Rf = 0.57 (3:2

EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.68 (dd, J = 1.8 and 7.0 Hz,
3H), 1.98-2.25 (m, 3H), 2.60-2.78 (m, 3H), 3.08 and 4.06 (2d, J = 13.2 Hz, 2H),
3.27 (dt, J = 2.9 and 9.5 Hz, 1H), 3.50 (dd, J = 13.2 and 38.5, 2H), 5.43 (bt, J =
9.5 Hz, 1H), 5.58-5.70 (m, 1H), 7.12-7.38 (m, 10H); 13C NMR (CDCI3, 100 MHz)
5 13.6, 51.2, 52.8, 58.1, 58.3, 58.8, 62.9, 126.7, 126.9, 127.2, 128.0, 128.1,
129.1, 129.2, 131.4, 137.9, 138.8.
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2-Propylpiperazine dihydrochloride (150). 5% Pd/C (1.2 g) was added to a
stirred solution of 1,4-dibenzyl-2-(prop-1-enyl)piperazine 149 (0.78 g, 2.6 mmol)
in MeOH (25 mL) and HCI (0.45 mL, 12 M, 5.4 mmol) with stirring. The flask was
sealed with a septum and hydrogen gas was bubbled through the solution at
atmospheric pressure. The reaction mixture was filtered over a pad of Celite.
The pad was rinsed with MeOH and concentrated in vacuo to give 150 (0.48 g,
92%) as a white solid: 1H NMR (D20 , 400 MHz) 5 0.76 (t, J = 7.3, 3H), 1.18-1.32
(m, 2H), 1.46-1.60 (m, 2H), 3.02 (dd, J = 12.1 Hz, 1H), 3.18-3.30 (m, 2H), 3.393.49 (m, 1H), 3.51-3.61 (m, 3H); 13C NMR (D20 , 100 MHz) 5 12.8, 17.5, 32.0,
40.1,40.5,44.5, 52.6.

CIC(Ph)3, Et3N
CH 2 CI2, 0 °C
H

3-Propyl-1-tritylpiperazine (151). To a stirred solution of 2-propylpiperazine
dihydrochloride 150 (0.48 g, 2.4 mmol) in dry CH2CI2 (12 mL) under argon was
added dry Et3N (1.3 mL, 9.5 mmol). The solution was cooled at 0° C, and trityl
chloride (0.64 g, 2.28 mmol) in dry CH2CI2 (5 mL) was added drop-wise. Once
the addition was complete the ice bath was removed and the reaction stirred
overnight at room temperature. The reaction mixture was washed with saturated
NaHC03 (75 mL), water (75 mL), and then brine (75 mL). The organic portions
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were combined, dried (K2C 0 3), and concentrated in vacuo to give 151 (0.84 g,
99% yield) as a white amorphous foam. The crude material was used without
further purification or spectroscopic characterization: TLC Rf = 0.15 (1:9
MeOH/CH2CI2).

n-BuLi, 2-chloroquinoline
Et2 0 , 0 °C;
6

M HCI, acetone

2-(2-Propylpiperazin-1-yl)quinoline

(152).

H

A

solution

of

3-propyl-1-

tritylpiperazine 151 (0.85 g, 2.28 mmol) in dry Et20 (30 mL) cooled at 0° C, was
treated with n-BuLi (dropwise)(0.93 mL, 2.45 M in hexanes), generating a light
orange solution.

The solution was allowed to stir for 20 min. A solution of 2-

chloroquinoline (0.25 g, 1.52 mmol) in dry Et20 (5 mL) was added drop-wise to
the lithium amide. The resulting mixture was allowed to stir for 1 h at 0 °C then
the ice bath was removed. The reaction was allowed to warm to RT °C and stir
for 4 h, giving a brown colored solution.

The reaction was quenched with

saturated NaHCOa (30 mL). The organic layer was separated, and then washed
with water (20 mL) and brine (20 mL). The organic portion was dried (K2C 0 3),
filtered, and concentrated in vacuo to give a white foam. The foam was purified
by column chromatography over silica gel (45 g) loaded with CHCI3 and eluted
with 1:9 EtOAc/hexanes to give the N-trityl protected product as a clear yellow oil
(0.54 g, 71% yield). The oil was dissolved in Acetone (8 mL) and HCI (6 M, 2.5
mL), the mixture was allowed to stir 20 min. The reaction mixture was diluted
with 1 M HCI (20 mL) and extracted with CH2CI2 (4 x15 mL), the aqueous layer
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was basified to pH 12 with 4 M NaOH and then buffered to pH 10 with saturated
NaHCOs. The aqueous layer was then extracted with CH2CI2 ( 4 x 1 5 mL), dried
with

K 2 C O 3 ,

and concentrated in vacuo to give 152 (0.18 g, 64%) as a light

yellow oil: 1H NMR

(C D C I3,

400 MHz) 5 0.93 (t,

J

= 7.3 Hz, 3H), 1.20-1.46 (m,

2H), 1.60-1.72 (m, 1H), 1.76-1.90 (m, 2H), 2.81-2.91 (m, 1H), 2.96-3.22 (m, 4H),
4.34-4.46 (bm, 2H), 6.93 (d,
= 8.1 Hz, 1H), 7.66 (d,

J

J

= 9.2 Hz, 1H), 7.2 (m, 1H), 7.5 (m, 1H), 7.57 (d,

= 8.4 Hz, 1H), 7.85 (d,

J

J

= 9.2 Hz, 1H).

2-(2-propylpiperazin-1-yl)-6-nitroquinoline (52).

A stirred solution of 2-(2-

propylpiperazin-1-yl)quinoline 152 (0.16 g, 0.64 mmol) in H2 SO4 (16 M, 4 mL)
was cooled at 0° C. To the cooled solution was added HNO3 (15.4 M, 0.17 mL)
(dropwise). The reaction was stirred for 20 min, then quenched pouring onto ice.
The acid was neutralized with 4 M NaOH to give a bright yellow solution, and the
resulting solution was buffered to pH 10 with sat NaHC03. The aqueous solution
was extracted with CH2CI2 until minimal yellow color persisted in the aqueous
layer. The organic portions were combined, dried (K2 CO3 ), and concentrated in
vacuo to give a bright yellow oil 52 (0.20 g, quantitative yield): TLC Rf = 0.11 (1:9

MeOH/CH2 CI2);

1H NMR (CDCI3, 400 MHz) 5 0.94 (t, J = 7.3 Hz, 3H), 1.20-1.42

(m, 2H), 1.63-1.91 (2m, 3H), 2.83 (dt, J = 3.3 and 12.1 Hz, 1H), 3.00-3.24 (m,
4H), 4.50 (bs, 2H), 7.00 (d, J = 9.5 Hz, 1H), 7.57 (d, J = 9.2 Hz, 1H), 7.89 (d, J =
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9.2 Hz, 1H), 8.24 (dd, J = 2.6 and 9.2 Hz, 1H), 8.47 (d, J = 2.6 Hz, 1H); 13C NMR
(CDCI3, 100 MHz) 6 14.0, 19.7, 30.7, 40.3, 46.2, 48.2, 51.8, 110.8, 120.7, 123.5,
124.1, 126.8, 138.4, 141.5, 151.6, 158.4; HRMS (ESI-TOF) m /z (M + H)+ calcd.
for C16H21 N4 O2 301.1665 found 301.1655.

Racemic Pent-NQP Series.

6 .6

n

n-BuLi, (Et 0 )2 P( 0 )CH 2 (CH) 2 C 0 2Et

1
< TVH ^ N' Bn-------------------THF, 0 °C

Et°

H

O

Ethyl 5-(1,4-dibenzylpiperazin-2-yl)penta-2,4-dienoate (76). A stirred solution
of n-BuLi (2.45 M, 5.6 mL in hexanes, 13.6 mmol) in dry THF (20 mL) was
treated with triethylphosphonocrotonate (2.8 g, 13.6 mmol) at 0 °C under argon,
to give a yellow solution. After 30 min a solution of the 1,4-dibenzyl-piperazine-2carbaldehyde 44 (2.0 g, 13.6 mmol) in dry THF (10 mL) was added dropwise to
the cooled ylide solution, and stirring was maintained for 45 min. The reaction
mixture was allowed to warm to room temperature, stir for 20 h. The reaction
was quenched by the addition of water (15 mL) and concentrated in vacuo to
remove THF.

The resulting aqueous layer was treated with 20 mL of sat.

NaHCCh and extracted with Et2 <D (3 x 30 mL). The combined organic extracts
were washed with brine (20 mL), dried

(K 2 C O 3 )

and concentrated in vacuo, to

give an orange oil. The crude oil was purified by column chromatography over
silica gel (70 g) loaded with

C H C I3

and eluting with 1:3 EtOAc/hexanes followed

162

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

by 2:3 EtOAc/hexanes to give 76 as a light tan oil (1.8 g,

66

% 2 steps overall):

TLC Rf = 0.36 (4:6 EtOAc/Hexanes); 1H NMR (CDCI3> 400 MHz) 5 1.29 (t, J =
7.1

Hz, 3H), 2.08-2.32 (2m, 3H), 2.60-2.80 (m, 3H), 3.00-3.18 (2m, 2H,

overlapped doublet at 3.11, J = 13.6 Hz, 1H, C/-/2-AxAr), 3.49 (s, 2H, C/-/2Ar), 3.94
(d, J = 13.6 Hz, 2H, CH2Ar), 4.20 (q, J = 7.1 Hz, 2H), 5.85 (d, J = 15.2 Hz, 1H),
6.08-6.24 (m, 1H), 6.37 (dd, J = 11.0 and 15.2 Hz, 1H), 7.18-7.48 (m, 11H,
overlapped, 10H Ar); 13C NMR (CDCI3, 100 MHz) 5 14.3, 50.7, 52.9, 58.5, 59.5,
60.3, 62.8, 63.6, 121.1, 126.9, 127.0, 128.1, 128.2, 128.9, 129.1, 130.7, 137.8,
138.4, 143.5, 143.8, 166.9.

ISL
H

H2, 5% Pd/C
--------------------- ► EtO
Bn AcOH, MeOH

Ethyl 5-(1,4-dibenzylpiperazin-2-yl)pentanoate (77). To a solution of ethyl 5(1,4-dibenzylpiperazin-2-yl)penta-2,4-dienoate 76 (1.6 g, 4.1 mmol) in HPLC
grade MeOH (20 mL) and acetic acid (1.2 g, 20.5 mmol) was added 5% Pd/C
(0.32 g).

The reaction flask was sealed with a septum, fitted with hydrogen

balloon and a bleed needle. One balloon of hydrogen was bubbled through the
stirred solution; the bleed needle was removed and a second balloon was
attached and the reaction was stirred overnight. The reaction was filtered over a
pad of Celite, the pad was rinsed with MeOH and the filtrate was concentrated in
vacuo. The resulting oil was dissolved in CH2 CI2, basified with 4 M NaOH and

then buffered to pH 10 with sat. NaHC03. The organic layer was separated and
the aqueous layer was extracted with CH2 CI2 ( 3 x 1 0 mL). The organic portions
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were combined, dried (K2CO 3 ) and concentrated in vacuo. The crude oil was
purified by column chromatography over silica gel (60 g) loaded with CHCI3 and
eluted

1.5

column

lengths

with

1:3

EtOAc/hexanes

followed

by

2:3

EtOAc/hexanes to give the product 77 after concentration as clear oil (3.5 g,
78%):

product was visualized in two different TLC solvent systems; Rf = 0.27

(2:3 EtOAc/Hexanes) and Rf = 0.6 (1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400
MHz) 5 1.16-1.50 (m, 5H, overlapped triplet at 1.25, J = 7.1 Hz, 3H,
C 0 2CH2 CH3), 1.52-1.76 (m, 4H), 2.10-2.80 (m, 9H), 3.20 (d, J = 13.2 Hz, 1H,
CH2.AxAr), 3.49 (dd, J = 13.2 and 41.7 Hz, 2H, CH2.AMAr), 4.00 (d, J = 13.2 Hz,
1H, CH2.AxAr), 4.12 (q, J = 7.1 Hz, 2H, C 0 2CH2 CH3), 7.18-7.45 (m, 10H); 13C
NMR (CDCI3 , 100 MHz) 5 14.2, 25.0, 25.4, 29.3, 34.2, 50.7, 52.8, 57.5, 57.6,
59.4, 60.1, 63.0, 126.7, 126.8, 128.1, 128.8, 128.9, 138.2, 139.0, 173.5.

5-(1,4-Dibenzylpiperazin-2-yl)pentan-1-ol

(78).

A

solution

ethyl

5-(1,4-

dibenzylpiperazin-2-yl)pentanoate 77 (1.0 g, 2.5 mmol) in dry ether (20 mL) was
treated at

0

°C with portions LiAIH4 powder (0 . 1 2 g, 3.0 mmol), then placed under

an atmosphere of argon.

The ice bath was removed and the reaction was

allowed to stir for 35 min at 25 °C.

The reaction was quenched by the

consecutive addition of H20 (0.12 mL), NaOH (0.24 mL 4 M), and H20 (0.12 mL).
The inorganic salts were filtered over a pad of Celite and the pad was rinsed with
EtOAc. The filtrate was concentrated in vacuo to give 78 (2.8 g, 95%): TLC
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Rf =

0.06 (2:3 EtOAc/Hexanes);

1H NMR (CDCI3, 400 MHz) 5 1.20-1.45 (m, 4H),

1.48-1.68 (m, 5H), 2.10-2.28 (m, 3H), 2.40-2.76 (m, 4H), 3.20 (d, J = 13.2 Hz,
1H, CH2-AxAr), 3.49 (dd, J = 13.2 and 44.0 Hz, 2H, CH2.AMAr), 3.58-3.64 (bm,
2H), 4.00 (d, J = 13.2 Hz, 1H, C H 2.AxAr), 7.20-7.35 (m, 10H); 13C NMR (CDCI3,
100 MHz) 5 25.3, 26.2, 29.6, 32.6, 50.8, 52.7, 57.5, 59.5, 62.5, 63.0, 126.7,
126.9, 128.0, 128.9, 129.0, 137.9, 138.9(1 unresolved peak).

DMF, 0 °C

H

1,4-Dibenzyl-2-(5-methoxypentyl)piperazine (79). A stirred solution of 5-(1,4dibenzylpiperazin-2-yl)pentan-1-ol 78 (0.69 g, 2.0 mmol) in dry DMF (10 mL) at 0
°C was treated with NaH powder (0.14 g, 5.9 mmol) to give a turbid white
suspension. The flask was placed under argon and stirring was continued for 30
min.

lodomethane (0.30 g, 2.1 mmol) was added dropwise to the cooled

solution. The reaction was allowed to stir on ice for 30 min, followed by stirring at
room temperature for 3.5 h. The reaction was quenched by the addition of water
(20 mL) followed by sat. NaHC0 3 (20 mL). The aqueous layer was extracted with
Et20 (4 x 10 mL).

The organic portions were combined, dried (K2 C0 3 ), and

concentrated in vacuo to give a tan oil. The oil was purified by column
chromatography over silica gel (30 g) loaded with CHCI3 and eluted with 2:3
EtOAc/hexanes to give 79 after concentration as a clear oil (0.44 g, 60%): TLC
Rf = 0.39 (2:3 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.22-1.48 (m, 4H),

1.52-1.70 (m, 4H), 2.08-2.32 (m, 3H), 2.40-2.78 (3m, 4H), 3.20 (d, J = 13.2 Hz,
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1H, C/-/2-AxAr), 3.32-3.40 (m, 5H, overlapped singlet, 3.33, 3H, OCH3), 3.49 (dd, J
= 13.2 and 43.6 Hz, 2H, CH2.AMAr), 4.02 (d, J = 13.2 Hz, 1H, CH 2.AxAr), 7.20-7.40
(m, 10H); 13C NMR (CDCI3, 100 MHz)

6

25.4, 26.6, 29.0, 29.5, 50.8, 52.8, 57.6,

58.5, 59.6, 63.0, 72.0, 72.7, 126.6, 126.8, 128.0, 128.9, 129.0, 138.2, 139.0.

H2, 5% Pd/C
N„ Bn 12 M HCI, MeOH

• 2 HCI

H N ^

H3C

H

2-(5-Methoxypentyl)piperazine dihydrochloride (80).

A solution of 1,4-

dibenzyl-2-(5-methoxypentyl)piperazine 79 (0.23 g, 0.64 mmol) in HPLC grade
MeOH (14 mL) and HCI (12 M, 1.92 mmol, 0.16 mL) was treated with 5% Pd/C
(0.07 g). The flask was sealed with a septum and a balloon of hydrogen was
bubbled through the stirred solution. The reaction mixture was filtered over a pad
of Celite rinsing with MeOH and concentrated in vacuo to give a white solid 80
(0.17 g, quantitative).

• 2 HCI
H3 C

' °

^

HN^^i
^

^
H

NH

CIC(Ph)3, Et3N
CH 2 CI2i 0 °C

3-(5-Methoxypentyl)-1-tritylpiperazine

(81).

H N "^
H3 C ' ° v X 'V s^

A

v X £ 'N- ' ' N 'C P h 3
H

solution

of

2-(5-

methoxypentyl)piperazine dihydrochloride 80 (0.38 g, 1.5 mmol) in dry CH2CI2
(10 mL) and dry Et3N (0.59 g, 0.81 mL, 5.8 mmol) at 0 °C, was treated dropwise
with a solution of trityl chloride (0.41 g, 1.5 mmol) in dry CH2 CI2 (5 mL). The ice
bath was removed and the reaction stirred for 20 h at room temperature. The
reaction mixture was transferred to a separatory funnel and diluted to 15 mL with
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CH2CI2. The organic portion was washed with saturated NaHC0 3 (25 mL), brine
(25 mL). The organic portion was dried (K2 C 0 3), filtered, and concentrated in
vacuo to give an amorphous white foam 81 (0.62 g, 99% yield): TLC 0.34 (1:9

MeOH/CH2 CI2); 3-(5-Methoxypentyl)-1-tritylpiperazine 81 was used without
further purification, or spectroscopic characterization.

1)n-BuLi, 2-chloroquinoline
Et2 0 , 0 °C
N
CPh 3

2)

6

M HCI, acetone

H3C

.0.

2-(2-(5-Methoxypentyl)piperazin-1-yl)quinoline (82). A stirred solution of 3-(5methoxypentyl)-1-tritylpiperazine 81 (0.40 g, 0.93 mmol) in dry Et20 (25 mL) at 0
°C was treated with n-BuLi (0.38 mL, 2.45M in hexanes, 0.93 mmol) giving a pale
orange-white suspension. The solution was allowed to stir at 0 °C for 20 min,
then treated with a solution of 2-chloroquinoline (0.10 g, 0.62 mmol) in Et20 (4
mL) to give an orange-white suspension. The mixture was allowed to stir for 30
min, then warmed to RT °C and stirred overnight. The reaction was quenched by
the addition water (10 mL). The organic portion was separated and washed with
sat. NaHC0 3 (10 mL) and brine (10 mL).

Then the organic layer was dried

(K 2C 0 3), filtered, and concentrated in vacuo. The crude material was purified by
column chromatography over silica gel (30 g) loaded with CHCI3 and eluted with
1:9 EtOAc/hexanes to give the N-trityl protected product as a light yellow oil (0.23
g,

6 6 %).

acetone

TLC Rf = 0.57 (2:3 EtOAc/Hexanes). The product oil was dissolved in
(8

mL) and HCI

(6

M, 4 mL) and allowed to stir (20 min). The reaction

was diluted with 1 M HCI (20 mL) and extracted with CH2CI2 (4 x15 mL). The
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aqueous layer was brought to pH 12 with 4 M NaOH and then buffered to pH 10
with saturated NaHC0 3 . The aqueous layer was extracted with CH2 CI2 ( 4 x 1 5
mL), dried with K2 CO3 , and concentrated in vacuo to give 82 as a light yellow oil
(0.11 g,

8 8 %,

58% 2 steps overall): 1H NMR (CDCI3, 400 MHz) 5 1.18-1.42 (m,

4H), 1.44-1.58 (m, 2H), 1.60-1.72 (m, 1H), 1.76-1.90 (m, 1H), 2.11 (bs, 1H), 2.84
(m, 1H), 2.94-3.18 (m, 4H), 3.24-3.34 (m, 5H, overlapped singlet, 3.28, 3H,
OCH3 ), 4.38 (bd, 2H), 6.90 (d, J = 9.5 Hz, 1H), 7.18 (t, J = 8.06 Hz, 1H), 7.50 (t, J
= 8.4 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 9.2
Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 26.0, 26.4, 27.7, 29.4, 40.1, 46.0, 47.8,
51.7, 58.4, 72.6, 109.3, 121.9, 122.7, 126.3, 127.0, 129.3, 137.2, 147.9, 157.0.

0 2N
h 2 s o 4, h n o 3

►
'

NH

0

°C

N

N '^ i

x0.
H3 C"

2-(2-(5-Methoxypentyl)piperazin-1-yl)-6-nitroquinoline

((±)-83).

A stirred

solution of 2-(2-(5-methoxypentyl)piperazin-1-yl)quinoline 82 (0.11 g, 0.36 mmol)
in H2SO4 (16 M, 4 mL) was cooled at 0° C. HNO3 (15.4 M, 0.09 mL) was added
drop-wise, and the reaction stirred for 20 min at 0 °C.

The reaction was

quenched by pouring onto ice, the acid was neutralized with 4 M NaOH to give a
bright yellow solution, and the resulting solution was buffered to pH 10 with sat.
NaHCOs. The yellow aqueous solution was extracted with CH2 CI2 until no yellow
color was extracted into the organic layer.

The organics were dried (K2 C 0 3),

filtered and concentrated in vacuo to give a bright yellow oil (±)-83 (0.13 g,
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quantitative yield):

TLC Rf = 0.16 (1:9 MeOH/CH2CI2);

1H NMR (CDCI3, 400

MHz) 5 1.26-1.46 (m, 4H), 1.50-1.60 (m, 2H), 1.71-1.96 (m, 2H), 2.06 (bs, 1H),
2.85 (dt, J = 3.6 and 12.3 Hz, 1H), 2.98 (dd, J = 3.6 and 12.3 Hz, 1H), 3.06-3.26
(m, 3H), 3.29 (s, 3H), 3.33 (m, 2H), 4.52 (bs, 2H), 7.01 (d, J = 9.1 Hz, 1H), 7.61
(d, J = 9.4 Hz, 1H), 7.93 (d, J = 9.4 Hz, 1H), 8.27 (dd, J = 2.6 and 9.4 Hz, 1H),
8.51 (d, J = 2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 26.0, 26.2, 28.2, 29.4,
40.3, 46.1, 48.0, 51.8 58.4, 72.5, 110.7, 120.7, 123.4, 124.1, 126.8, 138.4, 141.4,
151.6, 158.3; HRMS (ESI-TOF) m /z (M + H)+ calcd. for C i 9 H27N40 3 359.2083
found 359.2086.

88

N

N '^ 'j

% formic acid
Ac20
H,C

H,C

N-Formyl-3-(5-methoxypentyl)-4-(6-nitroquinolin-2-yl)piperazine

(84).

A

stirred solution of 2-(2-(5-methoxypentyl)piperazin-1-yl)-6-nitroquinoline (±)-83
(0.049 g, 0.14 mmol) in

88

% formic acid (0.35 mL) was treated with Ac20 (0.13 g,

0.12 mL, 1.23 mmol) and the reaction was stirred for 30 min. The reaction was
quenched by pouring onto ice, then brought to basic pH with 4 M NaOH, buffered
to pH 10 with sat. NaHCOs, and then extracted with CH2 CI2 ( 3 x 1 0 mL). The
organic portions were combined, dried (K2 COs), and concentrated in vacuo to
give 84 as a yellow oil (0.053 g, 97%): TLC Rf = 0.55 (1:9 MeOH/CH2 CI2).
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o 2n

o K1
BBr3, CH 2 CI2

Br-

N

H3C'

N

H

H

N-Formyl-3-(5-bromopentyl)-4-(6-nitroquinolin-2-yl)piperazine
solution

of

rH°

(85).

A

N-formyl-3-(5-methoxypentyl)-4-(6-nitroquinolin-2-yl)piperazine

(0.038 g, 0.098 mmol) in dry CH2 CI2

(8

84

mL) was cooled at -78 °C in a dry ice,

acetone bath. A solution of BBr3 (0.59 mL, 1M in CH2 CI2 , 0.59 mmol) was added
dropwise under argon giving a deep purple suspension.

The reaction was

allowed to warm to RT °C while stirring overnight, giving a tan suspension. The
reaction was quenched by the addition of sat. NaHC0 3 (20 mL). The organic
layer was separated and the aqueous was extracted with CH2 CI2 (3 x

20

mL).

The organic portions were combined, dried (K2 C 0 3), filtered and concentrated in
vacuo.

The crude material was purified by column chromatography over silica

gel (3 g) eluting with 4:1 EtOAc/CHCI3 to give 85 as a yellow oil (0.40 g, 93%
yield): TLC Rf = 0.48 (1:9 MeOH/CH2 CI2); 1H NMR (CDCI3, 400 MHz) (mixture
of amide rotamers) 5 1.25-1.90 (m,

8

H), 2.86-2.95 (m, 0.5H), 2.99 (dd, J = 4.2

and 13.3 Hz, 0.5H), 3.16-3.39 (m, 4H), 3.44-3.60 (m, 1H), 3.68-3.75 (bm, 0.5H),
4.40-4.52 (m, 1.5H), 4.70 (bs, 0.5H), 4.91 (bs, 0.5H), 7.06 (dd, J = 3.2 and 9.4
Hz, 1H), 7.66 (d, J = 9.1 Hz, 1H), 8.01 (d, J = 9.4 Hz, 1H), 8.10 (s, 0.5H), 8.24 (s,
1H), 8.30 (dd, J = 2.6 and 9.1 Hz, 1H), 8.54 (d, J = 2.6 Hz, 1H);

13C NMR

(CDCI3, 100 MHz) (mixture of amide rotamers) 5 25.0, 25.2, 27.8, 28.0, 28.2,
32.3, 33.6, 33.7, 38.6, 39.6, 39.7, 42.3, 45.1, 47.9, 50.9, 51.5, 110.7, 121.2,
123.8, 124.2, 127.2, 139.1, 142.1, 151.1, 158.0, 161.3.
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o 2n

o 2n

AgOTs, CH3CN
Br-

N

H

65 °C

TsO.
H

H

5-(4-Formyl-1-(6-nitroquinolin-2-yl)piperazin-2-yl)pentyl

4-methylbenzene-

sulfonate (8 6 ). A cooled (0 °C) stirred solution of N-formyl-3-(5-bromopentyl)-4(6-nitroquinolin-2-yl)piperazine 85 (0.040 g, 0.092 mmol) in dry acetonitrile (ACN)
(0.5 mL) was treated with silver tosylate (AgOTs) (0.051 g, 0.18 mmol) giving a
clear solution. The solution was stirred for 5 min at 0 °C, 4 h at 25 °C, and 4 h at
65 °C, forming a silvery-black precipitate.

The reaction was cooled and filtered

over cotton, rinsing with ACN and concentrating in vacuo. The crude material
was purified over silica gel (4 g) loading with CHCI3 and eluting with 2:3
EtOAc/hexanes followed by 4:1 EtOAc/CHCI3, concentration in vacuo gave
a yellow oil (0.042 g,

88

%):

86

as

1H NMR (CDCI3, 400 MHz) 5 1.21-1.49 (m, 4H),

1.51-1.80 (m, 4H), 2.43 (s, 3H), 2.84-3.02 (m, 1H), 3.12-3.26 (bm, 1H), 3.27-3.39
(m, 0.5H), 3.42-3.60 (m, 1H), 3.65-3.77 (m, 0.5H), 3.91-4.02 (m, 2H), 3.36-4.51
(m, 1.5H), 4.69 (bs, 0.5H), 4.86 (bs, 0.5H), 7.00-7.10 (m, 1H), 7.31 (d, J = 8.1 Hz,
2H), 7.61-7.68 (bm, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.96-8.04 (m, 1H), 8.08 (s,
0.5H), 8.23 (s, 0.5H), 8.25-8.32 (m, 1H), 8.52 (bs, 1H).
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o 2n

o 2n

TBAF, THF
N

TsO.
H

5 5 ° c

F-

N
H

H

N-Formyl-3-(5-fluoropentyl)-4-(6-nitroquinolin-2-yl)piperazine (87).

r°
H
In an

8

mL vial a solution of 5-(4-formyl-1-(6-nitroquinolin-2-yl)piperazin-2-yl)pentyl 4methylbenzene-sulfonate

(0.042 g, 0.080 mmol) in dry THF (0.4 mL) was

86

treated with TBAF (0.12 mL, 1 M in THF, 0.12 mmol) to give a dark orange
solution. The vial was capped and heated at 55 °C for 3.5 h. The reaction was
cooled then concentrated in vacuo and dissolved in CHCI3 . The solution was
purified by column chromatography over silica gel (4 g) eluting with 3:2
EtOAc/hexanes followed by 4:1 EtOAc/CHCh, concentration in vacuo gave 87 as
a yellow oil (0.025 g, 84%):
rotamers) 5 1.26-1.82 (m,

8

1H NMR (CDCI3, 400 MHz) (mixture of amide

H), 2.85-3.04 (2m, 1H), 3.15-3.39 (m, 1.5H), 3.43-

3.63 (m, 1H), 3.67-3.77 (m, 0.5H), 4.06-4.18 (m, 1H), 4.30-4.37 (m, 0.5H), 4.404.54 (m, 2H), 4.71 (bs, 0.5H), 4.90 (bs, 0.5H), 7.00-7.10 (m, 1H), 7.66 (d, J = 9.1
Hz, 1H), 8.01 (d, J = 9.1 Hz, 1H), 8.10 (s, 0.5H), 8.25 (s, 0.5H), 8.31 (dd, J = 2.6
and 9.1 Hz, 1H), 8.54 (d, J = 2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) (mixture
of amide rotamers)

6

24.9, 25.06, 25.12, 25.6, 25.7, 28.1, 28.2, 28.3, 30.0, 30.2,

38.6, 39.5, 39.6, 39.8, 42.4, 45.2, 47.9, 51.0, 51.6, 83.0, 84.6, 110.7, 123.8,
124.2, 127.3, 139.1, 142.2, 151.2, 158.1, 161.4.
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2-(2-(5-Fluoropentyl)piperazin-1-yl)-6-nitroquinoline (8 8 ).

A solution of N-

formyl-3-(5-fluoropentyl)-4-(6-nitroquinolin-2-yl)piperazine 87 (0.025 g, 0.067
mmol) in THF (0.25 mL) was treated with H2 SO4 (16 M, 0.75 mL) and heated at
60 °C for 2 h. The reaction was quenched by pouring onto ice, the solution was
brought to a basic pH with 4 M NaOH, and buffered to pH 10 with sat. NaHC0 3 The aqueous layer was extracted with CH2CI2 ( 3 x 1 0 mL), the organic portions
were combined, dried (K2C 0 3), filtered and concentrated in vacuo to give 88 as
yellow oil (0.021 g, 91%): 1H NMR (CDCI3, 400 MHz) 5 1.25-2.04 (m, 9H), 2.85
(dt, J = 3.6 and 12.0 Hz, 1H), 2.98 (dd, J = 3.9 and 12.3 Hz, 1H), 3.06-3.28 (m,
3H), 3.4703.64 (m, 1H), 4.35 (m, 0.5H), 4.42-4.66 (m, 2.5H), 7.01 (d, J = 9.4 Hz,
1H), 7.61 (d, J = 9.4 Hz, 1H), 7.93 (d, J = 9.4 Hz, 1H), 8.27 (dd, J = 2.6 and 9.4
Hz, 1H), 8.51 (d, J = 2.6 Hz, 1H).

6.7

Chiral Pent-NQP Series.

o

o

Methyl (f?)-3-(1,4-dibenzyl-3,6-dioxopiperazin-2-yl)propanoate ((R)-145).

A

stirred solution of methyl (R)-3-(4-benzyl-3,6-dioxopiperazin-2-yl)propanoate (/?)173
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134 (1.3 g, 4.6 mmol) in dry DMF (50 mL) at 0 °C was treated consecutively with
BU4 NI (0.68 g, 1.9 mmol), benzyl bromide (0.83 g, 4.9 mmol), and NaH (0.12 g,
4.9 mmol). The flask was sealed with a septum and placed under an atmosphere
of argon. The reaction was allowed to stir for 1 hour at 0 °C, then at 25 °C
overnight. The reaction was quenched by the cautious addition of water (50 mL),
then buffered to pH 10 using sat. NaHC0 3 (30 mL). The aqueous layer was
extracted with Et20 (3 x 30 mL) and EtOAc (2 x 30 mL). The organic portions
were combined, washed with water (30 mL) followed by brine (30 mL), dried
(K2 CO3 ), filtered, and concentrated in vacuo.

The oil was purified by column

chromatography over silica gel (90 g) loaded with CHCI3 and eluted with 0.4:19.6
MeOH/CHCl3 to give a clear oil (/?)-145 (1.57 g, 89%): Product was visualized by
two separate TLC solvent systems;

Rf

= 0.29 (6:4 EtOAc/Hexanes) or Rf = 0.73

(1:9 MeOH/CHCIs); 1H NMR (CDCI3, 400 MHz) 5 1.98-2.10 (m, 1H), 2.16-2.28
(m, 1H), 2.32-2.50 (m, 2H), 3.66 (s, 3H), 3.84 (d, J = 17.5 Hz, 1H, CH2.AJAr),
3.92-4.02 (m, 3H), 4.42 (d, J = 14.6, 1H, CH2.AMAr), 4.69 (d, J = 14.6 Hz, 1H,
CH2.AMAr), 5.26 (d, J = 14.9 Hz, 1H, CH 2-a x ), 7.18-7.40 (m, 10H);
(CDCI3 , 100 MHz)

6

13C NMR

26.5, 29.0, 46.9, 48.9, 49.4, 51.9, 58.2, 128.0, 128.1, 128.2,

128.8, 128.9, 135.1, 135.4, 163.9, 165.5, 172.6.
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The opposing enantiomer was similarly prepared:
o
Bn' u

\

B0Yo ^ " h co N'Bn
Methyl

(S)-3-(1,4-dibenzyl-3,6-dioxopiperazin-2-yl)propanoate

((S)-145).

Clear oil; (1.62 g, 93%).

o
Reflux

(S?)-3-(1,4-Dibenzylpiperazin-2-yl)propan-1-ol ((/?)-56). A stirred suspension of
UAIH4 (0.86 g, 22.6 mmol) in dry THF (90 mL) at 0° C was treated with a solution
of methyl (R)3-(1,4-dibenzyl-3,6-dioxopiperazin-2-yl)propanoate (/?)-145 (1.57 g,
4.1 mmol ) in THF (20 mL) by syringe under argon maintaining a gentle
effervescence. The reaction flask was fitted with a water-cooled condenser and
the reaction was heated at reflux for 2 h. The solution was allowed to cool to
room temperature and stir overnight. The reaction was quenched by consecutive
addition of water (0.84 mL), NaOH (1.7 mL 4 M), and then water (0.84 mL). The
inorganic solids were filtered off with a pad of Celite and the pad was rinsed with
EtOAc. The filtrate was concentrated in vacuo, giving a clear oil (R)-56 (1.2 g, 98
% crude). The oil was purified by column chromatography over silica gel (50 g)
loaded with CHCI3 and eluted one column length with 0.4:19.6 MeOH/CHCl3
followed by 1:19 MeOH/CHCl3 , concentrated to give a clear oil (/?)-56 (1. 2 g,

175

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

92%): TLC Rf = 0.3 (1:9 MeOH/CHCI3); 1H NMR (CDCI3> 400 MHz) 5 1.52-1.95
(3m, 4H), 2.12-2.37 (2m, 3H), 2.48-2.80 (3m, 4H), 3.20 and 4.19 (2d, J = 12.8,
2H), 3.48 (dd, J = 17.9 and 13.2 Hz), 3.66 (m, 2H), 7.20-7.40 (m, 10H); 13C NMR
(CDCI3i 100 MHz) 5 27.6, 28.6, 50.5, 52.2, 56.4, 57.8, 59.4, 62.8, 63.0, 126.9,
127.1, 128.1, 128.3, 129.0, 129.3, 137.8, 138.0.

The opposing enantiomer was similarly prepared:
Bn,

T i

"L

% „

(S)-3-(1,4-Dibenzylpiperazin-2-yl)propan-1-ol ((S)-56).

Clear oil; (1.16 g,

90%).

DMSO, (COCI) 2
H

N'B n

Bn,

N

CH2CI2,E t 3N ,-7 8 « C
H

H

(R)-3-(1,4-Dibenzylpiperazin-2-yl)propanal ((/?)-89). A solution of DMSO (0.33
g, 4.3 mmol) and dry CH2 CI2 (1 mL) was added dropwise to a solution of oxalyl
chloride (2 M in CH2CI2, 1.1 mL, 2.1 mmol) in dry CH2 CI2 (5 mL) at -78 °C (dry
ice, acetone bath).

After 5 min, a solution of (R)-3-(1,4-dibenzylpiperazin-2-

yl)propan-1-ol (R)-56 (0.63 g, 1.9 mmol) in dry CH2CI2 (3 mL) was added
dropwise. The mixture was allowed to stir for an additional 20 min. The reaction
was treated with Et3N (0.98 g, 9.7 mmol), forming a tan precipitate.

The

suspension was allowed to stir for 5 min, then the reaction was warmed to room
temperature and stirred for 1 hour. The reaction was quenched by the addition of

176

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

water (25 mL).

The organic layer was separated and the aqueous layer was

extracted with an additional 15 mL of CH2CI2 .

The organic portions were

combined, washed with saturated NaHC03 (20 mL), dried (K2C 0 3) and
concentrated in vacuo. The aldehyde (/?)-89 was used in the next step without
further purification: TLC R f= 0.54 (2:3 EtOAc/hexanes).

The opposing enantiomer was similarly prepared:
BrUN ^
H

H

(S)-3-(1,4-Dibenzylpiperazin-2-yl)propanal ((S)-89).

Used directly in the

subsequent Horner-Emmons olefination.

n-BuLi, Triethylphosphonol
H

h

acetate, THF, 0 °C

BrUN ^ Y
Y
O

H

Ethyl (f?)-5-(1,4-dibenzylpiperazin-2-yl)pent-2-enoate ((R)-146).

A stirred

solution of n-BuLi (2.25 M in hexanes, 2.6 mL, 5.9 mmol) in dry THF (10 mL) at 0
°C was treated with triethylphosphonoacetate (1.3 g, 5.9 mmol) under argon, to
give a light yellow solution.

After 30

min, a solution of (R)-3-(1,4-

dibenzylpiperazin-2-yl)propanal (/?)-89 (0.6 g, 2.0 mmol) in dry THF (3 mL) was
added dropwise to the original solution. The reaction mixture was allowed to
warm to room temperature and was stirred for 20 h. The reaction was quenched
by the addition of water (25 mL) and concentrated in vacuo to remove the THF.
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The aqueous layer was treated with 20 mL of sat. NaHC03 and extracted with
Et20 ( 3 x 1 5 mL) and EtOAc ( 1 x 1 5 mL). The organic fractions were combined,
washed with brine (20 mL), dried (K2C 0 3), filtered and concentrated in vacuo.
The resulting orange oil was purified by column chromatography over silica gel
(30 g) loaded with CHCI3 and eluted with 3:2 EtOAc/hexanes and concentration
in vacuo to give (/?)-146 as a light tan oil (0.46 g, 60% 2 steps overall): TLC R f =

0.33 (3:2 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.29 (t, J = 7.1 Hz, 3H),
1.62-1.88 (bm, 2H), 2.06-2.34 (bm, 5H), 2.44-2.76 (bm, 4H), 3.26 (d, J = 13.3 Hz,
1H,

C H 2.AxAr),

3.49 (dd, J = 12.6 and 34.3 Hz, 2H,

C H 2.AMAr),

4.18 (q, J = 7.1 Hz,

2H), 5.78 (m, 1H), 6.88-6.98 (m, 1H), 7.18-7.36 (m, 10H); 13C NMR (CDCI3, 100
MHz) 6 14.3, 27.5, 28.2, 50.2, 52.8, 56.7, 57.6, 58.7, 60.2, 63.0, 121.3, 126.9,
127.0, 128.2, 128.8, 129.0, 148.9, 166.6, 183.8.

The opposing enantiomer was similarly prepared:

Ethyl (S)-5-(1,4-dibenzylpiperazin-2-yl)pent-2-enoate ((S)-146). Light tan oil;
(0.47 g, 66% 2 steps overall).
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AcOH, MeOH

Ethyl (/?)-5-(1,4-dibenzylpiperazin-2-yl)pentanoate ((/?)-77). To a solution of
ethyl (R)-5-(1,4-dibenzylpiperazin-2-yl)pent-2-enoate (/?)-146 (0.46 g, 1.2 mmol)
in HPLC grade MeOH (10 mL) and acetic acid (0.35 g, 5.9 mmol) was added 5%
Pd/C (0.9 g). The reaction flask was sealed with a septum, fitted with hydrogen
balloon and a bleed needle. One balloon of hydrogen was bubbled through the
stirred solution, the needle was removed a second balloon was attached and the
mixture was stirred overnight.

The reaction was filtered over a pad of Celite.

The pad was rinsed with MeOH and concentrated in vacuo. The resulting oil was
dissolved in CH2CI2, free based with 4 M NaOH to a basic pH then buffered to pH
10 with sat. NaHC03. The organic layer was separated and the aqueous layer
was extracted with CH2CI2 (2 x 30 mL). The organic portions were combined,
dried (K2C 0 3) and concentrated in vacuo to give an tan oil. The crude oil was
purified by column chromatography over silica gel (15 g) loaded with CHCI3 and
eluted with 1:3 EtOAc/hexanes followed by 2:3 EtOAc/hexanes, concentration in
vacuo gave (/?)-77 as clear oil (0.28 g, 60%): The product was visualized by two

separate TLC solvent systems; TLC Rf = 0.27 (2:3 EtOAc/Hexanes), Rf = 0.6
(1:9 MeOH/CH2CI2); 1H NMR (CDCI3, 400 MHz) 5 1.16-1.50 (m, 5H, overlapped
triplet at 1.25, J = 7.1 Hz, 3H, C 0 2CH2CH3), 1.52-1.76 (m, 4H), 2.10-2.80 (m,
9H), 3.20 (d, J = 13.2 Hz, 1H, CH2.AxAr), 3.49 (dd, J = 13.2 and 41.7 Hz, 2H,
CH2.AMAr), 4.00 (d, J = 13.2 Hz, 1H, CH2.AxAr), 4.12 (q, J = 7.1 Hz, 2H,
C 02CH2CH3), 7.18-7.45 (m, 10H);

13C NMR (CDCI3, 100 MHz) 5 14.2, 25.0,
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25.4, 29.3, 34.2, 50.7, 52.8, 57.5, 57.6, 59.4, 60.1, 63.0, 126.7, 126.8, 128.1,
128.8, 128.9, 138.2, 139.0, 173.5.

The opposing enantiomer was similarly prepared:
B" ' N ^
H

Ethyl (S)-5-(1,4-dibenzylpiperazin-2-yl)pentanoate ((S)-77). Clear oil; (0.27 g,
57%).

LiAIH4, Et20

(/?)-5-(1,4-Dibenzylpiperazin-2-yl)pentan-1-ol ((/?)-78). A solution of ethyl ( R )5-(1,4-dibenzylpiperazin-2-yl)pentanoate (R)-77 (0.28 g, 0.7 mmol) in dry ether
(10 mL) was treated with LiAlhU powder (0.03 g, 0.8 mmol) at 0 °C, then placed
under an atmosphere of argon. The ice bath was removed and the reaction was
allowed to stir overnight at 25 °C. The reaction was quenched by consecutive
addition of H2 O (0.03 mL), NaOH (0.06 mL 4 M) and then H20 (0.03 mL). The
inorganic salts were filtered over a pad of Celite and the pad was rinsed with
EtOAc. The filtrate was concentrated in vacuo to give (R)-78 (0.24 g, 99%): TLC
Rf = 0.10 (2:3 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.20-1.45 (m, 4H),

1.48-1.68 (m, 5H), 2.10-2.28 (m, 3H), 2.40-2.76 (m, 4H), 3.20 (d, J = 13.2 Hz,
1H, CH2.AxAr), 3.49 (dd, J = 13.2 and 44.0 Hz, 2H, CH2.AMAr), 3.58-3.64 (bm,

180

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2H), 4.00 (d, J = 13.2 Hz, 1H, C H 2-AxAr), 7.20-7.35 (m, 10H); 13C NMR (CDCI3)
100 MHz) 5 25.3, 26.2, 29.6, 32.6, 50.8, 52.7, 57.5, 59.5, 62.5, 63.0, 126.7,
126.9, 128.0, 128.9, 129.0, 137.9, 138.9(1 overlapped peak).

The opposing enantiomer was similarly prepared:
Bn' N ^ |
H

5-((S)-1,4-Dibenzylpiperazin-2-yl)pentan-1-ol ((S)-78).

Clear oil; (0.24 g,

quantitative).

NaH, CH3l
%

n

DMF, 0 °C

H3 C " °

(R)-1,4-Dibenzyl-2-(5-methoxypentyl)piperazine ((/?)-79). A stirred solution of
(R)-5-(1,4-dibenzylpiperazin-2-yl)pentan-1-ol (/?)-78 (0.24 g, 0.69 mmol) in dry
DMF (5 mL) at 0 °C was treated with NaH powder (0.05 g, 2.1 mmol) to give a
turbid white suspension. The reaction was placed under argon and stirring was
continued for 20 min. lodomethane (0.10 g, 0.69 mmol) was added dropwise to
the cooled solution and the reaction was allowed to stir on ice for 30 min followed
by room temperature overnight. The reaction was quenched by the addition of
water (10 mL) followed by sat. NaHC03 (10 mL). The aqueous layer was
extracted with Et20 (4 x 20 mL).

The organic portions were combined, dried

(K2C 0 3), and concentrated in vacuo to give a tan oil. The oil was purified by
column chromatography over silica gel (9 g) loaded with CHCI3 and eluted with

181

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2:3 EtOAc/hexanes followed by 3:2 EtOAc/hexanes, concentration of the product
fractions gave (/?)-79 as a clear oil (0.14 g, 56%):
EtOAc/Hexanes); 1H NMR

(C D C I3,

TLC Rf = 0.39 (4:6

400 MHz) 5 1.22-1.48 (m, 4H), 1.52-1.70 (m,

4H), 2.08-2.32 (m, 3H), 2.40-2.78 (3m, 4H), 3.20 (d, J = 13.2 Hz, 1H,
3.32-3.40 (m, 5H, overlapped singlet, 3.33, 3H,
43.6 Hz, 2H,
13C

NMR

C H 2 .AMA r),

(C D C I3 ,

O C /-/3 ),

4.02 (d, J = 13.2 Hz, 1H,

C H 2 -AxAr),

3.49 (dd, J = 13.2 and

C H 2 -AxAr),

7.20-7.40 (m, 10H);

100 MHz) 5 25.4, 26.6, 29.0, 29.5, 50.8, 52.8, 57.6, 58.5, 59.6,

63.0, 72.0, 72.7, 126.6, 126.8, 128.0, 128.9, 129.0, 138.2, 139.0.

The opposing enantiomer was similarly prepared:
Bn' ^
H3( T
6

H

N ' Bn

(S)-1,4-Dibenzyl-2-(5-methoxypentyl)piperazine ((S)-79).

Clear oil; (0.14 g,

57%).

H2, 5% Pd/C
H ,C '

N' Bn 12 M HCI, MeOH

.
h 3C '0 ^

^

2

HCI

HN/ 'V |

/ ^ s^

H

(R)-2-(5-Methoxypentyl)piperazine dihydrochloride ((/?)-80).

^
H

NH

A solution of

(f?)-1,4-dibenzyl-2-(5-methoxypentyl)piperazine (R)-79 (0.14 g, 0.39 mmol) in
HPLC grade MeOH (8 mL) and HCI (12 M, 0.77 mmol, 0.06 ml_) was treated
with 5% Pd/C (0.021 g). The flask was sealed with a septum and three balloons
of hydrogen were bubbled through the stirred solution. The reaction mixture was
filtered over a pad of Celite, the pad was rinsed with MeOH and the combined
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organic portions were concentrated in vacuo to give a white solid (R)-80 (0.083 g,
83%).

The opposing enantiomer was similarly prepared:

(S)-2-(5-Methoxypentyl)piperazine dihydrochloride ((S)-80).

Clear oil; (0.10

g, 98%).

CIC(Ph)3, Et3N
CH 2 CI2, 0 °C

H 3 C'

(R)-3-(5-Methoxypentyl)-1-tritylpiperazine ((/?)-81). A solution of hydrochloride
(/?)-80) (0.082 g, 0.32 mmol) in dry CH2 CI2 (5 ml_) and dry EtsN (0.13 g, 0.18 ml_,
1.3 mmol) at 0 °C, was treated with a solution of trityl chloride (0.089 g, .32
mmol) in dry CH2 CI2

(2

mL) by dropwise addition. The ice bath was removed

after one hour and the reaction stirred for 20 h at room temperature. The reaction
mixture was transferred to a separatory funnel and diluted to

20

mL with CH2 CI2 .

The organic portion was washed with saturated NaHCC>3 ( 1 0 mL), water

(1 0

mL),

brine (10 mL), dried (K2 CO 3) and concentrated in vacuo to give an amorphous
white foam (R)-81 (0.14 g, 99% yield):
product was

used

TLC 0.34 (1:9 MeOH/CH2 CI2).

directly without further

purification,

The

or spectroscopic

characterization.
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The opposing enantiomer was similarly prepared:

CPh,

H,C

(S)-3-(5-Methoxypentyl)-1-tritylpiperazine ((S)-81).

White foam; (0.16 g,

97%).

n-BuLi, 2-CI-quinoline
Et2 0 , 0 °C;
N
H ,C

CPh,

6

M HCI, acetone
H,C

(R)2-(2-(5-Methoxypentyl)piperazin-1-yl)quinoline ((/?)-82). A solution of (R )3-(5-methoxypentyl)-1-tritylpiperazine (/?)-81 (0.14 g, 0.32 mmol) in dry Et20 (8
mL) under argon at 0° C, was treated dropwise with n-BuLi (0.93 mL, 2.45 M in
hexanes) generating an off-white suspension. The suspension was allowed to
stir for 20 min. A solution of 2-chloroquinoline (0.034 g, 0.21 mmol) in dry Et20
(2 mL) was added drop-wise, the mixture was allowed to stir for 1 h and then the
ice bath was removed. The reaction was allowed to stir for a total of 4 h giving a
red-brown colored suspension. The reaction was quenched with saturated
NaHC03 (20 mL), diluted to 40 mL with Et20 and the organic layer was
separated. The organic layer was washed with water (20 mL), brine (20 mL),
dried (K2C 0 3), and concentrated in vacuo to give a white foam. The foam was
purified by column chromatography over silica gel (9 g) loaded with CHCI3 and
eluted with 1:9 EtOAc/hexanes followed by 1:3 EtOAc/Hexanes to give the Ntrityl protected product (0.099 g, 85% yield) as a clear yellow oil. Rf = 0.3 (4:6
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EtOAc/Hexanes). The purified oil was dissolved in acetone (1.5 mL) and HCI

(6

M, 0.5 mL) and allowed to stir for 15 min. The reaction was diluted with 1 M HCI
(10 mL) and extracted with CH2 CI2 ( 3 x 1 5 mL), the aqueous layer was basified to
pH 12 with 4 M NaOH and then buffered to pH 10 with saturated NaHCOs. The
aqueous layer was extracted with CH2 CI2 ( 3 x 1 5 mL), the organic portions were
combined, dried (K2CO3 ), and concentrated in vacuo to give (/?)-82 (0.035 g,
53% 2 steps) as a light yellow oil: [a]25o = -39° (c = 0.001, CH2 CI2 ); 1H NMR
(CDCI3 , 400 MHz)

6

1.18-1.42 (m, 4H), 1.44-1.58 (m, 2H), 1.60-1.72 (m, 1H),

1.76-1.90 (m, 1H), 2.11 (bs, 1H), 2.84 (m, 1H), 2.94-3.18 (m, 4H), 3.24-3.34 (m,
5H, overlapped singlet, 3.28, 3H, OCH3), 4.38 (bd, 2H), 6.90 (d, J = 9.5 Hz, 1H),
7.18 (t, J = 8.06 Hz, 1H), 7.50 (t, J = 8.4 Hz, 1H), 7.56 (d, J = 8.1 Hz, 1H), 7.65
(d, J = 8.4 Hz, 1H), 7.84 (d, J = 9.2 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 26.0,
26.4, 27.7, 29.4, 40.1, 46.0, 47.8, 51.7, 58.4, 72.6, 109.3, 121.9, 122.7, 126.3,
127.0, 129.3, 137.2, 147.9, 157.0.

The opposing enantiomer was similarly prepared:

(S)2-(2-(5-Methoxypentyl)piperazin-1-yl)quinoline ((S)-82).

Light yellow oil;

(0.022 g, 29% 2 steps overall).
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o 2n

h n o 3, h 2 s o 4
NH

0 °C

NH

H

H

(R)-2-(2-(5-Methoxypentyl)piperazin-1-yl)-6-nitroquinoline ((/?)-83). A stirred
solution of (R)-2-(2-(5-methoxypentyl)piperazin-1-yl)quinoline (R)-B2

(0.035 g,

0.11 mmol) in H2 SO4 (16 M, 2 mL) was cooled at 0° C. HNO3 (15.4 M, 0.03 mL,
0.45 mmol) was added drop-wise, and the reaction stirred for 20 min at 0 °C. The
reaction was quenched by pouring into ice water. The acid was neutralized with
4 M NaOH to give a bright yellow solution, and the resulting mixture was buffered
to pH 10 with sat. NaHC0 3 . The yellow aqueous solution was extracted with
CH2CI2 until no yellow color was extracted into the organic layer. The organic
portions were combined, dried (K2 CO 3 ), and concentrated in vacuo to give a
bright yellow oil (/?)-83 (0.041 g, quantitative yield):

TLC Rf = 0.16 (1:9

MeOH/CH2 CI2); [a]25D = -105° (c = 0.0008, CH2 CI2); 1H NMR (CDCI3, 400 MHz)
51.26-1.46 (m, 4H), 1.50-1.60 (m, 2H), 1.71-1.96 (m, 2H), 2.06 (bs, 1H), 2.85 (dt,
J = 3.6 and 12.3 Hz, 1H), 2.98 (dd, J = 3.6 and 12.3 Hz, 1H), 3.06-3.26 (m, 3H),
3.29 (s, 3H), 3.33 (m, 2H), 4.52 (bs, 2H), 7.01 (d, J = 9.1 Hz, 1H), 7.61 (d, J = 9.4
Hz, 1H), 7.93 (d, J = 9.4 Hz, 1H), 8.27 (dd, J = 2.6 and 9.4 Hz, 1H), 8.51 (d, J =
2.6 Hz, 1H); 13C NMR (CDCI3, 100 MHz) 5 26.0, 26.2, 28.2, 29.4, 40.3, 46.1,
48.0, 51.8 58.4, 72.5, 110.7, 120.7, 123.4, 124.1, 126.8, 138.4, 141.4, 151.6,
158.3.
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The opposing enantiomer was similarly prepared:
o 2n

A1

h 3c "

H

(/?)-2-(2-(5-Methoxypentyl)piperazin-1-yl)-6-nitroquinoline ((/?)-83).

Bright

yellow oil; (0.024 g, 95%); [a]D = +8 6 ° (c = 0.0005, CH2 CI2).

6 .8

Racemic BuM-NQP Series.

DMSO, (COCl)2
HO

Bn

CH2 CI2, Et3 N, -78 °C

3-(1,4-Dibenzylpiperazin-2-yl)propanal (89). A solution of DMSO (0.55 g, 7.0
mmol) in dry CH2 CI2 (2.5 mL) was added dropwise to a solution of oxalyl chloride
(2 M in CH2 CI2, 1.75 mL, 3.5 mmol) in dry CH2 CI2
acetone bath).

(8

mL) at -78 °C (dry ice,

After 5 min, a solution of 1,4-dibenzyl-2-(3-hydroxypropyl)-

piperazine 56 (0.94 g, 2.9 mmol) in dry CH2 CI2 (5 mL) was added dropwise. The
combined mixture was allowed to stir for an additional 20 min at -78 °C. The
reaction was treated with Et3N (1.6 g, 16 mmol) forming a tan precipitate. The
suspension was allowed to stir for 5 min then warmed to room temperature and
stirred for 1 hour. The reaction was quenched by the addition of water (25 mL).
The organic layer was separated and the aqueous layer was extracted with 15
mL of CH2 CI2. The organic portions were combined, washed with saturated
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NaHCOs (20 mL), dried

(K 2 C O 3 ),

filtered, and concentrated in vacuo.

The

aldehyde 89 was used in the next step without further purification: TLC Rf = 0.54
(2:3 EtOAc/hexanes).

1,4-Dibenzyl-2-(but-3-enyl)piperazine (90).

A stirred suspension of methyl

triphenylphosphonium iodide (2.4 g, 5.9 mmol) in dry THF (15 mL) cooled at 0°
C, was treated with n-BuLi (2.4 mL, 2.45 M in hexanes, 5.8 mmol) giving an
yellow-orange suspension. The suspension was stirred for an additional hour at
0° C. A solution of 3-(1,4-dibenzylpiperazin-2-yl)propanal 89 (0.94 g, 2.9 mmol)
in dry THF (5 mL) was added dropwise to the ylide. After 1 h, the reaction was
allowed to warm to RT° C and stir for 18 h. The reaction was quenched with
water (15 mL). The THF was removed in vacuo, and aqueous layer was treated
with sat. NaHCC>3 (20 mL). The aqueous phase was extracted with CH2 CI2 (3 x
30 mL), the organic portions were combined, dried (K2 CO3 ) and concentrated in
vacuo to give a white/tan semi-solid (3.25 g). The crude material was purified by

column chromatography over silica gel (60 g) loaded with CHCI3 , eluting with 1:3
EtOAc/hexanes followed by 2:3 EtOAc/hexanes, after concentration in vacuo
gave (/?)-90 as a light tan oil (0.69 g, 74%, 2 steps overall): TLC

Rf

= 0.54 (2:3

EtOAc/hexanes); 1H NMR (CDCI3, 400 MHz) 5 1.68-1.79 (m, 2H), 1.93-2.34 (m,
5H), 2.45-2.79 (m, 4H), 3.24 (d, J = 13.3 Hz, 1H, CH2-AMAr), 3.51 (dd, J = 12.9
and 34.9 Hz, 2H, CH2-ABAr), 4.02 (d, J = 13.3 Hz, 1H, CH2.AMAr), 4.91-5.03 (m,
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1H), 5.74-5.87 (m, 1H), 7.20-7.38 (m, 10H); 13C NMR (CDCI3, 100 MHz) 5 28.7,
29.8, 50.6, 52.9, 57.2, 57.6, 59.1, 63.1, 114.4, 126.7, 126.9, 128.1, 128.9, 129.0,
138.2, 138.7, 139.1.

9-BBN THF, 50 °C;

H

Bn

H2 0 2, NaOH, 0 °C

HO

N
H

Bn

4-(1,4-Dibenzylpiperazin-2-yl)butan-1-ol (91). A cooled (0 °C) stirred solution
of 1,4-dibenzyl-2-(but-3-enyl)piperazine 90 (0.58 g, 1.8 mmol) in dry THF (15 mL)
was treated (dropwise) with a solution of 9-BBN (7.2 mL, 0.5 M in THF, 3.6
mmol), and then heated at 55 °C for 1.5 h. The reaction was cooled to 0 °C and
treated (dropwise) with a solution of NaOH (5.4 mL, 1 M), followed by 30% H20 2
(5.4 mL).
diluted with

The reaction was concentrated in vacuo to remove the THF, then
1

M HCI (10 mL) and extracted with CH2CI2 (3 x 20 mL).

The

resulting aqueous layer was brought to basic pH with 4 M NaOH, buffered to pH
10

with sat. NaHCOs, and extracted with CH2 CI2 ( 4 x 1 5 mL). The combined

organic portions were, dried (K2 CO3 ), and concentrated in vacuo. The crude oil
was purified by column chromatography over silica gel (37 g) loaded with CHCI3
and eluted with 3:2 EtOAc/hexanes to give a clear oil 91 (0.45 g, 73%): The
product was visualized using two separate TLC solvent systems; Rf = 0.06 (4:6
EtOAc/Hexanes) and Rf = 0.42 (1:9 MeOH/CH2 CI2); 1H NMR (CDCI3, 400 MHz)
5 1.25-1.70 (m,

6

H), 2.12-2.32 (m, 3H), 2.41-2.76 (m, 5H), 3.22 (d, J = 13.3 Hz,

1H, CH2-AMAr), 3.49 (dd, J = 12.9 and 42.7 Hz, 2H, CH2.ABAr), 3.62 (m, 2H,
CH2 OH), 4.01 (d, J = 13.3 Hz, 1H, CH2.AMAr), 7.20-7.36 (m, 10H);
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13C NMR

(CDCI3, 100 MHz) 6 21.8, 29.4, 33.1, 50.7, 52.7, 57.4, 57.6, 59.6, 62.5, 63.0
126.7, 126.9, 128.1, 128.9, 129.1, 138.0, 138.9.

NaH, CH3I
HO

H

Bn

DMF, 0 °C

h 3 c.

O

H

Bn

1,4-Dibenzyl-2-(4-methoxybutyl)piperazine (92). A stirred solution of 4-(1,4dibenzylpiperazin-2-yl)butan-1-ol 91 (1.6 g, 4.73 mmol) in dry DMF (40 mL) at 0
°C was treated with NaH powder (0.34 g, 14.2 mmol) to give a white suspension.
The flask was placed under argon and stirring was continued for 20 min.
lodomethane (0.71 g, 4.97 mmol) was added (dropwise) to the cooled solution.
The reaction was allowed to stir on ice for 30 min, followed by room temperature
overnight. The reaction was quenched by the addition of water (40 mL) followed
by sat. NaHC03 (40 mL). The aqueous layer was extracted with Et20 ( 4 x 1 5
mL), the organic portions were combined, washed with ether, dried (K2C 0 3),
filtered and concentrated in vacuo to give a tan oil. The oil was purified by
column chromatography over silica gel (56 g) loaded with CHCI3 and eluted with
2:3 EtOAc/hexanes, concentration in vacuo gave 92 as a clear oil (1.02 g, 61%):
TLC Rf = 0.35 (2:3 EtOAc/Hexanes), Rf = 0.48 (1:9 MeOH/CH2CI2);

1H NMR

(CDCI3, 400 MHz) 6 1.24-1.70 (m, 6H), 2.12-2.30 (m, 3H), 2.41-2.50 (bm, 1H),
2.52-2.60 (bm, 1H), 2.66-2.76 (m, 2H), 3.20 (d, J = 13.2 Hz, 1H, CH2Ar), 3.33 (s,
3H), 3.36 (m, 2H), 3.49 (dd, J = 13.2 and 41.8, 2H, CH2.ABAr), 4.02 (d, J = 13.2
Hz, 1H, CH2Ar), 7.20-7.40 (m, 10H); 13C NMR (CDCI3, 100 MHz) 5 22.2, 29.6,
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30.1, 50.8, 52.8, 57.6, 58.5, 59.6, 63.1, 72.6, 126.7, 126.8, 128.1, 128.9, 129.0,
138.2, 139.1.

Bn 12 M HCI, MeOH
2-(4-Methoxybutyl)piperazine dihydrochloride (93).

A solution of 1,4-

dibenzyl-2-(4-methoxybutyl)piperazine 92 (1.0 g, 2.9 mmol) in HPLC grade
MeOH (50 mL) and HCI (12 M, 6.1 mmol, 0.5 mL) was treated with 5% Pd/C
(0.15 g). The flask was sealed with a septum and a balloon of hydrogen was
bubbled through the stirred solution. The reaction mixture was filtered over a pad
of Celite; the pad was rinsed with MeOH and concentrated in vacuo to give a
white solid 93 (0.70 g, 98%): 1H NMR (D2 0 , 400 MHz) 51.40-1.52 (m, 2H), 1.561.68 (m, 2H), 1.70-1.84 (m, 2H), 3.21 (m, 1H), 3.34 (s, 3H), 3.41 (m, 1H), 3.49
(m, 2H), 3.56-3.80 (bm, 4H).

•2 HCI

H N ^

CIC(Ph)3, Et3N
CH2CI2, 0 ° c

3-(4-methoxybutyl)-1-tritylpiperazine

(94).

v

A

v

sv

solution

” 'CPh 3

of

2-(4-

methoxybutyl)piperazine dihydrochloride 93 (0.70 g, 2.8 mmol) in dry CH2 CI2 (20
mL) and dry Et3N (1.15 g, 1.6 mL, 11.4 mmol) at 0 °C, was treated (dropwise)
with a solution of trityl chloride (0.79 g, 2.8 mmol) in dry CH2 CI2 (10 mL). The ice
bath was removed after one hour and the reaction stirred for

20

h at room

temperature. The reaction mixture was transferred to a separatory funnel, diluted
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to 20 mL with CH2 CI2 . The organic fraction was washed with saturated NaHC0 3
(20 mL), water (20 mL), brine (20 mL), dried (K2 CO3) and concentrated in vacuo
to give an amorphous white foam 94 (1.11 g, 94% yield).

The product was

directly used without further purification or characterization.

1) n-BuLi, 2-chloroquinoline
Et2Q, 0 °C
2) 6 M HCI, acetone

2-(2-(4-Methoxybutyl)piperazin-1-yl)quinoline

(95).

A

solution

of 3-(4-

methoxybutyl)-1-tritylpiperazine 94 (0.54 g, 1.30 mmol) in dry Et2 0 (20 mL) under
argon at 0° C, was treated (dropwise) with />BuLi (0.6 mL, 2.2 M in hexanes,
1.30 mmol) generating a creamy white suspension. The suspension was allowed
to stir for 20 min. A solution of 2-chloroquinoline (0.14 g, 0.86 mmol) in dry Et2 0
(5 mL) was added dropwise to the lithium amide and the reaction was allowed to
stir for 1 h and the ice bath was removed. The reaction was allowed to stir for a
total of 4 h giving a purple colored suspension. The reaction was quenched with
saturated NaHCC>3 (20 mL), diluted to 40 mL with Et2<D and the organic layer was
separated. The organic layer was washed with water (20 mL), brine (20 mL),
dried (K2 CO3 ), and concentrated in vacuo to give a white foam. The foam was
purified by column chromatography over silica gel (9 g) loaded with CHCI3 and
eluted with 1:9 EtOAc/hexanes followed by 1:3 EtOAc/Hexanes to give the Ntrityl protected product (0.099 g, 85% yield) as a clear yellow oil.

Rf

= 0.3 (4:6

EtOAc/Hexanes). The purified oil was dissolved in acetone (1.5 mL) and HCI

(6

M, 0.5 mL) and the mixture was allowed to stir for 15 min. The reaction was
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diluted with 1 M HCI (10 mL) and extracted with CH2 CI2 (3 x15 mL).

The

aqueous layer was basified to pH 12 with 4 M NaOH and then buffered to pH 10
with saturated NaHCC>3 . The aqueous layer was extracted with CH2 CI2 ( 3 x 1 5
mL), the organic portions were combined, dried (K2 CO3 ), and concentrated in
vacuo to give 95 (0.035 g, 63%) as a light yellow oil: 1H NMR (CDCI3 , 400 MHz)

5 1.28-1.46 (m, 2H), 1.54-1.76 (2m, 3H), 1.81-1.94 (m, 1H), 2.18 (bs, 1H), 2.86
(m, 1H), 2.99 (dd, J = 4.0 and 12.5 Hz, 1H), 3.05-3.21 (m, 3H), 3.28 (s, 3H), 3.33
(m, 2H), 4.36-4.44 (bm, 2H), 6.91 (d, J = 9.2 Hz, 1H), 7.18 (m, 1H), 7.50 (m, 1H),
7.56 (m, 1H), 7.65 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 9.2 Hz, 1H); 13C NMR (CDCI3 ,
100 MHz)

6

23.3, 27.6, 29.5, 40.1, 46.0, 47.7, 51.7, 58.5, 72.6, 109.3, 122.0,

122.8, 126.4, 127.1, 129.4, 137.3, 148.0. 156.9.

2-(2-(4-Methoxybutyl)piperazin-1-yl)-6-nitroquinoline

((±)-96).

A

stirred

solution of 2-(2-(4-methoxybutyl)piperazin-1-yl)quinoline 95 (0.21 g, 0.70 mmol)
in H2 SO4 (16 M, 5 mL) was cooled at 0° C. Dropwise addition of HNO3 (15.4 M,
0.18 mL) to the solution was followed by stirring for 20 min at 0 °C. The reaction
was quenched by pouring into ice water, the acid was neutralized with 4 M NaOH
to give a bright yellow solution and the resulting solution was buffered to pH 10
with sat. NaHCOs.

The aqueous solution was extracted with CH2 CI2 until no

yellow color was extracted into the organic layer.

The organic portions were
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combined, dried (K2 C 0 3), and concentrated in vacuo to give a bright yellow oil
(±)-96 (0.21 g,
MHz)

6

8 8 %):

TLC Rf =

0 .2 2

(1:9 MeOH/CH2 CI2); 1H NMR (CDCI3, 400

1.24-1.42 (m, 2H), 1.52-1.62 (m, 2H), 1.65-1.95 (2m, 3H), 2.79 (dt, J =

2.9 and 12.1 Hz, 1H), 2.88-2.96 (m, 1H), 3.00-3.20 (m, 3H), 3.23 (s, 3H), 3.263.32 (m, 2H), 4.46 (bs, 2H), 6.97 (d, J = 9.5 Hz, 1H), 7.54 (d, J = 9.2 Hz, 1H),
7.86 (d, J = 9.5 Hz, 1H), 8.2 (dd, J = 2.6 and 9.5 Hz, 1H), 8.43 (d, J = 2.6 Hz,
1H); 13C NMR (CDCI3, 100 MHz) 5 23.0, 28.1, 29.4, 40.3, 46.0, 47.9, 51.8, 58.4,
72.4, 110.7, 120.7, 123.5, 124.1, 126.7, 138.3, 141.3, 151.5, 158.3; HRMS (ESITOF) m /z (M + H)+ calcd. for Ci8H25N4 0 3 345.1927 found 345.1938.

1) BBr3, CH2 CI2, -78 °C
NH

2) [(CH3 )3 C 0C 0] 2 0, CH2 CI2i 0 °C
HO'

A
ferf-Butyl-3-(4-hydroxybutyl)-4-(6-nitroquinolm-2-yl)piperazine-1carboxylate

(97).

A

solution

of

2-(2-(4-methoxybutyl)piperazin-1-yl)-6-

nitroquinoline (±)-96 (0.11g, 0.33 mmol) in dry CH2 CI2 (33 mL) was cooled at -78
°C in a dry ice, acetone bath. A solution of BBr3 (2.4 mL, 1M in CH2 CI2, 2.4
mmol) was added dropwise under argon giving a dark purple suspension. The
suspension was warmed to RT °C and stirred overnight giving a yellow-orange
suspension. The reaction was quenched by the addition of sat. NaHC0 3 (25 mL).
The organic layer was separated and the aqueous layer was extracted with
CH2 CI2 (3 x 20 mL). The organic portions were combined, dried (K2 C 0 3), filtered
and concentrated in vacuo. The resulting yellow semi-solid was transferred to a
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50 mL flask with CH2 CI2 and concentrated. The residue was treated with CH2 CI2
(15 mL) sonicated to suspend all the material, then cooled to 0 °C, and treated
with di-ferf-butyl dicarbonate (0.07 g, 0.33 mmol). After 2.5 h, the reaction was
warmed to RT °C. The solution was concentrated in vacuo (25 °C) and dissolved
in CHCI3 . The crude solution was purified by column chromatography over silica
gel

(8

g) eluting with 3:2 EtOAc/hexanes to give 97 as a yellow foam (0.088 g,

44% yield 2 steps): 1H NMR (CDCI3, 400 MHz) 5 1.30-1.85 (m, 15H), 2.80-3.43
(2bm, 4H), 3.63 (bs, 2H), 4.00-4.78 (3bm, 4H), 7.02 (d, J = 9.5 Hz, 1H), 7.63 (d, J
= 9.2 Hz, 1H), 7.97 (d, J = 9.2 Hz, 1H), 8.28 (dd, J = 2.6 and 9.2 Hz, 1H), 8.52 (d,
J = 2.6 Hz, 1H).

6.9

Chiral BuM-NQP Series.

Bn

n-BuLi, [(Ph)3P+CH3]l

H

(/?)-1,4-Dibenzyl-2-(but-3-enyl)piperazine ((/?)-90).

A stirred suspension of

methyl triphenylphosphonium iodide (3.0 g, 7.4 mmol) in dry THF (20 mL), cooled
at 0° C, was treated with n-BuLi (3.3 mL, 2.2 M in hexanes, 7.3 mmol) giving an
yellow-orange suspension. The mixture was stirred for 1 h at 0° C. A solution of
3-(1,4-dibenzylpiperazin-2-yl)propanal (/?)-89 (1.2 g, 3.7 mmol) in dry THF (5 mL)
was added dropwise to the ylide. After 1 hour, the reaction was allowed to warm
to RT° C and stir for 18 h. The reaction was quenched with water (15 mL). The
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THF was removed in vacuo, and the resulting aqueous solution was treated with
sat. NaHCOs (20 mL). The aqueous phase was extracted with CH2 CI2 (3 x 30
mL), the organic portions were combined, dried (K2CO 3) and concentrated in
vacuo to give a white-tan semi-solid. The crude material was purified by column

chromatography over silica gel (60 g) loaded with CHCI3 and eluted with 1:3
EtOAc/hexanes followed by 2:3 EtOAc/hexanes to give (/?)-90 as a light tan oil
(0.57 g, 49%, 2 steps): TLC Rf = 0.54 (4:6 EtOAc/hexanes); 1H NMR (CDCI3,
400 MHz) 5 1.68-1.79 (m, 2H), 1.93-2.34 (m, 5H), 2.45-2.79 (m, 4H), 3.24 (d, J =
13.3 Hz, 1H, CH2-AMAr), 3.51 (dd, J = 12.9 and 34.9 Hz, 2H, CH2.ABAr), 4.02 (d, J
= 13.3 Hz, 1H, CH2-AMAr), 4.91-5.03 (m, 1H), 5.74-5.87 (m, 1H), 7.20-7.38 (m,
10H);

13C NMR (CDCI3 , 100 MHz) 6 28.7, 29.8, 50.6, 52.9, 57.2, 57.6, 59.1,

63.1, 114.4, 126.7, 126.9, 128.1, 128.9, 129.0, 138.2, 138.7, 139.1.

The opposing enantiomer was similarly prepared:

(S)-1,4-Dibenzyl-2-(but-3-enyl)piperazine ((S)-90). Light tan oil; (0.56 g, 55% 2
steps).
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9-BBN THF, 50 °C;

"T
Bn

H20 2, NaOH, 0 °C

HO'

(/?)-4-(1,4-Dibenzylpiperazin-2-yl)butan-1-ol ((/?)-91). A cooled (0 °C) stirred
solution of (R)-1,4-dibenzyl-2-(but-3-enyl)piperazine (/?)-90 (0.57 g, 1.8 mmol) in
dry THF (15 mL) was treated (dropwise) with a solution of 9-BBN (5.4 mL, 0.5 M
in THF, 2.7 mmol), then heated at 55 °C for 1.5 h. The reaction was cooled to 0
°C and treated (dropwise) with a solution of NaOH (4.5 mL, 1 M), followed by
30% H2 O2 (4.5 mL). The reaction was then concentrated in vacuo to remove the
THF. The solution was subsequently diluted with 1 M HCI (10 mL) and extracted
with CH2CI2 (3 x 20 mL). The resulting aqueous layer was brought to basic pH
with 4 M NaOH, buffered to pH
15 mL).

10

with sat. NaHCOs, extracted with CH2 CI2 (4 x

The organic portions were combined, dried (K2 CO3 ), filtered and

concentrated in vacuo to give a tan oil. The resultant crude oil was purified by
column chromatography over silica gel (34 g) loaded with CHCI3 and eluted with
0.4:9 .6 MeOH/CHCb followed by 1:19 MeOH/CHCb to give a clear oil (/?)-91
(0.58 g, 94%): TLC Rf = 0.06 (2:3 EtOAc/Hexanes); 1H NMR (CDCI3, 400 MHz)
6

1.20-1.45 (m, 4H), 1.48-1.68 (m, 5H), 2.10-2.28 (m, 3H), 2.40-2.76 (m, 4H),

3.20 (d, J = 13.2 Hz, 1H, CH2-AxAr), 3.49 (dd, J = 13.2 and 44.0 Hz, 2H, CH2.
AMAr), 3.58-3.64 (bm, 2H), 4.00 (d, J = 13.2 Hz, 1H, CH2-AxAr), 7.20-7.35 (m,
10H);

13C NMR (CDCI3, 100 MHz) 5 25.3, 26.2, 29.6, 32.6, 50.8, 52.7, 57.5,

59.5, 62.5, 63.0, 126.7, 126.9, 128.0, 128.9, 129.0, 137.9, 138.9 (1 overlapped
peak).
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The opposing enantiomer was similarly prepared:

Bn' 0
H

4-((S)-1,4-dibenzylpiperazin-2-yl)butan-1-ol ((S)-91). Clear oil; (0.58 g, 99%).
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1H
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